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Abstract 
 
Six imino sulfadoxine derivatised iridium complexes (C1 - C6), previously synthesized in literature, 
were investigated for drug like character by accessing their aqueous solubility through a turbidimetric 
assay and probing the potential active species by means of aquation experiments. The complexes 
C3, C5 and C6 had solubilities ranging between 20 µM and 160 µM, while C1, C2 and C4 had 
solubilities greater than 160 µM. Solubility was found to decrease with increasing addition of 
hydrophobic groups to the half-sandwich moiety coordinating via a centroidal bond to the iridium 
metal centre. Ease of hydrolysis of the chlorido ligand was found to decrease as the steric bulk 
around the metal centre was increased to the point that the chlorido of C3 remained in-tact under 
mild conditions in the presence of silver nitrate. This likely means the active species is the, as 
synthesized, chlorido complex. New synthetic methods were developed for the synthesis of the Schiff 
base ligands of these complexes to achieve a more efficient synthesis and obtain pure samples for 
testing. Though pure samples were not obtained, the efficiency of the synthesis was improved. 
Six new amido sulfadoxine derivatised iridium complexes (C7 – C12), were synthesized in moderate 
to good yields of 56% – 84% as yellow powders. Their ligands were synthesized through in situ 
generation of an acid chloride and subsequent quenching with sulfadoxine. A crystal structure was 
obtained for the pyridyl amido sulfadoxine ligand which crystallised in the triclinic, P1, space group 
as transparent needle like crystals. The drug-like character was also investigated for this series of 
complexes and their solubilities of C9, C11 and C12 were between 20 µM and 60 µM, while C7, C8 
and C10 were greater than 160 µM. The same results were obtained for the aquation experiments 
as for C1 – C6. 
All complexes were tested against Mycobacterium tuberculosis (Mtb) strain H37Rv and Plasmodium 
falciparum strains, 3D7, Dd2 and HB3. Complex C6 was only tested against Mtb. The imino 
complexes were more active in general, with a MIC90 of 2.78 µM for C6 against strain H37Rv after 7 
days and an IC50 of 13.8 µM for C5 against strain 3D7. Although the amido complexes exhibited 
promising activity against P. falciparum with C12 having an IC50 of 0.975 µM against strain 3D7 and 
IC50 of 0.766 µM against multidrug resistant strain Dd2. The activity was generally seen to increase 
as the solubility decreased with the addition of hydrophobic groups to the complexes.  
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Opsomming 
 
Ses imino sulfadoksien-afgeleide iridium komplekse (C1 - C6), wat voorheen in die literatuur 
gesintetiseer is, is ondersoek vir dwelmagtige karakter deur hul wateroplosbaarheid deur middel van 
'n turbidimetriese toetsing te verkry, sowel as die potensiële aktiewe spesie deur middel van hidrolise 
van die chloriedligand te ondersoek. Die komplekse C3, C5 en C6 het oplosbaarheid tussen 20 μM 
en 160 μM getoon, terwyl C1, C2 en C4 oplosbaarheid groter as 160 μM getoon het. Oplosbaarheid 
is gevind om af te neem met toevoeging van hidrofobiese groepe tot die ‘half-sandwich’ groep wat 
koördineer via 'n sentroïedebinding na die iridium metaal sentrum. Die gemak waarmee die 
chloriedligand gehidroliseer het, het afgeneem soos die steriese massa rondom die metaalsentrum 
verhoog is tot en met die punt dat die chloriedligand van C3 onder matige toestande in die 
teenwoordigheid van silwernitraat onverander gebly het. Dit beteken waarskynlik dat die aktiewe 
spesie die onveranderde chloriedkompleks is. Nuwe sintetiese metodes is ontwikkel vir die sintese 
van die Schiff-basisligande van hierdie komplekse om 'n meer doeltreffende sintese te ontdek en 
suiwer monsters vir biologiese toetse te verkry. Alhoewel suiwer monsters nie verkry is nie, is die 
doeltreffendheid van die sintese verbeter.  
 
'n Tweede stel van ses amido sulfadoksien afgeleide iridium komplekse (C7 - C12), wat nie voorheen 
gemaak is nie, is met goeie opbrengste van 56% - 84% as geel poeiers gesintetiseer. Hul ligande is 
gesintetiseer deur in situ generasie van 'n suurchloried en daaropvolgende substitusie met 
sulfadoksien. 'n Kristalstruktuur is verkry vir die piridielamido-sulfadoksienligand wat in die P1 
ruimtegroep as deursigtige naaldagtige kristalle gekristalliseer het. Die dwelmagtige karakter is ook 
ondersoek vir hierdie reeks komplekse en die oplosbaarheid van C9, C11 en C12 was tussen 20 μM 
en 60 μM, terwyl C7, C8 en C10 oplosbaarheid groter as 160 μM getoon het. Dieselfde resultate is 
verkry vir die hidrolise van die chloriedligand van C7 – C12 as die van C1 - C6. 
 
Alle komplekse is getoets teen Mycobacterium tuberculosis (Mtb) stam H37Rv en Plasmodium 
falciparum stamme, 3D7, Dd2 en HB3. Kompleks C6 is slegs teen Mtb getoets. Oor die algemeen 
was die imino-komplekse meer aktief as die amido komplekse, met 'n MIK90 na sewe dae van 2.78 
μM vir C6 teen stam H37Rv en 'n IK50 van 13.8 μM vir C5 teen stam 3D7. Die amido-komplekse het 
wel belowende aktiwiteit teen P. falciparum vertoon met C12 wat 'n IK50 waarde van 0.975 μM teen 
stam 3D7 en ‘n IK50 waarde van 0.766 μM teen die multidwelmweerstandige stam Dd2 betoon het. 
Dit is waargeneem dat die toename van die aktiwiteit oor die algemeen gepaardgaande gegaan het 
met die afname van die oplosbaarheid, soos wat hidrofobiese groepe aan die komplekse bygevoeg 
is. 
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Chapter 1  
Tuberculosis, Malaria and Sulfonamide Metal Complexes – 
A Review 
 
1.1 Introduction 
The field of drug discovery has come a long way and developed into an intricate and complicated 
science requiring multiple steps and a host of information before drug candidates are identified.1 
Vital in the process of drug discovery is the investigation of the various properties of potential drug 
candidates such as aqueous solubility, cell membrane permeability, and solution stability.1 These 
factors end up being nearly as important as the biological activity of the drug when evaluating 
whether it can be used as an effective treatment. One method of finding drug candidates is to start 
from known clinical drugs, since it can be beneficial to start with known drugs that have already 
reached the market, due to the simplification of much of the safety research that is required in later 
stages of drug development.1  
Despite the streamlining of drug discovery and the new high throughput screening methods being 
employed for faster active pharmacophore identification, there is an ever-increasing need for more 
information and research as drug resistance in treatable diseases continues to rise worldwide.2–4 As 
we understand the mechanism of disease better, so we can further research more effective 
treatments and begin to target both specific and multiple aspects of disease thus limiting the rise of 
resistance against developed treatments. 
This review will focus on the use and discovery of sulfonamides and their metal conjugates as 
chemotherapeutic agents in medicine with a specific application to Mycobacterium tuberculosis and 
Plasmodium parasites. 
1.2 Tuberculosis 
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis (Mtb) which is a 
bacterium that most often infects the lungs, although other areas of the body may also be infected. 
The disease has plagued humanity for many years and its causative agent was first discovered and 
isolated by German doctor Robert Koch, in 1882.5,6 It is spread primarily through the air by infected 
individuals when they either sneeze or cough.  
Approximately 23% of the world’s population (1.7 billion people) are infected with latent Mtb, however 
only 5% - 10% of these individuals end up developing the disease in their lifetime.7 Despite this there 
were still 10 million new active infections worldwide in 2017, of which South Africa contributes a 
major portion, being one of 8 countries responsible for two thirds of these cases.7 Decline of infection 
rates per year are currently close to 2%, which is still far too little. If definitive progress towards the 
eradication of this epidemic is to be made then this percentage needs to be increased nearly three-
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fold.7 To further illustrate the importance of research in this field it is to be noted that Mtb remains 
one of the top ten causes of death worldwide; this is despite a 42% decrease in mortality rate 
between 2000 and 2017.7 
Many of the problems result partly from the resurgence of Mtb deaths due to increasing development 
of drug resistance.2 Multiple drug resistant Mtb (MDR-TB) is defined by the WHO as a strain that is 
resistant to at least two core drugs prescribed for standard treatment, whereas extensively drug 
resistant Mtb (XDR-TB) is a strain that is resistant to at least four of the core drugs.7 With the rise of 
MDR-TB and XDR-TB, treatment has greatly been complicated, with the latest reports showing a 
success rate of only 55% for MDR-TB and merely 34% for XDR-TB.7 This becomes an even larger 
problem in immune compromised individuals such as those suffering from HIV.7 This is of particular 
importance in South Africa with its large burden of TB-HIV comorbidity. Much is being done to spread 
awareness of this problem, for example a documented HIV test result was available for 82% of 
patients in the African region in 2015.7 Moreover, drug treatments have been significantly shortened, 
some from 20 months to 6 months, in the hope of decreasing the incidence of drug resistant strains.7 
A combination of four antimicrobial drugs (Figure 1.1) are currently recommended for drug sensitive 
Mtb (isoniazid, rifampicin, ethambutol and pyrazinamide) with several second line drugs reserved for 
MDR and XDR-TB, although these are much more toxic and treatment is required for an extended 
period.7  
 
Figure 1.1 - Standard drugs, employed in combination, recommended by the WHO for drug sensitive Mtb. 
1.3 Malaria 
Plasmodium parasites are the causative agents of malaria, which is a life-threatening infectious 
disease that is both curable and preventable.8  The disease is spread by infected female Anopheles 
mosquitoes known as malaria vectors. P. falciparum and P. vivax are the two species that are the 
most dangerous, with P. falciparum causing 99.7% of all malaria cases in the WHO African Region 
and most cases in the Eastern Mediterranean, Western Pacific and South-East Asian regions.8,9 
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Although great progress was made in reducing the number of cases worldwide up until 2015, no 
significant progress has been made since then.9 Children under the age of five are the most 
vulnerable group and account for 61% of the 435 000 deaths in 2017, of which 11 countries account 
for nearly 70% , all but 1 being in Africa.9 
There are three major stages to the lifecycle of the parasite, namely, the mosquito stage, the blood 
stage and the liver stage.10 Considering this, there are several approaches to targeting the parasite 
and preventing its spread. Firstly, one of the easiest is malaria vector control, which consists of 
preventing infection by long lasting insecticidal mosquito nets and indoor residual spraying of 
insecticides.8,9 These measures are both recommended by the WHO and if applied thoroughly 
across a wide enough area they can be very effective.8,9 
Secondly, and by far the most common of targets, is the intraerythrocytic blood stage. While the 
parasite is busy changing and breaking down the host’s erythrocytes it is also digesting a large 
amount of the haemoglobin, which results in the release of iron(II) protoporphyrin IX.11–13 This 
oxidises to the toxic iron(III) compound which the parasite then stores in microcrystalline form as 
non-toxic haemozoin.13–15  Many antimalarials target this process to prevent the formation of 
haemozoin, causing the parasite to die. Chloroquine (Figure 1.2) was one of the first and most 
effective synthetic antimalarial drugs and functions in this fashion. Unfortunately, resistance soon 
developed against it, requiring the ongoing search for new therapies.11,16,17   
 
Figure 1.2 – Structures of two antimalarial drugs chloroquine and primaquine that are active against the 
blood and liver stages, respectively. 
Another approach is to prevent the invasion of new erythrocytes. It is during this stage that the 
parasite is exposed to the immune system, albeit for a very brief duration.10 The asexual blood stage 
infection is responsible for the disease pathology, since it is the remodelling and rupturing of the 
erythrocytes of the host which causes symptoms - and often complications such as anemia due to 
erythrocyte rupturing, and cerebral malaria, as the parasite filled erythrocytes block blood vessels to 
the brain. As such, much effort has been put into developing an effective blood stage vaccine.9,10 
Unfortunately, no success has been achieved yet due to the antigenic diversity and complexity that 
the malarial parasite has developed.10 Furthermore, the lack of understanding of the protective host 
immune response towards these antigens has also hindered research efforts. 
Stellenbosch University https://scholar.sun.ac.za
4 
 
Finally, the liver stage of the parasite lifecycle may also be targeted, although primaquine 
(Figure 1.2), which also prevents reinfection, is currently the only marketable drug available for this 
stage.11,18 These factors, along with cases of resistance against most of the current antimalarials 
including the WHO recommended artemisinin-based combination therapy, illustrate the dire need for 
development of new effective treatments.19,20 
1.4 Sulfonamides 
Sulfonamide-containing drugs have been in use as antimicrobials since the early 20th century and 
were some of the first chemotherapeutics to be systematically employed.21,22 They are still prevalent 
in the pharmaceutical industry and are used for a wide range of treatments.23 Given their continued 
prevalence in the industry many different methods have been developed for their synthesis. One of 
the most common methods involves formation of the required sulfonyl chloride derivative, which is 
then followed by a nucleophilic substitution of the required amine.23 This is generally one of the most 
efficient ways of obtaining sulfonamides, even though the method suffers from requiring the handling 
of toxic chlorinating agents to produce the desired sulfonyl chloride.23 The sulfonyl chlorides can be 
obtained from either the respective thiols24 or the sulfonic acids.25 They can also be obtained by 
oxidation of their sulfenamide or sulfinamide analogues.26 Furthermore, there are a wide variety of 
transition metal catalysts which may be employed in their synthesis, primarily in N-arylation of the 
sulfonamide, with the foremost being palladium27, ruthenium28 and copper29 catalysts.23 Finally, an 
oxidative coupling of sodium sulfinates and amines via copper bromide can also provide a range of 
sulfonamides.30 
They are generally believed to function by preventing the synthesis of tetrahydrofolic acid 
(Figure 1.3), which is an important cofactor in the synthesis of DNA. This occurs through competitive 
inhibition of dihydropteroate synthase, a bacterial enzyme higher up in the pathway that produces 
the precursors for tetrahydrofolic acid from para-aminobenzoic acid (Figure 1.3).31  
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Figure 1.3 - Tetrahydrofolic acid and its precursor para-aminobenzoic acid. 
The low toxicity and affordability of sulfonamides make them very attractive candidates for drug 
research. They have been found to be effective for a wide variety of treatments, having been 
employed as antibacterial, antiviral, antitumour and antifungal agents, to name but a few.22,31–37 
Regarding malaria, they are no longer commonly used, but a sulfonamide combination therapy of 
sulfadoxine and pyrimethamine (Figure 1.4) is still used as a preventative treatment in pregnant 
women and for certain cases of malaria in combination with artesunate (Figure 1.4).9  
 
Figure 1.4 – Structures of sulfadoxine, pyrimethamine and artesunate which are used in combination 
therapies as antimalarials. 
They were initially employed as antitubercular drugs, but with the discovery of isoniazid, rifampicin 
and streptomycin, were largely made obsolete due to their lower efficacy.38 With the rise of drug 
resistance against current therapies and the trend of repurposing, it could prove beneficial to once 
again look to these pharmacophores for answers.Two cases illustrating how derivatisation of the 
parent sulfonamide alone can influence the activity and properties are discussed below. 
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Figure 1.5 - General structure of the sulfanilamide derivatives investigated by Kolloff and Hunter.39 
Kolloff and Hunter39 performed a study on a range of N4 and N1 substituted aryl benzylidene 
sulfonamides to investigate the effect that substituting the N4 position would have on their activity 
against pneumonococcal and streptococcal bacteria. These positions are shown in Figure 1.5 and 
are used in sulfanilamide derivatives as a convenient naming method to distinguish which nitrogen 
is being modified. The derivatives containing a phenyl ring on both N4 and N1 positions were 
particularly unstable and susceptible to hydrolysis, and purification was complicated for all the 
derivatives. The activity was seen to decrease slightly with substitution of a phenyl ring, while the 
toxicity decreased significantly. This illustrates that some activity can be sacrificed to decrease the 
general toxicity of these systems and make them more viable for use. 
 
Figure 1.6 - Structure of the sulfonamide Schiff bases investigated by Mondal et al.40 
Mondal et al.40 investigated a series of Schiff bases for antimicrobial activity and drug-like potential. 
These drug candidates were derived from 2-hydroxynaphthaldehyde and the sulfonamides: 
sulfathiazole, sulfapyridine, sulfadiazine, sulfamerazine, and sulfaguanidine. They are shown in 
Figure 1.6. These sulfonamide-Schiff bases showed a significant increase in activity towards both 
gram-positive and gram-negative microbial strains that are resistant to their parent sulfonamides, 
with similar activity to sensitive strains. Additionally, the cytotoxicity was above that of the minimum 
inhibitory concentrations for the drug candidates and haemolysis assays indicated that 90% of blood 
cells remained viable. The ligands were also optimised via DFT calculations and used in docking 
studies with the enzyme dihydropteroate synthase, through which various hydrogen bonding 
interactions were observed. Complex energies with the enzyme were very similar, paralleling the 
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MIC data obtained, which ranged between 32 µg/ml - 128 µg/ml across the various drug candidates 
and microbial strains.  
1.5 Metals in medicine 
The use of metals in medicine has been practiced since the age of antiquity with ancient civilisations 
using copper, gold and iron for a great variety of therapies.41 More recently, syphilis was being 
treated with mercury salts, during which there was the very real risk of the patient dying of mercury 
poisoning, before Paul Ehrlich discovered Arsphenamine (an organoarsenic compound) which was 
much less toxic and more effective.21,42 Since then, with the discovery of cisplatin by Rosenberg and 
the use of bismuth for the treatment of syphilis and gastrointestinal disorders, bioinorganic chemistry 
has rapidly expanded and become increasingly more applicable in treatments.43,44  
This utility is due to the incredible versatility that can be achieved through metal complexes, which 
differ in oxidation state, coordination number, geometries, electronic properties and stability. 
Furthermore, each of these can be adjusted and modified by selecting the appropriate ligands and 
using various synthetic methods, allowing for an incredible variety of possibilities in design.21,45,46 
This in turn allows very specific targets to be chosen. Additionally, the careful choice of ligand can 
control the reactivity and toxicity of the metal complex and determine the secondary coordination 
sphere interactions, including which biological sites will be targeted specifically.46  
It is important to consider all the properties of the complex if it is to be biologically relevant. Both its 
stability and solubility must be carefully designed for the specific purpose to which it is intended. 
Though the potential for such specific design exists, and metal complexes have already found a 
great variety of applications in medicine as treatments for syphilis, arthritis, cancer, inflammation, as 
diagnostic and imaging agents and as antibacterials, it is still difficult to achieve and continued 
research is necessary to broaden our knowledge and available technology.21,45–50 
More recently there has been a surge of research into metal complexes of drugs that have already 
been used in treatments and their direct repurposing or derivatisation for other therapies. In cases 
where resistance has appeared to the original therapy, the metal complex may be active and function 
via a different mode of action against the disease. 21,46,51–53  
1.6 Sulfonamide metal complexes as antimicrobials 
There are several articles that have been published reporting an increase in activity when the ligand 
or parent drug is administered in the form of a metal complex, which is especially advantageous 
against drug resistant variants of diseases.21,51,54–58 This increase in activity, especially as 
antimicrobials, has been well documented for sulfonamides and depends on the metal ion used, and 
a vast range of different sulfonamide metal complexes have been developed over recent years.54,59,60 
They have been tested for a multitude of diseases and applications, some of which include 
cancer,61,62 antimicrobials and antifungals63,64 and carbonic anhydrase inhibitors (which have 
application to a variety of conditions and diseases).65–68 Given the large number of heteroatoms 
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contained in especially heterocyclic sulfonamides and the various ways in which coordination can 
occur, the scope of activity and application is broad, as is illustrated by some of the most recent 
cases discussed hereafter. 
Kremer et al.54 decided to pursue this versatility with the incorporation of copper and investigated a 
series of copper complexes based on sulfonamides incorporating nitrogen containing heterocycles. 
Figure 1.7 shows the wide range of sulfonamides used in their study. 
 
Figure 1.7 – Range of sulfonamides used by Kremer et al.54 
Note that each of the respective ligands are clinical drugs and thus this work also focusses on the 
repurposing of current therapies. The complexes were formed by deprotonation of the sulfonamide 
in an aqueous solution followed by addition of the hydrated copper salt. This resulted in the targeted 
complexes precipitating out of solution. Seven of the complexes showed coordination through 
multiple sites on the ligand, where two ligands coordinated through the free amine, one in a bidentate 
fashion through the sulfonamide and heterocyclic nitrogen, and the last one through another 
heterocyclic atom. This resulted in four ligands coordinating to one metal ion. The other ligands 
coordinated in a monodentate fashion through one of the heterocyclic heteroatoms in 2:1 ligand to 
metal ratio, with the remaining positions taken up by water and hydroxide. Biological evaluation of 
these complexes showed variable activity against Staphylococcus aureus (4 µg/mL – 128 µg/mL) 
and Escherichia coli (2 µg/mL – 128 µg/mL). In both strains in the lab and strains isolated from 
patients, sulfonamides containing five-membered heterocycles were the most active. Sulfadiazine, 
sulfamerazine and sulfapyridine complexes are all less active than the native sulfonamides. The 
authors proposed that this could be due to the specific coordination of these ligands through the free 
amine.  
Mansour and Abdel Ghani69 investigated the various computational and physical properties of a 
sulfamethazine-salicylaldehyde Schiff base by density functional theory (Figure 1.8). These included 
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natural bond orbital analysis, mulliken atomic charges and non-linear effects arising from 
electromagnetic fields, amongst others. The difference in biological activity between the parent 
sulfonamide and the resulting Schiff base is proposed to be affected by the ability to penetrate the 
membrane of the target cells. This is directly influenced by the lipophilicity of the compounds. 
Mansour70 then went on to investigate the influence on biological activity of this sulfamethazine Schiff 
base against strains of S. aureus and E. coli along with three copper(II) complexes of this ligand 
(Figure 1.8). Both ligands and complexes were prepared via a one-pot synthesis in water by using 
the amine salt and were obtained without significant difficulty.  
 
Figure 1.8 - The salicylaldehyde-sulfamethazine Schiff base investigated by Mansour and Abdel Ghani69, 
and its copper complexes.70 
For all complexes the S-N stretch, disappearance of N-H and phenolate ion stretch are used to 
identify coordination with the copper. EPR was used to determine if there was any magnetic coupling 
between copper centres of the dinuclear complex (Figure 1.8); none was found. Antibacterial activity 
(IC50) of the ligand (120 µM) was much less than the free sulfonamide, with the incorporation of the 
metal reducing activity even further. The IC50 for both copper(SASM) A and B was 270 µM while it 
was 620 µM for copper(SASM) C, as measured against S. aureus. Higher activity was seen for gram 
positive bacteria than gram negative bacteria.  
These two studies illustrate that although the general trend of incorporating a metal centre is an 
increase in activity, this is not always the case and the results depend on the metal used as well as 
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where it is incorporated. Unlike the hypothesis presented, the activity is not totally dependent upon 
the lipophilicity of the drug candidates, even though this has often been shown to be the case. 
Nakahata et al.71 prepared an aqueous dimeric silver sulfameter complex, which was shown to 
coordinate through the oxygen and nitrogen of the sulfonamide group and one of the heterocyclic 
nitrogens of the pyrimidine ring (Figure 1.9, left). A range of spectroscopic data was obtained to 
confirm this along with a crystal structure. Antibacterial testing against both gram positive and gram 
negative strains showed that sulfameter was inactive, the complex was mildly active against E. coli 
and P. aeruginosa strains with a MIC (inhibition of visible growth) of 40.9 µM and silver nitrate was 
the most active with sub micro molar activity. The activity is attributed to the release of silver ions, 
which are well known for their antimicrobial activity, where the complex is slow to release these ions. 
The cytotoxicity of the compounds was not tested but it is likely that the silver nitrate would be 
significantly more cytotoxic than the complexes incorporating the ligands, as it is believed that the 
toxicity of metal complexes are modulated by the ligands. This is especially in light of a solution of 
silver nitrate applied as a topical application being regarded as toxic to the tissues affected if it is 
concentrated enough.72  
 
Figure 1.9 - Dimeric silver-sulfameter complex obtained by Nakahata et al.71 (Left) and the general structure 
of the complexes synthesized by Ashraf et al.73 (Right) The Mn complex had an additional two H2O 
molecules coordinated to it. 
Ashraf et al.73 synthesized a series of benzimidazole-sulfonamide hybrid metal complexes with the 
divalent transition metal ions Mn, Co, Ni, Cu and Zn (Figure 1.9, right). The antimicrobial efficacy 
was evaluated via the agar disc diffusion method and compared to the clinical drugs cefixime and 
roxithromycin. The bacterial strains used were Micrococcus luteus, Bordetella bronchiseptica, 
Salmonella typhi, S. aureus, Enterobacter aerogens and E. coli. The fungal species were Mucor 
species, Aspergillus niger, Aspergillus flavus, Aspergillus fumigatus, Alternaria species and 
Fusarium solani. None of the complexes were found to inhibit fungal growth and the only significant 
inhibition of bacterial strains were shown by the Co and Zn complexes, with the cobalt complex 
exhibiting a comparable inhibition zone to cefixime for two of the bacterial strains, namely, M. luteus 
and S. aureus. Coordination takes place primarily through the nitrogen of the benzimidazole and that 
of the sulfonamide (Figure 1.9, right).   
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Alaghaz et al.74 synthesized a sulfanilamide azo dye and prepared its chromium(III), manganese(II), 
cobalt(II), nickel(II), copper(II) and cadmium(II) complexes (Figure 1.10, left). The authors did a 
detailed spectroscopic analysis of the various properties of the compounds, looking at electronic 
spectra, magnetic moment and a variety of other parameters. The structures of the complexes were 
determined through a combination of NMR (for non-paramagnetic samples) and IR spectroscopy 
which was supported by a range of other techniques.  
 
Figure 1.10 – The sulfanilamide azo dye investigated by Alaghaz et al.74 (Left) and the Schiff base ligand 
derived from sulfametrole and acetyl acetone used by Sharaby et al.55 (Right).  
Coordination was proposed to occur through the hydroxyl and imine functional groups with 
coordinated water and acetate molecules to fill the remaining spaces which results in the proposed 
octahedral geometry. The biological activity was evaluated by means of the agar disc diffusion 
method which showed some inhibition against S. aureus, Staphylococcus epidermidis, Klebsiella 
pneumonia, Shigella flexneri, A. fumigatus, Aspergillus clavatus, and Candida albicans sensitive 
strains. Inhibition was generally weaker than that of the standards used.  
Sharaby et al.55 synthesized a Schiff base ligand derived from the clinical sulfa drug sulfametrole 
and acetyl acetone (Figure 1.10, right). Purity was confirmed through various characterisation 
techniques (IR, 1H NMR, MS, elemental analysis and UV-vis) and a sharp melting point (155 °C). 
Complexes were then formed by reacting with copper, zinc, cadmium, ferric chloride and ferrous 
sulphate. Mixed ligand complexes were formed by introducing glycine as a secondary ligand with 
the metals copper, zinc and cadmium chloride. The following range of techniques were employed 
for the analysis of the various complexes: elemental analyses (C, H, N, S and Cl), IR, 1H NMR, molar 
conductance, magnetic moment studies and thermal analyses (TG and DTA). Molar conductance 
tests provide insight into the potential ways in which compounds can interact under physiological 
conditions and can be combined with information on lipophilicity and solubility to solidify hypotheses 
on drug interactions. Results from the molar conductance studies indicate these complexes are not 
strong electrolytes. Furthermore, IR of the mixed complexes show a shift in the C-O stretch of the 
carboxylate group of glycine indicating coordination through this group to the metal. Thermal analysis 
on the copper and cadmium Schiff base complexes showed that water coordinates to the metal 
through the inner coordination sphere, whereas this is not the case for the mixed ligand complexes.  
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Antimicrobial activity was tested against a variety of gram-positive (S. aureus and Bacillus subtilis) 
and gram-negative bacteria (Salmonella typhimurium and E. coli) along with some fungal species 
(C. albicans and A. fumigatus). The complexes were also tested for anticancer activity against the 
breast cancer cell line MCF-7. Biological activity against bacteria, yeast and fungi was determined 
by means of inhibition zones. The complexes showed good antimicrobial activity against the bacteria 
and yeast but were not very effective against the fungus. The anticancer activity displayed was good 
for all except the iron complexes, with IC50 values ranging between 1.8 and 11.1 µg/ml. The mixed 
ligand complexes were more active than the standard complexes, and the cadmium complexes were 
generally the most active for both the cancer and the bacterial testing, with the zinc complexes 
displaying moderate activity. 
Ebrahimi et al.75 aimed to investigate sulfonamide Schiff base metal complexes along with their beta 
lactam derivatives as both these moieties have shown considerable biological potential. The 
respective Schiff bases were synthesized by reacting sulfamethoxazole and sulfathiazole with o-
vanillin, from which the beta lactam derivatives could then be made by reacting the Schiff bases with 
triethylamine and chloroacetyl chloride. Complexes of the two groups of ligands were made with 
copper and zinc. All compounds were characterised through a wide range of techniques (IR, 1H and 
13C NMR, MS, TG/DTG). The ligands are shown in Figure 1.11.  The agar disc diffusion method was 
used to determine the biological activity of the compounds. All the compounds were found to have 
biological activity against E. coli, P. aeruginosa, Proteus species and S. aureus. Additionally, 
enhanced activity was observed once the ligands had been complexed with the metals. This is 
proposed to be due to the increased hydrophobicity which allows for easier transfer across bacterial 
membranes. There was no significant difference in activity between the beta lactam ligands and the 
standard sulfonamide ligands. Furthermore, a brief computational study was also performed using 
DFT, investigating the HOMO and LUMO orbitals of the ligands. 
 
Figure 1.11 - Beta lactams and Schiff bases used as ligands for copper and zinc complexes 
by Ebrahimi et al.75 
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Although much of their work focusses on carbonic anhydrases,76 Supuran and co-workers have 
worked on a range of sulfonamides, including their cobalt, nickel, copper and zinc metal complexes 
with application to their biological activity as antimicrobials.64,77–82 The compounds were tested 
against both gram-positive and gram-negative bacterial strains, various fungal strains and several 
cancer cell lines. It was generally found that activity of the compounds was increased upon 
metalation as has been discussed previously, and that the antimicrobial activity was moderate to 
good. Chohan and co-workers have also done several studies in the same field and obtained similar 
results for their complexes.63,83 
1.7 Sulfonamide metal complexes targeting Mtb 
Despite this multitude of research on sulfonamide metal complexes as general antibacterials and 
antifungals, very little research has investigated the application of these complexes on malaria and 
tuberculosis specifically. Three more recent examples are discussed below that focus on targeting 
mycobacteria.  
Mondelli et al.84 were prompted to investigate cobalt sulfonamide complexes of sulfapyridine, 
sulfadimethoxine, sulfamethazine, sulfamerazine, sulfamethoxazole and sulfamethizole 
(Figure 1.12).  
 
Figure 1.12 - Sulfonamides used by Mondelli et al.84 
They investigated the various means of coordination that sulfonamides display along with the 
cytotoxicity and the activity against Mtb. From the shifts in the infrared spectrum, especially those of 
the N-heterocyclic and aryl amines, they were able to tentatively determine that these complexes 
coordinated primarily through the free amine and the heterocyclic nitrogen groups to the cobalt ion 
(Figure 1.13). A crystal structure of the sulfamethoxazole complex was obtained and showed that 
the coordination occurs through the ligand acting in a bridging fashion between two metal centres 
through the groups previously mentioned. It is postulated that the sulfapyridine complex coordinates 
in a similar fashion, although crystal structures were not obtained for it. The complexes generally 
showed comparable activity to that of the free ligands. The exception being sulfapyridine which had 
the greatest activity among all compounds tested, even though none of the compounds showed 
significant activity against Mtb, with all values being in the millimolar range.  
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Figure 1.13 – Structure of the Co-Sulfamethoxazole complex made by Mondelli et al.84 
Marques et al.85 discovered gold and silver complexes of sulfamethoxazole (Figure 1.14) which 
functioned synergistically with trimethoprim as antibacterial agents in a 5 to 1 ratio.  
 
Figure 1.14 – Gold and silver sulfamethoxazole complexes discovered by Marques et al.85 
Agertt et al.86 subsequently decided to test these new compounds along with trimethoprim against 
mycobacterial strains to investigate if the same effect was seen and if they would be active, given 
the urgent need for new therapies against Mtb. They also incorporated cadmium, mercury and 
copper complexes into their investigations. They found only one complex, [Au(sulfathiazolato)(PPh3)] 
(Figure 1.15), that showed synergistic effects against Mycobacterium smegmatis. They confirmed 
this synergistic effect with trimethoprim against Mtb and found activity levels (0.24 µg/mL) close to 
that of isoniazid which warranted further investigation.  
 
Figure 1.15 - Sulfathiazole complex found to be very active by Agertt et al.86  in synergism with trimethoprim. 
They went on to test these same complexes along with gold complexes of sulfadiazine, against 
rapidly growing mycobacteria to see if they achieved better activity and synergism.87 Rapidly growing 
mycobacteria are a class of non-tubercular mycobacteria that function as opportunistic pathogens. 
They found that in most of the cases there was a symbiotic interaction and the drugs acted 
synergistically against all three strains of rapidly growing mycobacteria tested. The gold 
sulfamethoxazolate, silver methoxazole and dimeric gold sulfadiazine complexes had bactericidal 
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activity, as demonstrated by time kill curves, whereas all other complexes exhibited bacteriostatic 
activity. All the complexes were weakly active with MIC values in the low millimolar range. Upon 
administration with trimethoprim these values decreased to the mid micromolar range.87 
Quintana et al.88 investigated the effect of electron donating and electron withdrawing organometallic 
fragments on the activity and properties of sulfonamide complexes. They used a ferrocenyl amine 
as the electron donating metal and a cyrhetrenyl amine as the electron withdrawing metal. The 
general structure of the complexes are shown in Figure 1.16.  
 
Figure 1.16 - General structure of the complexes synthesized by Quintana et al.88 
The complexes were then tested against Mtb and the minimum concentration when 99% of all cell 
growth is inhibited (MIC99) was determined. The activity was only moderate compared to isoniazid 
and lay in the range of 186 µM to 281 µM with the cyrhetrenyl complexes exhibiting the highest 
activity. The authors used DFT calculations to explain the nature of each of the organometallic 
fragments and postulated that the difference in activity was due to the electron withdrawing nature 
of the cyrhetrenyl group which influences the nucleophilicity of the sulfonamide group, generally 
believed to be responsible for the activity of sulfonamides. 
There has been some research on purely organic sulfonamides, as well as platinum group metal 
complexes, targeting Mtb and malaria parasites, which both showed promising results.52,89–92 Given 
the sparse nature of studies specifically targeting these infectious diseases, it was sought to combine 
these two concepts and investigate a series of platinum group sulfonamide metal complexes and 
their activities against malaria and Mtb. 
1.8 Aims and Objectives 
The first aim of the project was to synthesize a series of imino derivatised sulfadoxine iridium 
conjugates. These complexes are shown in Scheme 1.1 and had been prepared before by Chellan 
et al.50, although they had not succeeded in investigating the difference in biological activity of the 
ligands as compared to the metals. It was subsequently decided it would be of value to obtain data 
on the activity difference, thus the purification and testing of the ligands were set as a secondary 
objective.  
η5 
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Scheme 1.1 - Imino sulfadoxine derivatised iridium conjugates to be prepared in this study. 
The second aim of the project was to synthesize a small library of amido derivatised sulfadoxine 
iridium complexes. Both the complexes and ligands in this library had not been prepared before and 
their structures are shown in Scheme 1.2. The ligands were prepared by converting the appropriate 
carboxylic acid to its acid chloride and then quenching with sulfadoxine to afford the amide.  
 
 
Scheme 1.2 - Amido derivatised sulfadoxine iridium complexes prepared in this study. 
Thirdly, it was planned to investigate selected physico-chemical properties of these potential drug 
candidates to determine their suitability as pharmaceuticals and their drug-like character. In 
particular, the solubility of the complexes was to be investigated by means of a turbidimetric assay 
which analyses the dynamic light scattering of serial dilutions of the compounds to be tested and 
from which a graph of solubility can be drawn. It was also decided to investigate the nature of the 
active species and whether this is the chlorido or aqua analogue. This was done by comparing in 
situ synthesized aqua analogues with their incubated chlorido parent complexes with 1H NMR and 
an internal standard under the same conditions. This allowed for different species to be identified 
and the determination of whether the aquation of the metal centre was a facile process. A complex, 
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C2 (Scheme 1.1), was also selected for a detailed study of the aquation process and was followed 
via 1H NMR overnight. 
Finally, the complexes were all to be tested against strains Dd2, 3D7 and HB3 of P. falciparum and 
the H37Rv strain of Mtb via dose response assays to determine their activity against these infectious 
diseases, respectively. Their cytotoxicity against HEK cells was also to be investigated. From the 
results, structure activity relationships were to be determined and the best candidates selected for 
further study and derivatisation.  
Stellenbosch University https://scholar.sun.ac.za
18 
 
1.9 References 
(1)  Blass, B. E. Drug Discovery and Development; Academic Press: Amsterdam, 2015. 
(2)  Antimicrobial resistance http://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-
resistance (accessed Jun 30, 2018). 
(3)  Who. WHO Global Strategy for Containment of Antimicrobial Strategy for Containment of 
Antimicrobial Resistance. World Health 2001, WHO/CDS/CS, 105. 
(4)  Butler, J. C.; Hofmann, J.; Cetron, M. S.; Elliott, J. A.; Facklam, R. R.; Breiman, R. F. The 
Continued Emergence of Drug-Resistant Streptococcus Pneumoniae in the United States: An 
Update from the Centers for Disease Control and Prevention’s Pneumococcal Sentinel 
Surveillance System. J. Infect. Dis. 1996, 174 (5), 986–993. 
(5)  Koch, R. Die Aetiologie Der Tuberkulose. Berliner Klin. Wochenschrift 1882, 15, 221–230. 
(6)  Cambau, E.; Drancourt, M. Steps towards the Discovery of Mycobacterium Tuberculosis From 
Ancient Times to the Discovery of the Tubercle Bacillus. Clin Microbiol Infect 2014, 20, 196–
201. 
(7)  World Health Organization. Global Tuberculosis Report 2018; 2018. 
(8)  World Health Organization. WHO Malaria Fact sheet https://www.who.int/news-room/fact-
sheets/detail/malaria (accessed Jan 23, 2019). 
(9)  WHO. World Malaria Report; 2018. 
(10)  Cowman, A. F.; Berry, D.; Baum, J. The Cellular and Molecular Basis for Malaria Parasite 
Invasion of the Human Red Blood Cell. J. Cell Biol. 2012, 198 (6), 961–971. 
(11)  Bonilla-Ramirez, L.; Rios, A.; Quiliano, M.; Ramirez-Calderon, G.; Beltrán-Hortelano, I.; 
Franetich, J. F.; Corcuera, L.; Bordessoulles, M.; Vettorazzi, A.; López de Cerain, A.; et al. 
Novel Antimalarial Chloroquine- and Primaquine-Quinoxaline 1,4-Di-N-Oxide Hybrids: 
Design, Synthesis, Plasmodium Life Cycle Stage Profile, and Preliminary Toxicity Studies. 
Eur. J. Med. Chem. 2018, 158, 68–81. 
(12)  Egan, T. J.; Combrinck, J. M.; Egan, J.; Hearne, G. R.; Marques, H. M.; Ntenteni, S.; Sewell, 
B. T.; Smith, P. J.; Taylor, D.; Van Schalkwyk, D. A.; et al. Fate of Haem Iron in the Malaria 
Parasite Plasmodium Falciparum. Biochem. J. 2002, 365 (2), 342–347. 
(13)  De Villiers, K. A.; Egan, T. J. Recent Advances in the Discovery of Haem-Targeting Drugs for 
Malaria and Schistosomiasis. Molecules 2009, 14 (8), 2868–2887. 
(14)  Chou, A. C.; Fitch, C. D. Hemolysis of Mouse Erythrocytes by Ferriprotoporphyrin IX and 
Chloroquine. Chemotherapeutic Implications. J. Clin. Invest. 1980, 66 (4), 856–858. 
Stellenbosch University https://scholar.sun.ac.za
19 
 
(15)  Brown, W. H. Malarial Pigment (so-Called Melanin): Its Nature and Mode of Production. J. 
Exp. Med. 1911, 13 (2), 290 - 299. 
(16)  Farooq, U.; Mahajan, R. C. Drug Resistance in Malaria. J. Vector Borne Dis. 2004, 41, 45–
53. 
(17)  Price, R. N.; Uhlemann, A. C.; Brockman, A.; McGready, R.; Ashley, E.; Phaipun, L.; Patel, 
R.; Laing, K.; Looareesuwan, S.; White, N. J.; et al. Mefloquine Resistance in Plasmodium 
Falciparum and Increased Pfmdr1 Gene Copy Number. Lancet 2004, 364 (9432), 438–447. 
(18)  Li, Q.; O’Neil, M.; Xie, L.; Caridha, D.; Zeng, Q.; Zhang, J.; Pybus, B.; Hickman, M.; Melendez, 
V. Assessment of the Prophylactic Activity and Pharmacokinetic Profile of Oral Tafenoquine 
Compared to Primaquine for Inhibition of Liver Stage Malaria Infections. Malar. J. 2014, 13, 
141 - 154. 
(19)  Na-Bangchang, K.; Karbwang, J. Current Status of Malaria Chemotherapy and the Role of 
Pharmacology in Antimalarial Drug Research and Development. Fundam. Clin. Pharmacol. 
2009, 23 (4), 387–409. 
(20)  L’abbate, F. P.; Müller, R.; Openshaw, R.; Combrinck, J. M.; de Villiers, K. A.; Hunter, R.; 
Egan, T. J. Hemozoin Inhibiting 2-Phenylbenzimidazoles Active against Malaria Parasites. 
Eur. J. Med. Chem. 2018, 159, 243–254. 
(21)  Rizzotto, M. Metal Complexes as Antimicrobial Agents. In A Search for Antibacterial Agents; 
Bobbarala, V., Ed.; INTECH, 2012; pp 73–88. 
(22)  Henry, R. J. The Mode of Action of Sulfonamides *. Bacteriol. Rev. 1943, 7 (4), 175–262. 
(23)  Kołaczek, A.; Fusiarz, I.; Lawecka, J.; Branowska, D. Biological Activity and Synthesis of 
Sulfonamide Derivatives: A Brief Review. Chemik 2014, 68 (7), 620–628. 
(24)  Veisi, H.; Ghorbani-Vaghei, R.; Hemmati, S.; Mahmoodi, J. Convenient One-Pot Synthesis of 
Sulfonamides and Sulfonyl Azides from Thiols Using N -Chlorosuccinimide. Synlett 2011, 16, 
2315 - 2320. 
(25)  Rad, M. N. S.; Khalafi-Nezhad, A.; Asrari, Z.; Behrouz, S.; Amini, Z.; Behrouz, M. One-Pot 
Synthesis of Sulfonamides from Primary and Secondary Amine Derived Sulfonate Salts Using 
Cyanuric Chloride. Synthesis (Stuttg). 2009, 23, 3983 - 3988. 
(26)  Revankar, G. R.; Hanna, N. B.; Ramasamy, K.; Larson, S. B.; Smee, D. F.; Finch, R. A.; Avery, 
T. L.; Robins, R. K. Synthesis and In Vivo Antitumor and Antiviral Activities of 2′‐
deoxyribofuranosyl and Arabinofuranosyl Nucleosides of Certain Purine‐6‐sulfenamides, 
Sulfinamides and Sulfonamides. J. Heterocycl. Chem. 1990, 27, 909 - 918. 
  
Stellenbosch University https://scholar.sun.ac.za
20 
 
(27)  Rosen, B. R.; Ruble, J. C.; Beauchamp, T. J.; Navarro, A. Mild Pd-Catalyzed N -Arylation of 
Methanesulfonamide and Related Nucleophiles: Avoiding Potentially Genotoxic Reagents 
and Byproducts. Org. Lett. 2011, 13, 2564 - 2567. 
(28)  Watson, A. J. A.; Maxwell, A. C.; Williams, J. M. J. Borrowing Hydrogen Methodology for 
Amine Synthesis under Solvent-Free Microwave Conditions. J. Org. Chem. 2011, 76, 2328 -
2331. 
(29)  Deng, W.; Liu, L.; Zhang, C.; Liu, M.; Guo, Q. X. Copper-Catalyzed Cross-Coupling of 
Sulfonamides with Aryl Iodides and Bromides Facilitated by Amino Acid Ligands. Tetrahedron 
Lett. 2005, 46, 7295 - 7298. 
(30)  Tang, X.; Huang, L.; Qi, C.; Wu, X.; Wu, W.; Jiang, H. Copper-Catalyzed Sulfonamides 
Formation from Sodium Sulfinates and Amines. Chem. Commun. 2013, 49, 6102 - 6104. 
(31)  Connor, E. Sulfonamide Antibiotics. Prim. Care Updat. Ob Gyns 1998, 5 (1), 32–35. 
(32)  Maren, T. H. Relations Between Structure and Biological Activity of Sulfonamides. Annu. Rev. 
Pharmacol. Toxicol. 1976, 16, 309 - 327. 
(33)  Owa, T.; Nagasu, T. Novel Sulphonamide Derivatives for the Treatment of Cancer. Expert 
Opin. Ther. Pat. 2000, 10, 1725 - 1740. 
(34)  Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D. Pharmaceutical Substances: Syntheses, 
Patents, Applications, 1st ed.; Thieme: Stuttgart, 1999. 
(35)  Roush, W. R.; Gwaltney, S. L.; Cheng, J.; Scheidt, K. A.; McKerrow, J. H.; Hansell, E. Vinyl 
Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine 
Proteases. J. Am. Chem. Soc. 1998, 120, 10994–10995. 
(36)  Roush, W. R.; Cheng, J.; Knapp-Reed, B.; Alvarez-Hernandez, A.; McKerrow, J. H.; Hansell, 
E.; Engel, J. C. Potent Second Generation Vinyl Sulfonamide Inhibitors of the Trypanosomal 
Cysteine Protease Cruzain. Bioorganic Med. Chem. Lett. 2001, 11, 2759–2762. 
(37)  Burger, A.; Wolff, M. Burger’s Medicinal Chemistry and Drug Discovery, 1st ed.; Wiley: New 
York, 1995. 
(38)  Forgacs, P.; Wengenack, N. L.; Hall, L.; Zimmerman, S. K.; Silverman, M. L.; Roberts, G. D. 
Tuberculosis and Trimethoprim-Sulfamethoxazole. Antimicrob. Agents Chemother. 2009, 53 
(11), 4789–4793. 
(39)  Kolloff, H. G.; Hunter, J. H. Sulfanilamide Compounds. II. Arylidine Derivatives of N1-
Substituted Sulfanilamides. J. Am. Chem. Soc. 1940, 62 (6), 140–144. 
  
Stellenbosch University https://scholar.sun.ac.za
21 
 
(40)  Mondal, S.; Mandal, S. M.; Mondal, T. K.; Sinha, C. Spectroscopic Characterization, 
Antimicrobial Activity, DFT Computation and Docking Studies of Sulfonamide Schiff Bases. J. 
Mol. Struct. 2017, 1127, 557–567. 
(41)  Thompson, K. H.; Orvig, C. Metal Complexes in Medicinal Chemistry: New Vistas and 
Challenges in Drug Design. Dalt. Trans. 2006, No. 6, 761–764. 
(42)  Heynick, F. Jews and Medicine: An Epic Saga; KTAV Publishing House, Inc.: Hoboken, 2002. 
(43)  Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Platinum Compounds: A New 
Class of Potent Antitumour Agents. Nature 1969, 222, 385–386. 
(44)  Li, H.; Sun, H. Recent Advances in Bioinorganic Chemistry of Bismuth. Curr. Opin. Chem. 
Biol. 2012, 16 (1–2), 74–83. 
(45)  Bruijnincx, P. C.; Sadler, P. J. New Trends for Metal Complexes with Anticancer Activity. Curr. 
Opin. Chem. Biol. 2008, 12 (2), 197–206. 
(46)  Obaleye, J. A.; Tella, A. C.; Bamigboye, M. O. Metal Complexes as Prospective Antibacterial 
Agents. In A Search for Antibacterial Agents; Bobbarala, V., Ed.; INTECH, 2012; pp 197–218. 
(47)  Neirinckx, R. D.; Canning, L. R.; Piper, I. M.; Nowotnik, D. P.; Pickett, R. D.; Holmes, R.; 
Volkert, W.; Forster, M.; Weisner, P. S.; Marriott, J. Technetium-99m d,l-HM-PAO: A New 
Radiopharmaceutical for SPECT Imaging of Regional Cerebral Blood Perfusion. J. Nucl. Med. 
1987, 28 (2), 191–202. 
(48)  Sorenson, J. R. J. Copper Complexes – A Unique Class of Anti-Arthritic Drugs. Prog. Med. 
Chem. 1978, 15, 211–260. 
(49)  Sorenson, J. R. J.; Kishore, V.; Pezeshk, A.; Oberley, L. W.; Leuthauser, S. W. C.; Oberley, 
T. D. Copper Complexes: A Physiological Approach to the Treatment of “Inflammatory 
Diseases.” Inorganica Chim. Acta 1984, 91 (4), 285–294. 
(50)  Chellan, P.; Avery, V. M.; Duffy, S.; Triccas, J. A.; Nagalingam, G.; Tam, C.; Cheng, L. W.; 
Liu, J.; Land, K. M.; Clarkson, G. J.; et al. Organometallic Conjugates of the Drug Sulfadoxine 
for Combatting Antimicrobial Resistance. Chem. - A Eur. J. 2018, 24 (40), 10078–10090. 
(51)  Xing, B.; Yu, C. W.; Ho, P. L.; Chow, K. H.; Cheung, T.; Gu, H.; Cai, Z.; Xu, B. Multivalent 
Antibiotics via Metal Complexes: Potent Divalent Vancomycins against Vancomycin-Resistant 
Enterococci. J. Med. Chem. 2003, 46 (23), 4904–4909. 
  
Stellenbosch University https://scholar.sun.ac.za
22 
 
(52)  Eiter, L. C.; Hall, N. W.; Day, C. S.; Saluta, G.; Kucera, G. L.; Bierbach, U. Gold(I) Analogues 
of a Platinum-Acridine Antitumor Agent Are Only Moderately Cytotoxic but Show Potent 
Activity against Mycobacterium Tuberculosis. J. Med. Chem. 2009, 52 (21), 6519–6522. 
(53)  Sousa, E. H. S.; Basso, L. A.; Santos, D. S.; Diógenes, I. C. N.; Longhinotti, E.; De França 
Lopes, L. G.; De Sousa Moreira, Í. Isoniazid Metal Complex Reactivity and Insights for a Novel 
Anti-Tuberculosis Drug Design. J. Biol. Inorg. Chem. 2012, 17 (2), 275–283. 
(54)  Kremer, E.; Facchin, G.; Estévez, E.; Alborés, P.; Baran, E. J.; Ellena, J.; Torre, M. H. Copper 
Complexes with Heterocyclic Sulfonamides: Synthesis, Spectroscopic Characterization, 
Microbiological and SOD-like Activities: Crystal Structure of [Cu(Sulfisoxazole)2(H2O)4] · 
2H2O. J. Inorg. Biochem. 2006, 100 (7), 1167–1175. 
(55)  Sharaby, C. M.; Amine, M. F.; Hamed, A. A. Synthesis , Structure Characterization and 
Biological Activity of Selected Metal Complexes of Sulfonamide Schiff Base as a Primary 
Ligand and Some Mixed Ligand Complexes with Glycine as a Secondary Ligand. J. Mol. 
Struct. 2017, 1134, 208–216. 
(56)  Ming, L. J. Structure and Function of “Metalloantibiotics.” Med. Res. Rev. 2003, 23 (6), 697–
762. 
(57)  Liu, Y. T.; Lian, G. D.; Yin, D. W.; Su, B. J. Synthesis, Characterization and Biological Activity 
of Ferrocene-Based Schiff Base Ligands and Their Metal (II) Complexes. Spectrochim. Acta 
- Part A Mol. Biomol. Spectrosc. 2013, 100, 131–137. 
(58)  Keypour, H.; Shayesteh, M.; Rezaeivala, M.; Chalabian, F.; Elerman, Y.; Buyukgungor, O. 
Synthesis, Spectral Characterization, Structural Investigation and Antimicrobial Studies of 
Mononuclear Cu(II), Ni(II), Co(II), Zn(II) and Cd(II) Complexes of a New Potentially 
Hexadentate N2O4 Schiff Base Ligand Derived from Salicylaldehyde. J. Mol. Struct. 2013, 
1032, 62–68. 
(59)  Mondelli, M.; Bruné, V.; Borthagaray, G.; Ellena, J.; Nascimento, O. R.; Leite, C. Q.; Batista, 
A. A.; Torre, M. H. New Ni(II)-Sulfonamide Complexes: Synthesis, Structural Characterization 
and Antibacterial Properties. X-Ray Diffraction of [Ni(Sulfisoxazole)2(H2O)4] · 2H2O and 
[Ni(Sulfapyridine)2]. J. Inorg. Biochem. 2008, 102 (2), 285–292. 
(60)  Coombs, R. R.; Ringer, M. K.; Blacquiere, J. M.; Smith, J. C.; Neilsen, J. S.; Uh, Y. S.; Gilbert, 
J. B.; Leger, L. J.; Zhang, H.; Irving, A. M.; et al. Palladium(II) Schiff Base Complexes Derived 
from Sulfanilamides and Aminobenzothiazoles. Transit. Met. Chem. 2005, 30 (4), 411–418. 
  
Stellenbosch University https://scholar.sun.ac.za
23 
 
(61)  Zaki, M.; Arjmand, F.; Tabassum, S. Current and Future Potential of Metallo Drugs: Revisiting 
DNA-Binding of Metal Containing Molecules and Their Diverse Mechanism of Action. 
Inorganica Chim. Acta 2016, 444, 1–22. 
(62)  Chohan, Z. H.; Shad, H. A. Metal-Based New Sulfonamides: Design, Synthesis, Antibacterial, 
Antifungal, and Cytotoxic Properties. J. Enzyme Inhib. Med. Chem. 2012, 27 (3), 403–412. 
(63)  Chohan, Z. H.; Shad, H. A.; Youssoufi, M. H.; Ben Hadda, T. Some New Biologically Active 
Metal-Based Sulfonamide. Eur. J. Med. Chem. 2010, 45 (7), 2893–2901. 
(64)  Chohan, Z. H.; Mahmood-Ul-Hassan; Khan, K. M.; Supuran, C. T. In-Vitro Antibacterial, 
Antifungal and Cytotoxic Properties of Sulfonamide - Derived Schiff’s Bases and Their Metal 
Complexes. J. Enzyme Inhib. Med. Chem. 2005, 20 (2), 183–188. 
(65)  Khan, N. U. H.; Zaib, S.; Sultana, K.; Khan, I.; Mougang-Soume, B.; Nadeem, H.; Hassan, M.; 
Iqbal, J. Metal Complexes of Tosyl Sulfonamides: Design, X-Ray Structure, Biological 
Activities and Molecular Docking Studies. RSC Adv. 2015, 5 (38), 30125–30132. 
(66)  Nocentini, A.; Ferraroni, M.; Carta, F.; Ceruso, M.; Gratteri, P.; Lanzi, C.; Masini, E.; Supuran, 
C. T. Benzenesulfonamides Incorporating Flexible Triazole Moieties Are Highly Effective 
Carbonic Anhydrase Inhibitors: Synthesis and Kinetic, Crystallographic, Computational, and 
Intraocular Pressure Lowering Investigations. J. Med. Chem. 2016, 59 (23), 10692–10704. 
(67)  Yenikaya, C.; Ilkimen, H.; Demirel, M. M.; Ceyhan, B.; Bülbül, M.; Tunca, E. Preparation of 
Two Maleic Acid Sulfonamide Salts and Their Copper(II) Complexes and Antiglaucoma 
Activity Studies. J. Braz. Chem. Soc. 2016, 27 (10), 1706–1714. 
(68)  Bruno, E.; Buemi, M. R.; Di Fiore, A.; De Luca, L.; Ferro, S.; Angeli, A.; Cirilli, R.; Sadutto, D.; 
Alterio, V.; Monti, S. M.; et al. Probing Molecular Interactions between Human Carbonic 
Anhydrases (HCAs) and a Novel Class of Benzenesulfonamides. J. Med. Chem. 2017, 60 
(10), 4316–4326. 
(69)  Mansour, A. M.; Abdel Ghani, N. T. Hydrogen-Bond Effect, Spectroscopic and Molecular 
Structure Investigation of Sulfamethazine Schiff-Base: Experimental and Quantum Chemical 
Calculations. J. Mol. Struct. 2013, 1040, 226–237. 
(70)  Mansour, A. M. Selective Coordination Ability of Sulfamethazine Schiff-Base Ligand towards 
Copper(II): Molecular Structures, Spectral and SAR Study. Spectrochim. Acta - Part A Mol. 
Biomol. Spectrosc. 2014, 123, 257–266. 
  
Stellenbosch University https://scholar.sun.ac.za
24 
 
(71)  Nakahata, D. H.; Lustri, W. R.; Cuin, A.; Corbi, P. P. Crystal Structure, Spectroscopic 
Characterization and Antibacterial Activities of a Silver Complex with Sulfameter. J. Mol. 
Struct. 2016, 1125, 609–615. 
(72)  J.Gallagher, J.; K.Branski, L.; Williams-Bouyer, N.; Villarreal, C.; N.Herndon, D. Treatment of 
Infection in Burns. In Total Burn Care; Herndon, D. N., Ed.; Saunders Elsevier, 2012; pp 137–
156. 
(73)  Ashraf, A.; Siddiqui, W. A.; Akbar, J.; Mustafa, G.; Krautscheid, H.; Ullah, N.; Mirza, B.; Sher, 
F.; Hanif, M.; Hartinger, C. G. Metal Complexes of Benzimidazole Derived Sulfonamide: 
Synthesis, Molecular Structures and Antimicrobial Activity. Inorganica Chim. Acta 2016, 443, 
179–185. 
(74)  Alaghaz, A. N. M. A.; Bayoumi, H. A.; Ammar, Y. A.; Aldhlmani, S. A. Synthesis, 
Characterization, and Antipathogenic Studies of Some Transition Metal Complexes with N,O-
Chelating Schiff’s Base Ligand Incorporating Azo and Sulfonamide Moieties. J. Mol. Struct. 
2013, 1035, 383–399. 
(75)  Ebrahimi, H. P.; Hadi, J. S.; Almayah, A. A.; Bolandnazar, Z.; Swadi, A. G.; Ebrahimi, A. Metal-
Based Biologically Active Azoles and β-Lactams Derived from Sulfa Drugs. Bioorganic Med. 
Chem. 2016, 24 (5), 1121–1131. 
(76)  Supuran, C. T. Carbonic Anhydrases: Novel Therapeutic Applications for Inhibitors and 
Activators. Nat. Rev. Drug Discov. 2008, 7 (2), 168–181. 
(77)  Chohan, Z. H.; Supuran, C. T. Structure and Biological Properties of First Row D-Transition 
Metal Complexes with N-Substituted Sulfonamides. J. Enzyme Inhib. Med. Chem. 2008, 23 
(2), 240–251. 
(78)  Chohan, Z. H.; Shad, H. A.; Supuran, C. T. Synthesis, Characterization and Biological Studies 
of Sulfonamide Schiff’s Bases and Some of Their Metal Derivatives. J. Enzyme Inhib. Med. 
Chem. 2012, 27 (1), 58–68. 
(79)  Chohan, Z. H.; Supuran, C. T.; Ben Hadda, T.; Nasim, F. U. H.; Khan, K. M. Metal Based 
Isatin-Derived Sulfonamides: Their Synthesis, Characterization, Coordination Behavior and 
Biological Activity. J. Enzyme Inhib. Med. Chem. 2009, 24 (3), 859–870. 
(80)  Mastrolorenzo, A.; Scozzafava, A.; Supuran, C. T. Antifungal Activity of Ag(I) and Zn(II) 
Complexes of Aminobenzolamide (5-Sulfanilylamido-1,3,4-Thiadiazole-2-Sulfonamide) 
Derivatives. J. Enzyme Inhib. 2000, 15 (6), 517–531. 
(81)  Mastrolorenzo, A.; Scozzafava, A.; Supuran, C. T. Antifungal Activity of Silver and Zinc 
Complexes of Sulfadrug Derivatives Incorporating Arylsulfonylureido Moieties. Eur. J. Pharm. 
Sci. 2000, 11 (2), 99–107. 
Stellenbosch University https://scholar.sun.ac.za
25 
 
(82)  Chohan, Z. H.; Arif, M.; Akhtar, M. A.; Supuran, C. T. Metal-Based Antibacterial and Antifungal 
Agents: Synthesis, Characterization, and in Vitro Biological Evaluation of Co(II), Cu(II), Ni(II), 
and Zn(II) Complexes with Amino Acid-Derived Compounds. Bioinorg. Chem. Appl. 2006, 
2006, 1–13. 
(83)  Chohan, Z. Metal-Based Sulfonamides: Their Preparation, Characterization and in-Vitro 
Antibacterial, Antifungal & Cytotoxic Properties. X-Ray Structure of 4-[(2-
Hydroxybenzylidene) Amino] Benzenesulfonamide. J. Enzyme Inhib. Med. Chem. 2008, 23 
(1), 120–130. 
(84)  Mondelli, M.; Pavan, F.; De Souza, P. C.; Leite, C. Q.; Ellena, J.; Nascimento, O. R.; Facchin, 
G.; Torre, M. H. Study of a Series of Cobalt(II) Sulfonamide Complexes: Synthesis, 
Spectroscopic Characterization, and Microbiological Evaluation against M. Tuberculosis. 
Crystal Structure of [Co(Sulfamethoxazole)2(H2O)2]·H2O. J. Mol. Struct. 2013, 1036, 180–187. 
(85)  Marques, L. L.; Manzoni de Oliveira, G.; Schulz Lang, E.; Anraku de Campos, M. M.; Soccol 
Gris, L. R. New Gold(I) and Silver(I) Complexes of Sulfamethoxazole: Synthesis, X-Ray 
Structural Characterization and Microbiological Activities of 
Triphenylphosphine(Sulfamethoxazolato-N2)Gold(I) and (Sulfamethoxazolato)Silver(I). Inorg. 
Chem. Commun. 2007, 10 (9), 1083–1087. 
(86)  Agertt, V. A.; Marques, L. L.; Bonez, P. C.; Dalmolin, T. V.; Manzoni De Oliveira, G. N.; De 
Campos, M. M. A. Evaluation of Antimycobacterial Activity of a Sulphonamide Derivative. 
Tuberculosis 2013, 93 (3), 318–321. 
(87)  Agertt, V. A.; Bonez, P. C.; Rossi, G. G.; Flores, V. da C.; Siqueira, F. dos S.; Mizdal, C. R.; 
Marques, L. L.; de Oliveira, G. N. M.; de Campos, M. M. A. Identification of Antimicrobial 
Activity among New Sulfonamide Metal Complexes for Combating Rapidly Growing 
Mycobacteria. BioMetals 2016, 29 (5), 807–816. 
(88)  Quintana, C.; Silva, G.; Klahn, A. H.; Artigas, V.; Fuentealba, M.; Biot, C.; Halloum, I.; Kremer, 
L.; Novoa, N.; Arancibia, R. New Cyrhetrenyl and Ferrocenyl Sulfonamides: Synthesis, 
Characterization, X-Ray Crystallography, Theoretical Study and Anti-Mycobacterium 
Tuberculosis Activity. Polyhedron 2017, 134, 166–172. 
(89)  Krátký, M.; Dzurková, M.; Janoušek, J.; Konečná, K.; Trejtnar, F.; Stolaříková, J.; VinŠová, J. 
Sulfadiazine Salicylaldehyde-Based Schiff Bases: Synthesis, Antimicrobial Activity and 
Cytotoxicity. Molecules 2017, 22 (9), 1–15. 
(90)  Noreljaleel, A. E. M.; Wilhelm, A.; Bonnet, S. L.; Van Der Westhuizen, J. H. Synthesis and 
Bioactivity of Reduced Chalcones Containing Sulfonamide Side Chains. J. Nat. Prod. 2018, 
81 (1), 41–48. 
Stellenbosch University https://scholar.sun.ac.za
26 
 
(91)  Gama, N. H.; Elkhadir, A. Y. F.; Gordhan, B. G.; Kana, B. D.; Darkwa, J.; Meyer, D. Activity 
of Phosphino Palladium(II) and Platinum(II) Complexes against HIV-1 and Mycobacterium 
Tuberculosis. BioMetals 2016, 29 (4), 637–650. 
(92)  Chan, H.; Pearson, C. S.; Green, C. M.; Li, Z.; Zhang, J.; Belfort, G.; Shekhtman, A.; Li, H.; 
Belfort, M. Exploring Intein Inhibition by Platinum Compounds as an Antimicrobial Strategy. J. 
Biol. Chem. 2016, 291 (43), 22661–22670. 
 
  
Stellenbosch University https://scholar.sun.ac.za
27 
 
Chapter 2  
Synthesis and characterisation of imino pyridyl- and quinolyl 
iridium half-sandwich complexes 
 
2.1 Introduction 
Schiff bases and especially their metal complexes have been widely used for a vast multitude of 
applications and are vital in a number of fields not least of which include catalysis,1 metal extraction,2 
electrochemistry3 and several medical applications.4–7 Schiff bases also play very important roles in 
biological systems, both of human and microbial origin and are widely found in nature.8,9 This, 
coupled with the large scope of sulfonamides in medicine, as detailed in Chapter 1 and exemplified 
by sulfadiazine, sulfadoxine and sulfasalazine, make the combination of these two pharmacophores 
into one molecule the ideal drug candidate.10 Such systems have widely been pursued in recent 
years with a further interest in the incorporation of metals which can greatly increase activity and 
provide an alternative targeting mechanism, thus decreasing chances of the development of drug 
resistance against such drug candidates.  
Chellan et al.11 previously found that such a system showed promising activity against malaria and 
surprisingly, a moderate activity against Mycobacterium tuberculosis. They had not, however, 
successfully purified some of their ligands as this was not the aim of their study nor was it vital to the 
final complexes that they were making. This however, meant that the ligands were not able to be 
tested alongside that of their complexes.11 It could thus, not be definitively confirmed that the 
incorporation of the metal increased the activity for their system, though there was significant 
evidence for this, especially given the complete inactivity of their parent sulfonamide, sulfadoxine.11  
It was therefore decided to investigate the purification of this ligand and if this proved unsuccessful, 
search for an alternative method of synthesis to obtain a pure sample. A variety of methods are 
available to synthesize Schiff bases with the most common method of preparation being the simple 
condensation of an aldehyde and an amine. It is this approach which was chosen to focus on. The 
ligands to be investigated are shown in Scheme 2.1. 
2.2 Results and Discussion 
2.2.1 Synthesis and characterisation of the Schiff base ligands, L1 – L3 
An imino pyridyl sulfadoxine derivative, L1 (Scheme 2.1), was synthesized through the Schiff base 
reaction of sulfadoxine and 2-pyridinecarboxaldehyde. The Schiff base condensation does not go to 
completion and purification is required, however, the polarity of sulfadoxine and the resulting ligand 
(L1) are very similar and their solubilities are near identical making the separation of these two 
compounds and the purification of the desired ligand challenging. 
Stellenbosch University https://scholar.sun.ac.za
28 
 
 
Scheme 2.1 – General reaction scheme for the synthesis of the sulfadoxine Schiff bases (L1, L2 and L3). 
Purification of L1 is further complicated by its hydrolysis on silica, as numerous attempts with 
different solvent combinations failed to achieve any separation of sulfadoxine and L1. This is most 
likely due to the acidic nature of silica which can cause hydrolysis of these products.12,13 Slight 
separation was achieved using neutral alumina TLC plates, however, subsequent attempts at using 
column chromatography with alumina only lead to co-elution of sulfadoxine and L1 due to the 
similarity of their Rf values and the tailing of the compounds as they interact with the alumina. 
Recrystallisation using ethanol, methanol, toluene, acetone and dichloromethane was attempted, 
however, it was found that both sulfadoxine and L1 would crystallise out together, requiring a large 
excess of L1 to be in solution if this method was to result in a pure sample.  
All infrared frequencies for the ligands and complexes were assigned while consulting a variety of 
references and more detailed information is available in the Experimental section.14–17 The stretching 
frequencies observed for the imine bond and several other signals are generally lower than that seen 
in the references consulted, likely due to the greater electron-withdrawing nature of the systems 
under investigation. 
L1 exhibits characteristic shifts in the IR spectrum (Figure 2.1) as the C=N stretches present in the 
pyrimidine ring of sulfadoxine shift from two strong absorption bands at 1597 cm-1 and 1580 cm-1 to 
a broad band at 1578 cm-1. The C=N stretch of the imine is believed to contribute to the broad peak 
at 1578 cm-1 along with the C=N stretches of the pyrimidine and pyridine rings and as such, is 
masked. Additionally, the disappearance of the primary amine stretches at 3461 cm-1 and 3373 cm-1 
and the N-H bend at 1650 cm-1 provide further support for its successful synthesis. The symmetric 
and asymmetric stretch of the S=O bond is seen at 1165 cm-1 and  1323 cm-1, respectively. They 
have slightly shifted from their earlier positions in sulfadoxine at 1158 cm-1 and 1319 cm-1. The C-O 
stretches of the methoxy groups are also clear, appearing at 1083 cm-1, previously at 1090 cm-1.  
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Figure 2.1 - IR spectrum of L1 (ATR). 
 
Figure 2.2 - 1H NMR spectrum in CDCl3 of L1. 
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The 1H NMR spectrum in chloroform (Figure 2.2) shows the imine signal at 8.53 ppm and the proton 
ortho to the nitrogen of the pyridyl ring downfield at 8.73 ppm. The formation of L1 is further confirmed 
by the shifting of the doublets of the benzene ring of sulfadoxine, usually seen around 6.7 ppm and 
7.9 ppm, to 7.3 ppm and 8.2 ppm, respectively. The downfield shift is caused by withdrawal of 
electron density from the benzene ring which results in less effective shielding of the nuclei from the 
magnetic field. The two methoxy singlets are visible at 3.98 ppm and 3.87 ppm while the presence 
of trace amounts of sulfadoxine can be seen by the duplicate peaks slightly upfield at 3.97 ppm and 
3.84 ppm. 
The percentage product present can be calculated through the signals identified as those of 
sulfadoxine, L1 and the aldehyde by means of quantitative NMR. There are two methods of 
quantitative NMR that can be used, namely, the relative method and the absolute method. The 
absolute method requires immense precision and all parameters to be kept constant. Additionally, it 
has certain prerequisites and conditions that need to be met regarding the experimental settings and 
experiment design.18,19 The advantage of the absolute method is that it gives detailed information on 
the exact concentrations of the species in solution.18,19  
The relative method is significantly less complicated and easy to use. It is based on the calculation 
of the mole fraction and the assumption that the signal intensity is directly related to the number of 
nuclei responsible for the signal.18,19 This allows for the percentage fraction of a substance to be 
calculated if a representative signal of each species in solution can be identified. There is a general 
error of 1.5% associated with the values obtained through these methods which can be reduced 
through rigorous calibration.18,19 If representative signals of all the species in solution are identified 
it is a simple matter to then calculate the percentage of each present. The ratio of sulfadoxine to 
ligand can easily be determined through the singlets of the methoxy protons in the case of the 
sulfonamide ligands worked with in this study (Figure 2.3).  
 
Figure 2.3 - Methoxy singlets of L1 (3.98 ppm and 3.87 ppm)  and sulfadoxine (3.97 ppm and 3.83 ppm) 
demonstrating the different ratios from which the yield can be calculated. 
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To determine the percentage yield of the product, the proton attached to the carbonyl of the aldehyde 
is also taken in to account. Equation 1 is then used, of which a full description can be found in 
literature.19 
(Equation 1) 
(
𝐼𝑋
𝑁𝑋
)
(
∑ 𝐼𝑖
𝑚
𝑖=1
𝑁𝑖
)
 × 100% = 𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑋 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑖𝑛 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ 𝑚 𝑐𝑜𝑚𝑝𝑜𝑛𝑒𝑛𝑡𝑠 
Where I, is the integral area and N, is the number of nuclei responsible for the signal. In summary, 
the mole fraction of the desired compound in solution is calculated and converted to mole percent. 
This method was used throughout this work to assist in optimising reactions to obtain a larger 
conversion of reagents to product and determine the yields obtained during synthesis. 
Considering that full conversion was not obtained for the synthesis of L1 and purification having 
proved unsuccessful, the search for a better method that would give a higher conversion of the Schiff 
base was continued with a preliminary investigation on a model system (L2, Scheme 2.1) using 
benzaldehyde as the aldehyde due to its greater affordability. Initially a microwave method similar to 
that employed in literature11 with times ranging between 3 – 5 minutes and temperatures between 
110 °C and 140 °C in ethanol was used. The percentage yield as determined by relative integration 
of the mixture of reagents and the product showed that 44% product had been obtained with no 
significant variation in yield obtained within these temperature and time variations. The crude was 
left to recrystallize from ethanol and after two weeks a precipitate formed which showed 74% product 
present leading to a hypothesis that a lengthy reaction time may be required, as the amine of 
sulfadoxine is not strongly nucleophilic due to the electron-withdrawing nature of the attached 
benzene ring. This was believed to be the case as previous recrystallisations had not led to any 
significant purification of the product due to the great similarity in solubility and polarity between the 
starting materials and the product as mentioned before.  
In the pursuit of finding different synthetic methods for this reaction, the reagents were heated under 
reflux for 18 hours in ethanol. This led to a similar conversion as found for the microwave procedures 
thus far. The conversion to product was consistently close to the 50% mark, re-emphasising the 
equilibrium nature of this reaction. Attempts to push the equilibrium to form more product with 
catalytic amounts of acid, decreased its formation instead and a lower conversion was obtained, 
likely due to the increased rate of hydrolysis of the formed imine.  
Crude L2 was characterised by IR and 1H NMR and very little variation was seen compared to the 
spectra of L1, as such its spectra have not been included. The characteristic broad signals of the 
ligand in the IR were seen at 1579 cm-1 , which was due to the overlapping of the various C=N 
stretches from the imine, pyridine and pyrimidine rings. The C-O stretches from the methoxy groups 
were at 1079 cm-1. The imine is observed at 8.58 ppm and the two doublets of the sulfadoxine 
benzene ring at 7.43 ppm and 8.20 ppm.  
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Having determined that shorter microwave reaction times were not favourable and that lengthy 
reaction times in protic solvents did not significantly increase the yield obtained, it was decided to 
continue with the target molecule, L1. Wanting to compare the relative rates of the reactions, the 
reagents were heated under reflux in ethanol for 2.5 hours which led to a conversion of 69 %, 
significantly greater than that observed for L2. This is likely due to the presence of the nitrogen in 
the ring which is both more electron-withdrawing than carbon and can facilitate additional interactions 
between the amine. This occurs in the form of weak hydrogen bonding which helps orientate the 
molecule correctly for nucleophilic attack. The activation barrier is likely subsequently lowered, 
allowing the reaction to proceed much easier and faster than would be the case with benzaldehyde.  
Toluene was used as a solvent following this, as water can have an adverse effect on the reaction. 
The reagents were heated under reflux in toluene for 48 hours giving a similar yield to the shorter 
reaction time in ethanol. It was decided to adapt the method with toluene for use in the microwave, 
which led to a reaction time of 1.5 hours at 175 °C, by estimating that half the reaction time is required 
for every 10 °C increase in reaction temperature. The new method gave a similar conversion to that 
of the non-microwave method in toluene, thus the reaction was increased to 2 hours which led to an 
increased yield of 78 %. This was significantly greater than had been achieved before. The improved 
conversion allowed for further purification via recrystallisation and trituration with ether, which had 
thus far proved inefficient, resulting in a sample that was 94% pure according to NMR, with only 
trace amounts of sulfadoxine still present. 
Having obtained these promising results from the modification of the method, it was decided to apply 
this same method to the synthesis of the other ligand made by Chellan et al.11 2-
Quinolinecarboxaldehyde and sulfadoxine were added together to a microwave vial and heated at 
175 °C for 2 hours to obtain the crude ligand, L3 (Scheme 2.1). The method was significantly less 
effective for this system and only 31% yield was obtained. Column chromatography was investigated 
and found that these Schiff bases were separable using silica TLC plates, however upon attempting 
a flash chromatography separation, several by-products formed with a large amount of tailing of the 
compounds on the silica, resulting in coelution. Various column conditions were probed, and a variety 
of percentages triethylamine were investigated to prevent the compounds from tailing. These were 
largely unsuccessful and other methods of separation were subsequently investigated instead, such 
as trituration and recrystallisation. These did not however afford product that was significantly purer 
than the initial crude. The reaction time was subsequently increased to 5 hours; however, the yield 
did not change significantly. The use of both a catalytic amount of acid and molecular sieves also 
failed to provide any breakthrough in the shifting of the equilibrium. It was then decided to increase 
the temperature to 200 °C and run the reaction for 3 hours. This method, followed by stirring in ether 
overnight, finally provided a purer crude sample, with L3 constituting 50% of the sample. It exhibited 
characteristic signals at 1623 cm-1, 1593 cm-1 and 1580 cm-1 for the C=N stretches, while the C-O 
stretches were observed at 1080 cm-1. The symmetric and asymmetric S=O stretches were at 
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1161 cm-1 and 1317 cm-1, respectively. Comparing the IR data of the three systems thus far 
discussed, the signals appear virtually the same with only slight differences. This would seem to 
indicate that the changes in the structure did not affect the bond strengths significantly enough to be 
observed by IR. The method obtained for L3 was significantly less effective than that of L1, and the 
ligand signals of L3 are just barely identifiable (Figure 2.4). The imine is not the signal furthest 
downfield for L1, however, in L3 this is the case as the imine signal is at 8.72 ppm, while three of 
the four doublets of the quinoline ring are part of the multiplet between 8.28 ppm and 8.32 ppm, with 
the final doublet observed at 7.89 ppm. The phenylene protons are identified as doublets at 7.37 
ppm and 8.22 ppm due to their characteristic look. The proton on the pyrimidine ring is at 8.19 ppm 
with the remaining aromatic signals appearing as multiplets shown on the spectrum in Figure 4 along 
with the other signals.  
 
Figure 2.4 - 1H NMR in CDCl3 of crude L3 identifying the signals of the ligand from that of the starting materials. 
The crude ligand did not pose a major problem for the synthesis of the pure complexes as 
demonstrated by Chellan et al.11, though it did complicate the purification in the case of the quinolyl 
complexes as expounded on later.  
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2.2.2 Synthesis of the iridium chlorido dimers 
The iridium chlorido dimers were synthesized according to a literature method24 which entailed 
heating hydrated iridium trichloride and an excess of the appropriate ligand in methanol at 140 °C 
for 5 min in a microwave reactor. The purification was simple and involved removing remaining 
excess ligand by washing with pentane several times.  
Di-µ-chlorido(bis(chlorido(pentamethyl-η5-cyclopentadienyl))iridium(III)) (iridium chlorido Cp* dimer) 
was made by using pentamethylcyclopentadienyl as the ligand. 
To prepare di-µ-chlorido(bis(chlorido(tetramethyl-η5-cyclopentadienylbenzene))iridium(III))  (iridium 
chlorido CpxPh dimer) it was first necessary to synthesize its ligand. The ligand, (2,3,4,5-
tetramethylcyclopenta-1,3-dien-1-yl)benzene (CpxPh), was prepared according to a procedure found 
in literature25. Phenyl magnesium bromide was added dropwise to a solution of 3,4,5-tetramethyl-2-
cyclopentenone in freshly distilled THF and then heated under reflux for 3 hours after which it was 
quenched with HCl at 0 °C to give the required ligand in 67% yield. A detailed procedure can be 
found in the experimental section. Björgvinsson et al. noted that there are three positional isomers 
that can form.26 These isomers are distinguished by the splitting pattern of the proton on the 5-
membered ring (indicated in Figure 2.5 by an asterisk). 
 
Figure 2.5 - 1H NMR spectrum illustrating the major isomer (top left insert A) and two minor isomers (middle 
and top right inserts B and C) of the CpxPh ligand. 
A B C 
  
* 
* * 
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Insert A in Figure 2.5 is that of the major isomer and shows a quartet of septets. The other two 
isomers each have a quartet of quartets (insert B) and an ill resolved septet (insert C), respectively. 
One side of the peaks of the septets have been indicated with blue circles as they are difficult to spot 
due to the secondary splitting being the result of 4J W-coupling. The major isomer composes about 
90% of the product whereas the remaining two account for the other 10% of the product as seen 
from the relative integration of the protons in Figure 2.5. The ortho protons on the phenyl ring couple 
via w-coupling to the para proton indicated by their splitting and the same coupling constant of 1.3 
Hz, which is typical for this type of coupling interaction. Furthermore, the coupling between the meta 
and para protons is also shown through the shared constant of 7.4 Hz. Due to unrestricted rotation, 
the ortho and meta protons are each only seen as one signal. The difference in the methyl shifts are 
because of the arrangements of the double bonds. This is illustrated by the rather upfield shift at 
0.92 ppm which is the only methyl not attached to an alkene. This is further supported by considering 
the coupling constants of the methyl doublet and the CH quartet which both coincide, with a value of 
7.6 Hz. 
A comparison of the IR spectrum of CpxPh and its metal dimer shows a distinct shift in the ring 
substitution patterns of the phenyl ring, indicating that it has coordinated to the metal to form the 
bridged chlorido complex. Electron density is delocalized across the Cp ring as the ligand 
coordinates to the metal centre. Some of this delocalised charge feeds into the orbitals of the phenyl 
ring, thereby strengthening the bonds slightly as indicated by the shift to higher frequency of the ring 
substitution patterns between 1600 cm-1 and 2000 cm-1 as well as the C-H stretches around 
3000 cm-1. The Ir-Cl shift is unfortunately not visible as this usually appears below 500 
wavenumbers. The presence of the three isomers do not make a difference to the final product 
obtained during the dimerization with the Iridium salt. This is due to the deprotonation of the hydrogen 
in the Cp ring which occurs as the metal coordinates to the two alkene bonds allowing the proton to 
be removed by one of the chlorides, resulting in one final product due to the delocalisation of the 
system and HCl as a by-product. 
Samples of the third dimer, di-µ-chlorido(bis(chlorido(4-(tetramethyl-η5-cyclopentadienyl)-1,1’-
biphenyl))iridium(III)), were provided by a laboratory colleague, Lydia Jordaan. 
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2.2.3 Synthesis of the iridium (III) Schiff base complexes (C1 – C6) 
Having successfully synthesized the iridium chlorido dimers, L1 and L3, the complexes were 
subsequently synthesized by stirring the respective dimer in dry methanol at room temperature, 
followed by the addition of the required ligand. Ammonium hexafluorophosphate was added 24 hours 
later and the products were isolated as a microcrystalline red to orange powders 2 hours after its 
addition. Scheme 2.2 illustrates the complexes and their structures.  
 
Scheme 2.2 - General synthetic approach to complexes C1 through C6 and their respective structures. 
Complexes of L1 (C1 – C3) were easily synthesized and purified even though the crude ligand was 
used, however, the complexes of L3 (C4 – C6) were not as easily purified and several different 
purification methods and various recrystallizations were used to finally obtain pure complexes. This 
is most likely due to the significantly lower percentage of L3 present in the ligand samples used, as 
was for L1. The FTIR for all complexes generally had little variation with the C=N stretches between 
1579 cm-1 and 1582 cm-1 as a broad peak. The asymmetric sulfonamide stretches are found between 
1334 cm-1 and 1338 cm-1, while the symmetric stretches are between 1164 cm-1 and 1168 cm-1. The 
C-O stretch from the methoxy groups appears between 1077 cm-1 and 1083 cm-1. Finally, the 
counterion, PF6, exhibits stretching frequencies between 832 cm-1 and 844 cm-1 with its bending 
vibration seen between 557 cm-1 and 558 cm-1. There was a significant shift of the ligand signals 
upon complexation, indicating the large change in the distribution of electron density that takes place. 
A representative spectrum is shown in Figure 2.6.  
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Figure 2.6 - IR spectrum of C2. 
The reaction of L1 with the iridium chlorido CpxPh dimer resulted in an orange microcryalline powder 
(C2) in a good yield of 72%. The FTIR spectrum (Figure 2.6) showed the strong stretch of the PF6 
counter ion at 832 cm-1. A slight shift was also seen in the C=N stretch of the ligand from 1583 cm-1 
in L1 to 1578 cm-1, showing a weakening of the bond as electron density is withdrawn from the pi 
cloud. Similar small shifts were seen for the symmetric and asymmetric S=O stretches of the 
sulfonamide group which appear in the complex at 1165 cm-1 and 1334 cm-1, respectively, while no 
significant shift is observed for the C-O stretches.  
The 1H NMR spectra for the complexes in general show that the imine proton is observed between 
9.26 ppm and 9.86 ppm with a downfield shift occurring as the Cpx moiety is extended or moving 
from a pyridyl to quinolyl system. This is to be expected as the addition of groups with increasingly 
electron-withdrawing nature would result in the nuclei being less shielded from the external magnetic 
field. The same phenomenon was observed for the methyl signals on the Cpx moiety which had 
signals appearing between 1.32 ppm and 1.82 ppm. The Cp* complexes (C1 and C4) exhibited only 
one signal for the methyls due to the rapid rotation around the centroidal bond to the metal, while 
separate signals were seen for all the other complexes (C2, C3, C5 and C6). Both the methyl groups 
of the methoxys and the aromatic signals of the substituted Cpx ring did not show any significant 
shift. The methoxy methyls appeared around 3.82 – 3.83 ppm and 3.98 – 3.99 ppm and the aromatic 
region of the Cpx  moiety between 7.40 ppm and 7.82 ppm. Interesting to note are the protons of the 
phenylene ring attached to the sulfonamide which shift upfield with the increase in electron-
withdrawing nature of the group added and are identified as two doublets between 8.31 ppm – 
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8.37 ppm and 7.92 ppm – 8.21 ppm, respectively. The same occurrence is observed for the proton 
directly attached to the pyrimidine ring which appears between 8.08 ppm and 8.13 ppm. This upfield 
shift with the extension of the Cpx moiety could be due to an interaction between the respective 
aromatic rings which results in a greater shielding effect for these specific nuclei. Alternatively, the 
increased electron-withdrawing effect could be shifting the ring currents slightly which result in a 
more effective shielding of the protons.  
The synthesis of C2 is discussed below as a representative for the six complexes. The 1H NMR 
spectrum (Figure 2.7) of C2 in acetone showed the imine shift from 8.58 ppm in L1 to 9.55 ppm 
indicating coordination to the metal centre. The downfield shift occurred due to the withdrawal of 
electron density by the metal centre which caused de-shielding of the imine proton by shifting the pi 
electron cloud of the double bond. This also further confirmed earlier observations from the FTIR 
spectrum. 
 
Figure 2.7- 1H NMR spectrum in acetone-d6 of the complex, C2. 
The proton ortho to the nitrogen of the pyridyl ring shifts from 8.73 ppm to 8.83 ppm, showing the 
same pattern. Due to the chirality of the metal complex and addition of the phenyl group to the Cp* 
group, the methyls all have different shifts and are seen at 1.77 ppm, 1.64 ppm, 1.44 ppm and 1.32 
ppm. One of the phenylene doublets shifts from 7.29 ppm to the multiplet at 7.93 ppm in C2, while 
the other appears in L1 as a multiplet at 8.20 ppm which resolves upon complexation, appearing at 
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8.31 ppm in C2. Given that the doublet at 7.93 ppm experienced the largest downfield shift, it would 
likely indicate that this doublet is closest to the imine, while the doublet at 8.31 ppm is next to the 
sulfonamide group. Only one of the methoxy singlets shift from 3.87 ppm in L1 to 3.83 ppm in C2, 
while the other stays at 3.99 ppm. Because of the large distance between these nuclei and the 
coordinated metal centre, no change would be expected, it is thus interesting to note that the electron 
density is affected on one of these groups. The methoxy group at 3.99 ppm is in a meta position of 
the ring which is likely why no change was observed for these nuclei as this position is not sensitive 
to changes in electron density, whereas the ortho substituted methoxy group is affected to a much 
greater extent due to its closer proximity as well as the additional hydrogen bonding interaction that 
is possible between the NH of the sulfonamide and the oxygen on this group. This is also why it is 
significantly more shielded than the nuclei of the meta methoxy, as the additional electrons from the 
hydrogen bonding interaction shield it slightly from the external magnetic field. From the spectrum it 
is noted that there are no longer any signs of duplicate methoxy peaks, indicating that the sulfadoxine 
impurity was successfully removed during purification of the complex. HPLC purity for all the 
complexes except C5 was determined to be between 96.9% and 98.4%. The purity of C5 was > 
87%. 
2.3 Conclusion 
A successful method was developed for the synthesis of L1 which achieved good conversion of 78%, 
despite the equilibrium nature of the reaction. The use of a model system was fundamental to the 
successful development of the new synthetic method. Furthermore, this method was applied to L3 
as well, but found to be lacking. This resulted in the determination of a new method for the synthesis 
of L3 giving a final crude composition of 50% which was an improvement on that obtained previously, 
before other aspects of the project had to be focussed on. 
The synthesis of the iridium chlorido bridge dimers was generally a facile process except for the 
biphenyl chlorido dimer which was provided by Lydia Jordaan.  
Although the ligands had not been purified completely, this did not prevent the isolation of pure metal 
complexes in the case of C1 – C3, however, in the case of the complexes with L3 (C4 – C6) their 
purification proved more challenging. This was because of the crude ligand, L3, which was 
significantly less pure than L1 was. 
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2.4 Experimental 
Chemicals and reagents. Sulfadoxine (95 %), 2-pyridinecarboxaldehyde, 2-
quinolinecarboxaldehyde, 1,2,3,4,5-pentamethylcyclopentadiene, 2,3,4,5-tetramethyl-2-
cyclopentenone, 4-bromobiphenyl, ammonium hexafluorophosphate, phenyl magnesium bromide 
solution in THF (1 M), IrCl3•nH2O, n-butyllithium solution, benzaldehyde, glacial acetic acid, p-
toluenesulfonic acid monohydrate, all reagent solvents and deuterated solvents (methanol-d4, 
acetone-d6, dimethylsulfoxide-d6, chloroform-d1, deuterium oxide) were obtained from Sigma Aldrich 
(Merck). Di-µ-chlorido(bis(chlorido(pentamethyl-η5-cyclopentadienyl))iridium(III)), di-µ-chlorido-
(bis(chlorido(tetramethyl-η5-cyclopentadienylbenzene))iridium(III)) and di-µ-chlorido(bis(chlorido(4-
(tetramethyl-η5-cyclopentadienyl)-1,1'-biphenyl))iridium(III)) were synthesized according to a 
literature method.23 L1, L3, and C1 – C6 have been previously synthesized.10  
 
Instrumentation.  IR spectroscopy was performed using a Thermo Nicolet Nexus 470 by means of 
Attenuated Total Reflectance (ATR) mode and transmission esp. for compounds L1, L2, CpxPh, all 
Iridium chlorido dimers, C1 and C2, while potassium bromide pellets and transmission esp. was used 
for all remaining samples. NMR data (1H, 13C) were recorded on either a 300 MHz Varian VNMRS 
or a 400 MHz Varian Unity Inova spectrometer. 1H NMR chemical shifts are reported in ppm and 
coupling constants in Hertz and were internally referenced to methanol-d4 (3.31 ppm), acetone-d6 
(2.05 ppm), dimethylsulfoxide-d6 (2.50 ppm), chloroform-d1 (7.26 ppm), or deuterium oxide (4.79 
ppm). Data was processed using MestReNova 11.0.4-18998.  
  
Microwave syntheses were carried out in a CEM Discover SP microwave reactor. Solvents were 
removed in vacuo, using a rotary evaporator, followed by removal of trace amounts of the remaining 
solvent using a high vacuum pump at ca. 0.08 mm Hg. 
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2.4.1 Synthesis of N-(5,6-dimethoxypyrimidin-4-yl)-4-((pyridin-2-ylmethylene) 
amino)benzenesulfonamide (L1) 
 
Sulfadoxine (1.00 x 102 mg, 0.322 mmol) was suspended in toluene (3 mL) in a 10 mL microwave 
vial. 2-pyridinecarboxaldehyde (41.4 mg, 36.8 µl, 0.386 mmol) was added to this suspension and 
the vial was placed in the microwave reactor (175 °C, 200 W, 2 h). The resulting yellow solution was 
allowed to cool and the solvent removed which resulted in a cream coloured solid which was then 
triturated with ether 5 times, then dried under high vacuum for 7 hours. The crude powder was 
recrystalized from hot toluene resulting in a crude yield of 95.4 mg. 1H NMR (400 MHz, CDCl3) δ 
8.73 (d, 1H, Hb, 3J(Hb-Hc) 5.1 Hz), 8.53 (s, 1H, Hf), 8.23 - 8.15 (m, 4H, Hh, Ha and Hd), 7.88 - 7.80 (m, 
1H, Hc), 7.45 - 7.39 (m, 1H, He), 7.30 (d, 2H, Hg, 3J(Hg-Hh) 8.2 Hz), 3.98 (s, 3H, Hi), 3.86 (s, 3H, Hj). 
FT-IR: 1583 cm-1 (C=Nimine, C=Npyr, C=Npyrim). 
2.4.2 Synthesis of 4-(benzylideneamino)-N-(5,6-dimethoxypyrimidin-4-yl) 
benzenesulfonamide (L2) 
 
A suspension of sulfadoxine (507 mg, 1.63 mmol) in ethanol (10 mL) was added to a microwave vial 
(35.0 ml) followed by benzaldehyde (208 mg, 2.00 x 102 µl, 1.2 eq, 1.96 mmol) and the vial was 
sealed and placed in the microwave reactor (1.10 x 102  °C, 150 W, 3 min). The vial was then cooled, 
and the yellowish-brown solution filtered through Celite™. MgSO4 was then used to dry the solution 
and was filtered off and the solvent removed from the filtrate. Recrystallisation was then attempted 
in ethanol layered with hexane, after nearly two weeks a brown tinged powder formed. The product 
was then dried under high vacuum for 4 hours and a crude yield of 496 mg was isolated.  1H NMR 
(300 MHz, acetone) δ 8.73 (d, 1H, Ha, 3J(Ha-Hb) 4.8 Hz), 8.58 (s, 1H, Hf), 8.26 - 8.16 (m, 4H, Hb, Hd, 
and Hh), 8.11 (s, 1H, Hi), 7.99 - 7.93 (m, H, Hc), 7.56 - 7.50 (m, H, He), 7.43 (d, Hg, 2H, 3J(Hg-Hh) 8.8 
Hz), 3.97 (s, Hk, 3H), 3.81 (s, Hj, 3H). FT-IR: 1581 cm-1 (C=Nimine, C=Npyr, C=Npyrim). 
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2.4.3 Synthesis of N-(5,6-dimethoxypyrimidin-4-yl)-4-((isoquinolin-3-yl 
methylene)amino)benzenesulfonamide (L3) 
 
 
Sulfadoxine (50.0 mg, 0.161 mmol) was suspended in toluene (3.00 mL) in a microwave vial (10.0 
mL) and 2-quinolinecarboxaldehyde (30.4 mg, 0.193 mmol) was added. The vial was then placed 
in the microwave reactor (200 °C, 250 W, 3 h). The solution was cooled, and the solvent removed. 
It was then stirred in ether overnight to remove any excess aldehyde, thereafter it was dried under 
high vacuum for 4 hours and a crude yield of 31.1 mg was obtained. 1H NMR (400 MHz, CDCl3) δ 
8.72 (s, Hg, 1H), 8.32 - 8.28 (m, Hf and He, 2H), 8.22 (d, Hh, 2H, 3J(Hh-Hi) 8.6 Hz), 8.19 (s, Hj, 1H), 
8.16 (m, Ha, 1H), 7.91 - 7.87 (m, Hd, 1H), 7.79 (t, Hc, 1H, 3J(Hc-Hb,d) 7.5 Hz), 7.64 (t, Hb, 1H, 3J(Hb-
Hc,a) 7.5 Hz), 7.37 (d, Hi, 2H, 3J(Hi-Hh) 8.6 Hz), 3.99 (s, Hl, 3H), 3.88 (s, Hk, 3H). FT-IR: (C=Nimine, 
C=Npyr, C=Npyrim) 1580 cm-1.   
2.4.4 Synthesis of (2,3,4,5-tetramethylcyclopenta-1,3-dien-1-yl) benzene 
(HCpxPh)24 
 
2,3,4,5-tetramethyl-2-cyclopentenone (2.73 mL, 18.1 mmol) was added to freshly distilled THF (25.0 
mL). Phenyl magnesium bromide (23.5 mL ,1 M in THF, 23.5 mmol.) was added to this solution 
dropwise over 10 min and the reaction was heated under reflux (67.0 °C, 3 h) thereafter, while under 
positive pressure of argon. The reaction was cooled to 0 °C and quenched with HCl (25.0 mL, 1 M), 
stirring for a further 1 hour while allowing it to warm to room temperature. The mixture was diluted 
with ether (40.0 mL) and washed with distilled water (3 x 30.0 mL) and dried over MgSO4. It was 
then filtered, and the solvent removed to yield 3.50 g of a light pale-yellow liquid. This was dry loaded 
onto a column (220 - 440, approx. 24.0 g, hexane) and a pale-yellow liquid was obtained in 67% 
yield. 1H NMR (400 MHz, Acetone-d6) δ 7.35 (t, Hg, 2H, 3J(Hg-Hf,h) 7.4 Hz), 7.26 (dd, Hf, 2H, 3J(Hf-Hg) 8.3 
Hz, 4J(Hf-Hh) 1.3 Hz), 7.18 (tt, Hh, 1H, 3J(Hh-Hg) 7.4 Hz, 4J(Hh-Hf) 1.3 Hz), 3.22 (quartet of septets, He, 1H, 
3J(He-Hc) 7.6 Hz, 4J(He-Hb,d) 1.7 Hz), 2.00 (s, Hd, 3H), 1.92 (s, Ha, 3H), 1.85 (s, Hb, 3H), 0.92 (d, Hc, 3H, 
3J(Hc-He) 7.6 Hz). 
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2.4.5 General synthesis of the Schiff base complexes 
The respective Iridium chlorido dimer was stirred in MeOH for 2 minutes after which the crude ligand 
(L1 or L3) was added and the solution stirred at room temperature for 24 hours. Thereafter, NH4PF6 
was added and the solution stirred for a further 2 hours. The solvent was then removed and the 
crude residue redissolved in acetone and then filtered through a plug of Celite™ to remove the 
ammonium chloride that precipitated out. The crude residue was recrystallised from an appropriate 
solvent system and in the cases of C4 and C5, column chromatography was employed thereafter. 
2.4.6 Synthesis of [IrCl(C18H17N5O4S)(C10H15)PF6] (C1)  
 
Di-µ-chlorido(bis(chlorido(pentamethyl-η5-cyclopentadienyl))iridium(III)) (200 mg, 0.250 mmol),  
crude L1 (200 mg, 0.500 mmol) and NH4PF6 (81.6 mg, 0.500 mmol) was reacted in MeOH (35.0 mL) 
and recrystallised from MeOH/ether to give an orange microcrystalline powder in 82% yield (372 
mg). 1H NMR (400 MHz, Acetone-d6) δ 9.88 (broad singlet, NH (Hi)), 9.49 (s, Hf, 1H), 9.22 (d, He, 
1H, 3J(He-Hd) 5.4 Hz) 8.56 (d, Hb, 1H, 3J(Hb-Hc) 7.4 Hz), 8.43(t, Hd, 1H, 3J(Hd-Hc,e) 7.3 Hz), 8.37 (d, Hh, 2H, 
3J(Hh-Hg) 8.8 Hz), 8.11 (s, Hj, 1H), 8.05 (t, Hc, 1H, 3J(Hc-Hd,b) 7.3 Hz) , 7.97 (d, Hg, 2H, 3J(Hg-Hh) 8.8 Hz), 
3.98 (s, Hl, 3H), 3.83 (s, Hk, 3H), 1.52 (s, Ha, 15H). FT-IR: 1579 cm-1 (C=Nimine, C=Nquin, C=Npyrim), 
1338 cm-1 (SO2)As, 1168 cm-1 (SO2)Sym, 1079 cm-1 (C-O), 840 cm-1 (PF6). HPLC purity: 97.0%; tr’ = 
12.97 min. 
2.4.7 Synthesis of [IrCl(C18H17N5O4S)(C15H17)PF6] (C2)  
 
Di-µ-chlorido(bis(chlorido(tetramethyl-η5-cyclopentadienylbenzene))iridium(III))  (50.0 mg, 0.0626 
mmol), crude L1 (50.0 mg, 0.125 mmol) and NH4PF6 (20.4 mg, 0.125 mmol) was reacted in MeOH 
(5.00 mL) and recrystallised from acetone/hexane to give a microcrystalline red powder isolated in 
72% yield (80.1 mg).  1H NMR (300 MHz, Acetone-d6) δ 9.89 (broad peak, NH), 9.54 (s, Hf, 1H), 8.83 
(d, He, 1H, 3J(He-Hd) 5.6 Hz), 8.61 (d, Hb, 1H, 3J(Hb-Hc) 7.6 Hz), 8.41 (t, Hc, 1H, 3J(Hc-Hb,d) 7.6 Hz) , 8.32 
(d, Hh, 2H, 3J(Hh-Hg) 8.1 Hz), 8.09 (s, Hj, 1H), 7.88-7.97 (m, Hd and Hg, 3H), 7.42-7.57 (m, Hi, 5H), 3.99 
(s, Hl, 3H), 3.83 (s, Hk, 3H), 1.76 (s, Ha, 3H), 1.63 (s, Ha, 3H), 1.44 (s, Ha, 3H), 1.32 (s, Ha, 3H). FT-
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IR: 1578 cm-1 (C=Nimine, C=Nquin, C=Npyrim), 1334 cm-1 (SO2)As, 1165 cm-1 (SO2)Sym, 1077 cm-1 (C-O), 
832 cm-1 (PF6). HPLC purity: 98.4%; tr’ = 16.51 min. 
2.4.8 Synthesis of [IrCl(C18H17N5O4S)(C21H21)PF6] (C3)  
 
Di-µ-chlorido(bis(chlorido(4-(tetramethyl-η5-cyclopentadienyl)-1,1’-biphenyl))iridium(III)) (47.3 mg, 
0.0440 mmol), crude L1 (88.0 mg (40% pure), 0.0880 mmol) and NH4PF6 (14.4 mg, 0.0880 mmol) 
was reacted in MeOH (5.00 mL) and recrystallized from acetone/ether to give a red crystalline solid 
in 72% yield (66.0 mg). 1H NMR (400 MHz, Acetone-d6) δ 9.90 (broad peak, NH), 9.56 (s, Hf, 1H), 
8.88 (d, He, 1H, 3J(He-Hd) 5.6 Hz), 8.62 (d, Hb, 1H, 3J(Hb-Hc) 7.8 Hz), 8.42 (t, Hc, 1H, 3J(Hc-Hb,d) 7.8 Hz) , 
8.33 (d, Hh, 2H, 3J(Hh-Hg) 8.8 Hz), 8.08 (s, Hj, 1H), 7.98-7.91 (m, Hd and Hg, 3H), 7.82-7.71 (m, Hi and 
Hn, 4H), 7.65 (d, Hm, 2H, 3J(Hm-Hi) 8.5 Hz), 7.56 - 7.40 (m, Ho and Hp, 3H), 3.99 (s, Hl, 3H), 3.82 (s, 
Hk, 3H), 1.82 (s, Ha, 3H), 1.65 (s, Ha, 3H), 1.50 (s, Ha, 3H), 1.32 (s, Ha, 3H). FT-IR: 1581 cm-1, 1617 
cm-1 (C=Nimine, C=Nquin, C=Npyrim), 1336 cm-1 (SO2)As, 1166 cm-1 (SO2)Sym, 1082 cm-1 (C-O), 
842 cm-1 (PF6), 557 cm-1 (PF6). HPLC purity: 98.4%; tr’ = 20.73 min. 
2.4.9 Synthesis of [IrCl(C22H21N5O4S)(C10H15)PF6] (C4) 
 
Di-µ-chlorido(bis(chlorido(pentamethyl-η5-cyclopentadienyl))iridium(III)) (18.4 mg, 0.0230 mmol), 
crude L3 (52.0 mg (40% pure), 0.0460 mmol) and NH4PF6 (7.50 mg, 0.046 mmol) was reacted in 
MeOH (5.00 mL) and recrystallised from DCM/Hexane. A dark oily residue was isolated which was 
recrystallised two more times before it was purified using column chromatography (220 - 440, 
approx. 35 g, 2% MeOH/DCM) to give a dark brown powder in 40% yield (17.6 mg). 1H NMR (400 
MHz, CDCl3) δ 9.26 (s, Hg, 1H), 8.56 (d, Hd, 1H, 3J(Hd-He) 8.3 Hz), 8.50 (d, Hf, 1H, 3J(Hf-Ha) 8.8 Hz), 8.42 
(d, Hd, 1H, 3J(Hd-He) 8.3 Hz), 8.35 (d, Hi, 2H, 3J(Hi-Hh) 8.8 Hz), 8.21 (d, Hh, 2H, 3J(Hh-Hi) 8.8 Hz), 8.13 (s, 
Hj, 1H), 8.08 (d, Hc, 1H, 3J(Hc-Hb) 8.0 Hz), 7.95 (t, Ha, 1H, 3J(Ha-Hf) 7.6 Hz), 7.88 (t, Hb, 1H, 3J(Hb-Hc) 8.0 
Hz), 3.99 (s, Hl, 3H), 3.92 (s, Hk, 3H), 1.38 (s, Hm, 15H).  FT-IR: 1582 cm-1 (C=Nimine, C=Nquin, 
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C=Npyrim), 1338 cm-1 (SO2)As, 1167 cm-1 (SO2)Sym, 1083 cm-1 (C-O), 844 cm-1 (PF6), 558 cm-1 (PF6). 
HPLC purity: 98.1%; tr’ = 15.53 min. 
2.4.10 Synthesis of [IrCl(C22H21N5O4S)(C15H17)PF6] (C5) 
 
Di-µ-chlorido(bis(chlorido(tetramethyl-η5-cyclopentadienylbenzene))iridium(III))  (50.0 mg, 0.0543 
mmol), crude L3 (97.6 mg (50% pure), 0.109 mmol) and NH4PF6 (17.7 mg, 0.109 mmol) was reacted 
in MeOH (5.00 mL) and then recrystallized from Acetone/Hexane. The crude brown solid was then 
columned (220 - 440, approx. 35 g, 2% MeOH/DCM) to give a crude dark brown powder, which was 
stirred with NH4PF6 (17.7 mg, 0.109 mmol) in MeOH (5.00 mL) and recrystallised from DCM/Hexane 
resulting in 60.0 mg of a crude brown solid. 1H NMR (400 MHz, CDCl3) δ 10.29 (s, Hg, 1H), 8.96 (d, 
Hd, 1H, 3J(Hd-He) 8.5 Hz), 8.47 (d, Hf, 1H, 3J(Hf-Ha) 8.1 Hz), 8.43 - 8.37 (m, Hi, 2H), 8.30 (d, He, 1H, 3J(He-
Hd) 8.5 Hz), 8.28 - 8.23 (m, Hh, 2H), 8.11 (s, Hj, 1H), 7.95 (d, Hc, 1H, 3J(Hc-Hb) 8.1 Hz), 7.66 (m, Ha/b, 
1H), 7.57 - 7.38 (m, Hn,o,p, 5H), 7.27 - 7.22 (m, Ha/b, 1H), 3.98 (s, Hl, 3H), 3.88 (s, Hk, 3H), 1.73 (s, 
Hm, 3H), 1.57 (s, Hm, 3H), 1.30 (s, Hm, 3H), 1.15 (s, Hm, 3H). FT-IR: 1581 cm-1 1620 cm-1 (C=Nimine, 
C=Nquin, C=Npyrim), 1337 cm-1 (SO2)As, 1164 cm-1 (SO2)Sym, 1082 cm-1 (C-O), 844 cm-1 (PF6), 558 cm-
1 (PF6). HPLC purity: 87.7%; tr’ = 18.63 min. 
2.4.11 Synthesis of [IrCl(C22H21N5O4S)(C21H21)PF6] (C6) 
 
Di-µ-chlorido(bis(chlorido(4-(tetramethyl-η5-cyclopentadienyl)-1,1’-biphenyl))iridium(III)) (50.0 mg, 
0.0466 mmol), crude L3 (83.8 mg (50% pure), 0.0932 mmol) and NH4PF6 (15.2 mg, 0.0932 mmol) 
was reacted in MeOH (5.00 mL) and then recrystallized from acetone/ether 5 times to obtain a dark 
brown powder in 10% yield (10.2 mg).  1H NMR (300 MHz, Acetone-d6) δ 9.86 (s, Hg, 1H), 8.98 (d, 
Hd, 1H, 3J(Hd-He) 8.3 Hz), 8.63 (d, He, 1H, 3J(He-Hd) 8.3 Hz), 8.49 (d, Hf, 1H, 3J(Hf-Ha) 8.8 Hz), 8.36 (m, Hh, 
2H), 8.30 (d, Hc, 1H, 3J(Hc-Hb) 8.3 Hz), 8.15 (m, Hi, 2H), 8.10 (s, Hj, 1H), 7.94 - 7.88 (m, Ha/b, 1H), 7.78 
- 7.72 (m, Hn,o,a/b, 5H), 7.65 - 7.60 (m, Hp, 2H), 7.55 - 7.43 (m, Hq,r, 3H), 3.98 (s, Hl, 3H), 3.83 (s, Hk, 
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3H), 1.77 (s, Hm, 3H), 1.58 (s, Hm, 3H), 1.38 (s, Hm, 3H), 1.33 (s, Hm, 3H). FT-IR: 1582 cm-1, 1620 
cm-1 (C=Nimine, C=Nquin, C=Npyrim), 1338 cm-1 (SO2)As, 1166 cm-1 (SO2)Sym, 1082 cm-1 (C-O), 
843 cm-1 (PF6), 558 cm-1 (PF6). HPLC purity: 96.9%; tr’ = 22.39 min. 
2.4.12 HPLC method and purity determination 
Purity measurements by HPLC were carried out using the Agilent 1220 system with a DAD and 100 
µL loop. The column used was a Kinetex® 5 µm C18 100 Å, 150 x 4.6 mm with a 5 µm pore size. 
The mobile phase was H2O 0.1% TFA/MeCN 0.1% TFA at gradients of t=0 min 10% B, t=30 min 
80% B, t=40 min 80% B, t=41 min 10% B, and t=55 min 10% B over a 55 min period. The flow rate 
was 1 mL min-1, and the detection wavelength was set at 254 nm and 400 nm with the reference 
wavelength at 360 nm. Samples were dissolved in 10% MeCN/90% H2O at ca. 100 µM. Sample 
injections were half the loop volume (50 µL) with needle washes of MeCN and H2O between 
injections. It was assumed that all species in a sample have the same extinction coefficient at 254 
nm and 400 nm. All peaks were manually integrated. 
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Chapter 3  
Synthesis and characterisation of pyridyl and quinolyl amido 
iridium half-sandwich complexes 
 
3.1 Introduction 
The amide functional group is widely found in the natural environment and the human world and has 
found a great variety of applications in both areas. This is illustrated by its incredible importance in 
proteins as it is peptide linkages which are essentially the backbone of proteins and influence the 
secondary structure of these proteins through its hydrogen bonding interactions.1,2 Proteins are 
fundamental to many physiological processes and we could not exist without them. Furthermore, 
upon polymerisation to form polyamides many useful products such as nylon can be obtained which 
consists of chains of carbon atoms linked together through amide bonds.1,3,4 When the amide bonds 
link together benzene rings instead of aliphatic carbon chains then Kevlar is formed which has been 
extremely important in the production of body armour, bicycle tyres and sails to name but a few of 
its applications.1 The functional group consists primarily of a nitrogen atom bonded to a carbonyl 
group in a planar fashion due to the resonance between the lone pair of the nitrogen and that of the 
carbonyl double bond.1,3 Amides are primarily formed from their parent carboxylic acids and free 
amines by means of a condensation reaction after the acid has been activated, though there are a 
wide variety of other methods to obtain the functionality.1,3–6 Amides also have a wide variety of 
medicinal applications and are found in many useful drugs such as paracetamol and penicillin. It is 
estimated that at least a single amide bond is present in more than 25% of all drugs.1,2 
Given the relevance of the amido functionality as a potential potent pharmacophore against a variety 
of diseases it was decided to incorporate it as part of the sulfonamide derivatives that were being 
investigated. This was especially favoured in light of the equilibrium nature of the imine systems that 
had thus far been investigated and had posed significant hurdles in their synthesis and purification. 
In addition, several amide metal complexes have exhibited promising antimicrobial7,8  and 
antiproliferative9,10 activity, further prompting the synthesis and testing of the metal complexes of our 
derivatives in the hope that the metal complexes may prove effective against other diseases as well. 
3.2 Results and Discussion 
3.2.1 Synthesis and characterisation of the amido-sulfadoxine ligands, L4 and 
L5  
There are many ways that amides can be synthesized and various coupling agents can be employed 
when attempting these reactions.11 One of the most commonly used methods was chosen and 
involved the generation of an acid chloride followed by the subsequent substitution with the primary 
amine of sulfadoxine. The specific methodology used in this case was adapted from three different 
sources.12–14 The acid chloride was generated in situ from the parent acid (2-picolinic acid or 
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quinaldic acid) using oxalyl chloride and a catalytic amount of DMF as this method was envisioned 
to produce the least number of by-products, namely only carbon monoxide and carbon dioxide. 
Several literature methods15–22 used triethylamine to neutralise or limit the quantity of free HCl that 
is formed upon substitution with a free amine, however, it was a point of concern that this base, 
though weak, might be able to deprotonate the sulfonamide NH and thus potentially cause the 
reaction to fail or greatly impact the yield. A test reaction was thus carried out and sulfadoxine was 
stirred with two equivalents of triethylamine under the same conditions of the reaction procedure that 
would be followed. Thereafter, an extraction with water was done and both the organic and water 
layers analysed to see which layer sulfadoxine was in. Only the water layer contained sulfadoxine, 
which confirmed the earlier hypothesis that triethylamine would not only neutralise the HCl but could 
also affect the starting material.  
The base was initially left out, however after seeing no significant change in the TLC after 24 hours 
it was decided to add a weaker base such as pyridine. Likely due to the late stage that the base was 
added there was still no reaction seen. The low solubility of sulfadoxine in DCM could also have 
contributed to the absence of a reaction. After workup only starting material was obtained, thus the 
reaction was reattempted with the weaker base from the beginning while simultaneously changing 
the solvent in the quenching step to acetonitrile in which sulfadoxine is significantly more soluble. 
The general method for the reaction is shown in Scheme 3.1. 
 
Scheme 3.1 - Generation of the required amido ligands, L4 and L5, via an acid chloride in moderate yields. 
Under these new conditions the reaction was successful as indicated by both its IR spectrum 
(Figure 3.1) and the 1H NMR spectrum (Figure 3.2). 
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Figure 3.1 - IR spectrum (KBr) of L4 illustrating the N-H stretches clearly. 
The IR spectrum of L4 (Figure 3.1) shows the amide N-H stretch at 3339 cm-1 with the sulfonamide 
N-H stretch appearing at 3165 cm-1, with a slightly lower frequency as compared to sulfadoxine, 
indicating a slight weakening of the N-H bond induced by the increased electron withdrawing 
character of the aromatic moiety introduced. The carbonyl stretch appears at 1681 cm-1 previously 
seen in the acid as a very broad signal at 1720 cm-1.  
The  1H NMR (Figure 3.2) shows the two NH protons at 10.27 ppm (amide) and 7.82 ppm 
(sulfonamide) with the proton ortho to the nitrogen of the pyridyl ring appearing at 8.62 ppm. This 
ligand, nor its quinolyl analogue, had been synthesized before, thus their 13C NMR and MS spectra 
were also obtained.  
The 13C NMR is shown in Figure 3.3 and all seven of the quaternary carbons for L4 are seen, with 
the amide carbon identified as the most deshielded at 162.35 ppm. The methoxy CH3 carbons are 
also readily identified at 60.57 ppm and 54.15 ppm, respectively. The phenylene CH carbons overlap 
due to symmetry resulting in two signals instead of four. Overall, only six signals are observed 
instead of the expected seven for the CH carbon signals.  
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Figure 3.2 - 1H NMR of L4 in CDCl3. 
 
Figure 3.3 - 13C NMR of L4 in CDCl3. 
 
 
 
 
 
p 
SO2NH 
 
m 
h, b n, c 
j 
i 
j 
i 
k 
b, c 
CONH 
Stellenbosch University https://scholar.sun.ac.za
54 
 
This means, given that all other characterisation data shows that the structure of the compound is 
correct, that two other CH signals overlap due to the similarity of their environment. Alternatively, a 
third CH signal could overlap with one of the phenylene groups, which could explain the difference 
in intensity between the two signals which are hypothesized to appear at 129.98 ppm and 118.99 
ppm due to their higher intensity. Signal magnitude is related to the number of carbons contributing 
to a signal, though not as clearly as in proton NMR unless rigorous measures are taken so that 
quantitative carbon analysis is possible. Both the [M + H]+ ion and the [M + Na]+ ion are seen at 
416.1023 m/z and 438.0841 m/z, respectively, where 416.1023 m/z is the base peak. This coincides 
well with the molecular weight of L4, which is 415.42 g/mol. 
Crystals of L4 were obtained by layering a DCM solution of L4 with hexane and leaving to stand in 
a sealed vial for several days at room temperature. The crystal structure for L4 is shown in Figure 3.4 
below. 
 
Figure 3.4 - Molecular structure of L4 with atom labelling. ORTEP thermal ellipsoids are drawn at 50% 
probability level. Hydrogen atoms have been omitted for clarity. 
The needle like crystals were transparent and crystallised in the triclinic space group, P1 . Selected 
bond lengths and angles are given in Table 3.1 and general crystal data are shown in Table 3.2. The 
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bond lengths and angles of the sulfonamide group are generally similar to those found in 
literature.23,24 The majority of the sulfonamide angles conform to the traditional angles expected for 
tetrahedral geometry which lie in the region of 109.5 °. The N3-S1-C10 and N3-S1-O3 angles are 
slightly smaller at 103.45 ° and 105.71 °, respectively. This is due to both the double bond character 
of the S=O bonds and the two lone pairs on each oxygen atom which causes a greater repulsion 
between them increasing the O3-S1-O2 bond angle to 119.55 ° which in turn pushes the other atoms 
closer together. The sulfonamide nitrogens expected bond angles should be close to 120 ° due to 
the interaction with the pi orbitals of the adjacent pyrimidine ring which shift its character more 
towards sp2 hybridisation; this is also seen in the relatively shorter bond length of 1.396 Å of the N3-
C13 bond.25 The tetrahedral geometry of the sulfur, however, influences these bond angles resulting 
in a H-N3-S1 angle closer to tetrahedral geometry at 110.2 °. This results in a much larger S1-N3-
C13 angle of 125.5 °. The electron density of the N2 nitrogen of the amide group can conjugate with 
both the adjacent phenylene ring and the carbonyl group resulting in a near trigonal planar geometry 
with expected bond angles close to 120 °. The N2-C6 bond is 1.358 Å, even shorter than the previous 
example for the sulfonamide nitrogen. Due to the greater repulsion experienced between carbon - 
carbon atoms as compared to carbon – hydrogen atoms the C7-N2-C6 bond angle is larger at 
126.9 ° than the two subsequent angles with the hydrogen atom.  
 
Hydrogen bonding interactions through both the sulfonamide and amide moieties to each other 
stabilise the crystal packing and are shown in Figure 3.5 as dotted lines. Individual molecules act as 
both donors and acceptors from the oxygen and nitrogen of the functional groups mentioned and the 
hydrogen bonding interactions cause the molecules to pack along the a axis. The hydrogen bond 
between the sulfonamide oxygen and the amide nitrogen is 2.360 Å in length while that between the 
amide oxygen and sulfonamide nitrogen is slightly shorter, being 2.105 Å in length. 
Table 3.1 - Selected bond lengths and angles of L4 
At1 At2 
Length 
(Å) 
 At1 At2 At3 Angle (°)  At1 At2 At3 At4 
Torsion 
(°) 
N2 C6 1.358(2)  O3 S1 O2 119.55(9)  C4 C5 C6 N2 -166.8(2) 
O1 C6 1.230(2)  O3 S1 N3 103.45(9)  C6 N2 C7 C8 21.6(3) 
C7 N2 1.407(3)  O3 S1 C10 108.58(9)  S1 N3 C13 N5 -13.1(3) 
C6 C5 1.501(3)  O2 S1 N3 109.32(9)  N3 S1 C10 C11 105.9(2) 
C10 S1 1.761(2)  O2 S1 C10 109.29(9)       
S1 O3 1.434(1)  N3 S1 C10 105.71(9)       
S1 O2 1.429(1)  C7 N2 C6 126.9(2)       
S1 N3 1.649(2)  C7 N2 H5 117(2)       
N3 C13 1.396(2)  C6 N2 H5 116(2)       
O5 C15 1.339(3)  S1 N3 C13 125.5(1)       
C14 O4 1.372(2)  S1 N3 H6 110(2)       
H6 N3 0.84(2)  C13 N3 H6 118(2)       
H5 N2 0.84(3)            
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 There are also parallel-displaced pi stacking interactions between the phenylene and pyridyl rings, 
as well as what appears to be T-shaped stacking interactions between the pyrimidine and pyridyl 
rings.26,27 The aromatic rings involved in the parallel-displaced stacking interactions are at a slight 
angle so as to maximise the individual interactions possible for each molecule within the cluster, as 
illustrated in Figure 3.5.27 This results in four molecules that are at slight angles to each other to 
facilitate these stabilising interactions within the cluster and is also likely why the phenylene and 
pyridyl rings are not parallel but slightly twisted. The angle between the planes of the two rings can 
be estimated by examining two sets of torsion angles between them, one representing the phenylene 
plane and the other representing the pyridyl plane, the sum of which give you the angle between the 
planes of the ring. This method must be applied as the planes are not directly adjacent to each other. 
Doing this for the torsion angles of C4-C5-C6-N2 and C6-N2-C7-C8, the angle of the twist between 
the plane of the phenylene and pyridyl rings is 34.8 °. The angle between the plane of the pyrimidine 
ring and the phenylene ring, using torsion angles S1-N3-C13-N5 and N3-S1-C10-C11, is found to 
be 92.8 °. A visual confirmation of the geometry shown in Figure 3.5, ascertains that the estimate is 
close. 
 
Figure 3.5 - Packing of L4 demonstrating the favourable twisting of the aromatic rings to incorporate the 
maximum number of individual interactions within the cluster. 
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Table 3.2 - Crystal data and structure refinement for L4. 
Identification code  L4 
Empirical formula  C18H17N5O5S 
Formula weight  415.42 
Temperature (K)  100(2) 
Wavelength (Å)  0.71073 
Crystal system  triclinic 
Space group  P-1 
Unit cell dimensions (Å, °) a = 8.319(2)   =  109.559(4) 
 b = 10.194(3)  =  100.736(4) 
 c = 12.280(3)  =  103.451(4) 
Volume (Å) 913.9(4) 
Z  2 
Calculated density (g cm-3) 1.510 
Absorption coefficient (mm-1) 0.221 
F000 432 
Crystal size (mm3) 0.118  0.073  0.048 
 range for data collection () 1.838 to 27.572 
Miller index ranges -10  h  10, -13  k  13, -15  l  15 
Reflections collected 24537 
Independent reflections 4207 [Rint = 0.0496] 
Completeness to max (%) 0.998 
Max. and min. transmission 0.9354 and 1.000 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4207 / 0 / 272 
Goodness-of-fit on F2 1.045 
Final R indices [I2(I)] R1 = 0.0402, wR2 = 0.0970 
R indices (all data) R1 = 0.0512, wR2 = 0.1028 
Largest diff. peak and hole (e Å-3) 0.508 and -0.443 
 
The synthesis of L5 was completed in a similar fashion to L4, however, during the optimisation of 
the reaction it was found that an increase in time for both the generation of the acid chloride and the 
subsequent quenching with sulfadoxine gave an improvement in the yield. Furthermore, the workup 
required adjusting as the compound was remaining on the magnesium sulfate, as such, washing 
with brine was employed in the drying of the organic layer instead. The synthetic procedure and 
characterisation data for L5 was similar to L4 in all other respects, thus only one set of data has 
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been discussed in detail above. Detailed characterisation information can be found in the 
experimental section. 
3.2.2 Synthesis of the iridium (III) amido complexes (C7 – C12) 
Chelating the ligand to the metal centre via the nitrogens of the amide and pyridyl functionalities 
requires a base to remove the proton of the amide. Previously it had been hypothesized that the 
competing acidic NH of the sulfonamide was preventing the complexation from being a success 
when the N, O ligands were being investigated. In this case it was hoped that the softer donor atom 
and the longer reaction time would favour the formation of the complex. The complexation was thus 
attempted with L4 using triethylamine as base while being stirred overnight at room temperature in 
the presence of di-µ-chlorido(bis(chlorido(pentamethyl-η5-cyclopentadienyl))iridium(III)).  
Characterisation data showed that C7 (Scheme 3.2), the Cp* pyridyl amido complex had successfully 
been isolated, however, given the low yield of this reaction it is likely that the sulfonamide moiety 
was still largely competing for the base and complexation at the desired site was not as favourable 
as hoped. Having nonetheless established the success of this method it was decided to search for 
an alternative route as the current method suffered not only from low yield but also from long reaction 
times. A microwave protocol28 was found in literature and proved significantly more successful, giving 
yields of up to 84% as compared to the previous 10% - 20% that had been achieved. The specific 
conditions are detailed below. 
The ligand, L4, was combined with di-µ-chlorido(bis(chlorido(pentamethyl-η5-
cyclopentadienyl))iridium(III)) and sodium bicarbonate in methanol and subjected to microwave 
irradiation for 10 min at 150 °C, resulting in a canary yellow powder in good yield of 84% with 
characterisation data confirming that the same complex was made (C7). Having obtained a method 
which was both significantly faster and gave a higher yield, the remaining complexes were also made 
via this method using the relevant ligand and chlorido iridium dimer. The general synthetic procedure 
for the complexes is shown in Scheme 3.2. 
 
Scheme 3.2 - General synthetic procedure for the complexes C7 - C12. 
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The infrared spectra for all the complexes in this series along with their NMR had few differences 
due to the changing electron density on the metal centre and as such a representative example has 
been discussed in detail below with any notable changes or differences specifically mentioned.  
The IR spectrum of C7 (Figure 3.6) shows a large shift in the carbonyl signal from 1681 cm-1 in the 
ligand (L4) to 1621 cm-1 with the signal for the NH stretch of the amide disappearing from 3339 cm-1. 
Furthermore, the C=N stretch of the pyridine ring shifts from the region of 1584 cm-1 to 1603 cm-1. 
These shifts are indicative of coordination through the nitrogens of the pyridyl ring and that of the 
amide resulting in the strengthening and weakening of the bonds, respectively.28,29 This indicates 
that metalation has occurred at the desired site. The signal at 1525 cm-1 in the ligand, which is only 
present for the amido ligands also disappears and could be attributed to the amide N-H bend which 
would disappear upon complexation as was the case for the N-H stretch. As the electronegativity of 
the metal centre increases within the series there is a slight general shift to higher frequencies. In 
particular, the quinolyl C=N stretch combines with the C=O stretch to form a broad band from which 
they cannot be separately identified.  
 
Figure 3.6 - FTIR spectrum of C7, the pyridyl amido Cp* complex. 
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Figure 3.7 - 1H NMR spectrum of C7 in CDCl3. 
The successful formation of the complex is further confirmed through 1H NMR by the disappearance 
of the amide NH. The spectrum is shown in Figure 3.7. The shifts in the spectrum upon complexation 
are not large, with the proton attached ortho to the nitrogen of the pyridyl ring seen to shift from 8.62 
ppm to 8.58 ppm and similar sized shifts for protons e, f and g of the pyridyl ring (Figure 3.7). The 
protons for the methyls of the Cp* ring are seen at 1.38 ppm. Most of the protons are also seen to 
shift upfield, most likely due to the electron rich character of the metal centre which more effectively 
shields them. All complexes aside from those formed from the Cp* iridium dichloride dimer show 
separate methyl peaks for the coordinating Cpx moiety. This is the result of the inequivalence 
introduced by the attached phenyl or biphenyl ring along with the chirality of the metal centre. As the 
Cpx moiety is extended the addition of the new multiplets from the added phenyl rings appear 
between 7.3 ppm and 7.7 ppm. 
As discussed in the 13C NMR of L4, the phenylene carbons overlap in the complexes due to the 
symmetry involved.30,31 There are also two other CH carbon signals that overlap to only give one 
observed signal as was mentioned for the ligand. The quaternary carbons of the Cpx ring appear as 
one signal in C7 and C10 (the Cp* complexes) but, are seen separately for complexes C8, C9, C11 
and C12 for the same reasons as discussed for the methyl protons of these complexes in the 1H 
NMR spectrum. A representative spectrum for the series is shown in Figure 3.8. 
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Figure 3.8 - 13NMR in DMSO-d6 of C12, with the insert magnifying the region between 122 ppm and 134 ppm. 
The MS spectra for the complexes did not give the expected [M+H]+ ions as the base peak, but 
rather, the base peak was the [M – Cl]+ ion. The [M+H]+ ion was still observable though, especially 
under softer ionisation conditions. Detailed results are given in the experimental section. 
Instead of having N, N coordination it is possible that coordination occurs through the oxygen of the 
carbonyl to form a N, O system instead. The disappearance of the hydrogen on the amide does not 
provide any significant insight into the coordination mode as the subsequent ketoxime could have 
formed in which case the hydrogen would still be missing. Literature indicates that the current 
complexes should coordinate through both nitrogens.28,32 To confirm exactly in which manner 
coordination takes place on these systems, however, it is necessary to look for metal to nitrogen or 
metal to oxygen bands in the far IR region with FTIR or RAMAN spectroscopy or through obtaining 
a crystal structure.33,34 Unfortunately, despite many attempts only microcrystalline powders were 
obtained and thus single-crystal X-ray diffraction could not be used to confirm the coordination mode. 
The far IR region was thus investigated for both L5 and C10 as examples by pressing a pellet of 
caesium iodide which does not absorb in this region as potassium bromide is not adequate for 
analysis past 400 cm-1. The region analysed was between 200 cm-1 – 600 cm-1 to provide sufficient 
overlap with the mid IR region and confirm reproducibility between beam splitters and detectors. 
Comparing both the far-IR spectra of L5 and C10 with their respective mid-IR spectra gave good 
overlap between 600 cm-1 and 400 cm-1 confirming the reproducibility of analysing the two different 
t, s f’, g’, h’, i’ 
a’, b’, c’, 
d’, e’ 
j 
 
C12 
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regions. This was seen particularly for the signals at 583 cm-1 and 561 cm-1. The spectra of the 
compounds showing the overlap are shown in Figures 3.9 and 3.10, with Figure 3.11 showing the 
far-IR spectrum of L5 and C10 in comparison with one another.  
 
Figure 3.9 - A comparison of the mid-IR (top, red) region of L5 with that of the far-IR (bottom, blue) region with 
spectra displayed as absorbance data. 
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Figure 3.10 - A comparison of the mid-IR (top, red) region of C10 with that of the far-IR (bottom, blue) region 
with spectra displayed as absorbance data. 
 
Figure 3.11 – A comparison of the Far-IR of C10 (top, red) and the Far-IR of L5 (bottom, blue) illustrating 
M - N bonds at 488 cm-1 and 452 cm-1. The spectra are displayed as absorbance data. 
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The far-IR spectrum of L5 (Figure 3.11, bottom) shows a new ligand band not previously seen at 
370 cm-1 which shifts to higher frequency in C10. Additionally, in the far-IR of C10 (Figure 3.11, top) 
the iridium-chloride band is now visible at 274 cm-1 and the two bands at 488 cm-1 and 452 cm-1 are 
proposed to be due to the iridium-nitrogen bonding through the amide and heterocyclic nitrogen of 
the quinolyl moiety, respectively. Their low intensity is a consequence of the small difference in dipole 
moment between the respective groups. Both their proximity to each other as well as their relatively 
low frequency would indicate that they are the metal-nitrogen bonding bands as metal-oxygen bands 
generally appear at slightly higher frequencies.35,36 Coordination takes place in this fashion for all the 
complexes, given their similarity. Although metal to oxygen bonds are fairly prevalent in complexes 
of amides, the presence of an anchor group in the form of a heterocyclic nitrogen37 and the borderline 
softer character of iridium along with the data is evidence enough to support the hypothesis of metal 
to nitrogen bonding in the current systems. The purity of all ligands and complexes was determined 
by HPLC to be between 94.6% and 98.9% 
3.3 Conclusion 
Two new ligands – amido pyridyl (L4) and quinolyl (L5) sulfadoxine derivatives, were successfully 
identified, synthesized and purified for the second library of complexes that was to be tested against 
Mtb and malaria. Both ligands gave moderate yields of 73% and 60%, respectively. A crystal 
structure was obtained for L4 and crystallised in the triclinic space group.  
Three complexes were subsequently synthesized from each of the ligands (C7 – C12), through a 
facile microwave reaction that was discovered in the literature after initial synthetic routes that gave 
low yields and employed long reaction times. The microwave method had short reaction times and 
gave moderate to excellent yields ranging between 56% and 84% yield. The successful synthesis of 
C7 – C12 was characterized by the disappearance of the amide NH signal in both the IR and 1H 
NMR spectra. Additionally, the phenylene carbons symmetrical to one another overlapped in the 
NMR spectra with an additional tertiary carbon signal overlapping with either one of the phenylene 
signals or another tertiary signal as there was consistently one less carbon signal than expected 
(taking symmetry into account) for both the ligands and the complexes. The MS spectra for the 
complexes generally gave the [M-Cl]+ ion, though the [M+H]+ ion could also be observed in the 
spectrum. Finally, it was determined that coordination of the iridium metal centre takes place 
between the nitrogen of the amide and of the quinolyl moiety with far-IR, Identifying the iridium-
nitrogen bands at 488 cm-1 and 452 cm-1, respectively. It was proposed that this is the coordination 
for all the complexes presented in this chapter. All compounds discussed in this chapter had not 
been made before as far as we are aware. 
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3.4 Experimental  
Chemicals and reagents. Sulfadoxine (95 %), 2-picolinic acid, quinaldic acid, salicylaldehyde, 2-
hydroxynapthaldehyde, oxalyl chloride (2M in DCM), pyridine, magnesium sulfate, sodium 
bicarbonate, 1,2,3,4,5-pentamethylcyclopentadiene, 2,3,4,5-tetramethyl-2-cyclopentenone, phenyl 
magnesium bromide solution in THF (1 M), IrCl3•nH2O, all reagent solvents and deuterated solvents 
(dimethylsulfoxide-d6 and chloroform-d1) were obtained from Sigma Aldrich (Merck). Di-µ-
chlorido(bis(chlorido(pentamethyl-η5-cyclopentadienyl))iridium(III)), di-µ-chlorido(bis(chlorido(tetra
methyl-η5-cyclopentadienylbenzene))iridium(III)) and di-µ-chlorido(bis(chlorido(4-(tetramethyl-η5-
cyclopentadienyl)-1,1’-biphenyl))iridium(III)) were synthesized according to a literature method.38 
Instrumentation.  IR spectroscopy was performed using a Thermo Nicolet Nexus 470 by means of 
potassium bromide pellets and transmission esp for mid-IR spectra and using caesium iodide pellets 
and transmission esp for far-IR spectra except when comparisons had to be drawn between the mid 
and far IR regions in which case caesium iodide was used for both spectra. NMR data (1H, 13C) were 
recorded on either a 300 MHz Varian VNMRS or a 400 MHz Varian Unity Inova spectrometer. 1H 
NMR chemical shifts are reported in ppm and coupling constants in Hertz and were internally 
referenced to dimethylsulfoxide-d6 (2.50 ppm) or chloroform-d1 (7.26 ppm). Data was processed 
using MestReNova 11.0.4-18998. Mass spectrometry was performed on a Waters Synapt G2 with 
an ESI probe in ESI Positive mode using a Cone Voltage of 15 V.  
Microwave syntheses were carried out in a CEM Discover SP microwave reactor. Uv-Vis data were 
recorded with a Shimadzu Uv - vis spectrophotometer. Solvents were removed in vacuo, using a 
rotary evaporator, followed by removal of trace amounts of the remaining solvent using a high 
vacuum pump at ca. 0.08 mm Hg. 
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3.4.1 Synthesis of N-(4-(N-(5,6-dimethoxypyrimidin-4-yl)sulfamoyl) phenyl) 
picolinamide (L4) 
 
2-Picolinic acid (516 mg, 4.19 mmol) was stirred in dry DCM (100 mL) under nitrogen. Oxalyl chloride 
(2 M in DCM, 2.42 mL, 4.83 mmol) was added to this solution while it was kept on ice after which a 
catalytic amount of DMF (100 µL) was added. The solution was stirred for 2 hours at 0 °C before the 
solvent was removed and the crude residue re-dissolved in acetonitrile (50.0 mL). Sulfadoxine (1.00 
g, 3.22 mmol) was then added dropwise (50.0 mL) over 5 min while the solution was kept on ice. 
Pyridine  (389 µL, 4.83 mmol) was then added and the solution stirred at 0 °C for 30 min before 
stirring a further 1.5 hours at room temperature. The purple precipitate formed was filtered off, 
washed with acetonitrile and kept aside. The solvent was removed from the filtrate and the crude 
residue re-dissolved in DCM (80.0 mL). This was washed with a solution of saturated sodium 
bicarbonate (3 x 30.0 mL) and the organic portions dried over MgSO4. The solvent was removed 
and the off-white powder was combined with the purple precipitate and recrystallised from DCM/Hex 
and then washed with acetonitrile to give a pure white powder in 73% yield (979 mg). 1H NMR (300 
MHz, CDCl3) δ 10.27 (s, HNH(C=O), 1H), 8.62 (d, Hp, 1H, 3J(Hp-Ho) 4.7 Hz), 8.29 (d, Hm, 1H, 3J(Hm-Hn) 7.8 
Hz), 8.20 - 8.14 (m, Hb,h, 3H), 7.97 - 7.90 (m, Hc,n, 3H), 7.82 (s, HNH(SO2), 1H), 7.55 - 7.49 (m, Ho, 1H), 
3.97 (s, Hj, 3H), 3.86 (s, Hi, 3H). 13C NMR (75 MHz, CDCl3) δ 162.35 (Ck), 160.84 (C), 149.74 (C), 
148.99 (C), 148.10 (CH), 142.29 (C), 137.89 (CH), 134.04 (C), 129.98 (Cb/c), 126.99 (CH), 126.46 
(C), 122.63 (CH), 118.99 (Cc/b), 60.57 (Cj), 54.15 (Ci). FT-IR (KBr): 1681 cm-1 (C=O), 1584 cm-1, 
1525 cm-1 (C=Npyr, C=Npyrim), 3339 cm-1, 3165 cm-1 (N-H). (+)-HR-ESI-MS: m/z (%) 416.1023 ([M + 
H]+, 100 %), 438.0841 ([M+Na]+, 5 %); HPLC purity: 97.4%; tr’ = 15.08 min. 
3.4.2 Synthesis of N-(4-(N-(5,6-dimethoxypyrimidin-4-yl)sulfamoyl)phenyl) 
quinoline-2-carboxamide (L5) 
 
Quinaldic acid (109 mg, 0.628 mmol) was stirred in dry DCM (15.0 mL) under nitrogen. Oxalyl 
chloride (2 M in DCM, 363 µL, 0.725 mmol) was added to this solution while it was kept on ice after 
which a catalytic amount of DMF (50.0 µL) was added. The solution was stirred for 5 hours at 0 °C 
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before the solvent was removed and the crude residue re-dissolved in acetonitrile (10.0 mL). 
Sulfadoxine (150 mg, 0.483 mmol) was then added dropwise (10.0 mL) over 5 min while the solution 
was kept on ice. Pyridine  (58.4 µL, 0.725 mmol) was then added and the solution stirred at 0 °C for 
30 min before stirring a further 2.5 hours at room temperature. The solvent was removed from the 
reaction mixture and the crude residue re-dissolved in DCM (20.0 mL) and washed with saturated 
sodium bicarbonate (3 X 10.0 mL), distilled water (3 X 10.0 mL) and brine (2 X 10.0 mL). After the 
washing with brine the solvent was removed and left to dry overnight on the high vacuum pump 
where-after it was re-dissolved in DCM and filtered through Celite™ to remove any residual NaCl. 
The crude powder was recrystallised from DCM/hexane (1:2) to give a pure off-white microcrystalline 
solid in 60% yield (134 mg). 1H NMR (400 MHz, CDCl3) δ 10.49 (s, HNHC=O, 1H), 8.42 - 8.36 (m, Hm,n, 
2H), 8.24 - 8.16 (m, Hh,b,r, 4H), 8.05 - 7.99 (d, Hc, 2H, 3J(Hc-Hb) 8.8 Hz), 7.96 - 7.91 (d, Ho, 1H, 3J(Ho-Hp) 
8.2 Hz), 7.87 - 7.81 (m, Hp, 1H), 7.81 - 7.77 (s, HNHSO2, 1H), 7.72 - 7.65 (m, Hq, 1H), 3.98 (s, Hi, 3H), 
3.87 (s, Hj, 3H). 13C NMR (101 MHz, CDCl3) δ 162.67 (Ck), 160.97 (C), 149.88 (C), 148.95 (C), 146.39 
(C), 142.48 (C), 138.30 (CH), 134.19 (C), 130.75 (CH), 130.18 (CH), 129.79 (CH), 129.77 (C), 
128.69 (CH), 128.03 (CH), 126.58 (C), 119.20 (Cc/b), 118.83 (CH), 60.72 (Cj), 54.30 (Ci). FT-IR (KBr): 
1679 cm-1 (C=O), 1577 cm-1, 1531 cm-1 (C=Nquin, C=Npyrim), 3287 cm-1, 3177 cm-1 (N-H). (+)-HR-ESI-
MS: m/z (%) 466.1179 ([M + H]+, 100 %), 488.1001 ([M+Na]+, 2 %); HPLC purity: 98.1%; tr’ = 20.51 
min. 
3.4.3 General method for complex synthesis 
The appropriate ligand was added to a stirred suspension of the appropriate iridium metal dimer and 
NaHCO3  in dry methanol in a microwave vial. The vial was then placed in the microwave reactor 
(150 °C, 10 min, 150 W) after which any effervescence was allowed to subside before the vial was 
opened and cooled to room temperature. The resulting solid was filtered off and washed with 
MeOH/Ether before it was recrystallised from DCM/Hex to afford the pure metal complex. 
3.4.4 Synthesis of [IrCl(C18H16N5O5S)(C10H15)] (C7)  
 
 N-(4-(N-(6-hydroxy-5-methoxypyrimidin-4-yl)sulfamoyl)phenyl)picolinamide (L4) (52.1 mg, 0.126 
mmol), di-µ-chlorido(bis(chlorido(pentamethyl-η5-cyclopentadienyl))iridium(III)) (50.0 mg, 0.0628 
mmol) and NaHCO3 (10.5 mg, 0.126 mmol) was reacted in methanol (1.50 mL) in a 10 mL microwave 
vial to afford a canary yellow powder in 84% yield (82.8 mg). 1H NMR (400 MHz, CDCl3) δ 8.58 (d, 
Hc, 1H, 3J(Hc-Hd) 5.6 Hz), 8.19 - 8.07 (m, Hn,j,f, 4H), 7.94 (t, He, 1H, 3J(He-Hf) 7.7 Hz), 7.87 (d, Hk, 2H, 
3J(Hk-Hj) 8.8 Hz), 7.53 (m, Hd, 1H), 3.97 (s, Hr, 3H), 3.84 (s, Hq, 3H), 1.38 (s, Ha, 15H). 13C NMR (101 
MHz, DMSO) δ 167.86 (Ch), 161.52 (C), 153.46 (C), 152.99 (C), 151.40 (CH), 150.62 (C), 139.42 
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(CH), 134.79 (C), 128.59 (CH), 127.48 (Cj/k), 127.12 (C), 126.81 (Ck/j), 125.43 (CH), 86.39 (Cb), 60.26 
(Cq), 54.04 (Cr), 7.93 (Ca). FT-IR (KBr): 1619 cm-1 (C=O), 1599 cm-1, 1577 cm-1, 1561 cm-1 (C=Npyr, 
C=Npyrim). (+)-HR-ESI-MS: m/z (%) 742.1687 ([M - Cl]+, 100%), 778.1456 ([M+H]+, 2%); HPLC 
purity: 96.7%; tr’ = 10.93 min. 
3.4.5 Synthesis of [IrCl(C18H16N5O5S)(C15H17)] (C8)  
 
Di-µ-chlorido(bis(chlorido(tetramethyl-η5-cyclopentadienylbenzene))iridium(III)) (50.0 mg, 0.054 
mmol), L4 (45.1 mg, 0.109 mmol) and NaHCO3 (9.10 mg, 0.109 mmol) were reacted together in 
MeOH (1.50 mL) to afford a bright yellow powder in 75% yield (68.7 mg). 1H NMR (300 MHz, CDCl3) 
δ 8.28 (d, Hn, 1H, 3J(Hn-Ho) 5.4 Hz), 8.19 - 8.07 (m, Hq,u,a’, 4H), 7.94 – 7.86 (m, Ho, 1H), 7.82 (d, Hv, 
2H, 3J(Hv-Hu) 8.6 Hz), 7.49 - 7.38 (m, Hc,b,a, 5H), 7.38 - 7.34 (m, Hp, 1H), 3.98 (s, Hc’, 3H), 3.85 (s, Hb’, 
3H), 1.70 (s, Hf, 3H), 1.48 (s, Hm, 3H), 1.21 (s, Hh, 3H), 1.12 (s, Hj, 3H). 13C NMR (101 MHz, CDCl3) 
δ 168.69 (Cs), 160.77 (C), 154.54 (C), 153.19 (C), 149.88 (CH), 149.78 (C), 138.80 (CH), 134.12 
(C), 130.16 (C), 130.06 (Cu/v/b/c), 129.16 (Cu/v/b/c), 128.80 (CH), 128.62 (CH), 127.77 (CH), 127.21 
(Cu/v/b/c), 126.67 (CH), 126.42 (C), 99.00 (Ce/g/l/i/k), 92.58 (Ce/g/l/i/k), 86.04 (Ce/g/l/i/k), 82.64 (Ce/g/l/i/k), 81.65 
(Ce/g/l/i/k), 60.55 (Cb’), 54.10 (Cc’), 9.71 (Cf/m), 9.38 (Cf/m), 8.52 (Cj/h), 8.09 (Cj/h). FT-IR (KBr): 1623 cm-
1 (C=O), 1600 cm-1, 1577 cm-1, 1560 cm-1 (C=Npyr, C=Npyrim). (+)-HR-ESI-MS: m/z (%) 804.1844 ([M 
- Cl]+, 100 %), 840.1575 ([M+H]+, 2%); HPLC purity: 96.8%; tr’ = 13.79 min. 
3.4.6 Synthesis of [IrCl(C18H16N5O5S)(C21H21)] (C9)  
 
Di-µ-chlorido(bis(chlorido(4-(tetramethyl-η5-cyclopentadienyl)-1,1’-biphenyl))iridium(III)) (50.0 mg, 
0.0470 mmol), L4 (38.7 mg, 0.0930 mmol) and NaHCO3 (7.80 mg, 0.0930 mmol) were reacted 
together in MeOH (1.50 mL) to afford a light-yellow powder in 65% yield (55.9 mg). 1H NMR (300 
MHz, CDCl3) δ 8.32 (d, Ha, 1H, 3J(Ha-Hb) 5.5 Hz), 8.19 - 8.09 (m, Hm,h,d, 4H), 7.94 – 7.87 (m, Hc, 1H), 
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7.84 (d, Hi, 2H, 3J(Hi-Hh) 8.9 Hz), 7.67 - 7.61 (m, Hk’,l’ 4H), 7.58 - 7.32 (m, Hq’,p’,o’,b, 6H), 3.98 (s, Hn, 3H), 
3.85 (s, Ho, 3H), 1.74 (s, Hf’, 3H), 1.49 (s, Hi’, 3H), 1.27 (s, Hh’, 3H), 1.11 (s, Hg’, 3H). 13C NMR (75 
MHz, CDCl3) δ 168.84 (Cf), 160.91 (C), 154.62 (C), 153.30 (C), 150.07 (CH), 149.94 (C), 141.41 (C), 
140.03 (C), 138.97 (CH), 134.34 (C), 130.59 (CH), 129.22 (C), 129.10 (CH), 128.90 (CH), 127.98 
(CH), 127.95 (CH), 127.84 (CH), 127.34 (CH), 127.04 (CH), 126.77 (CH), 126.59 (C), 99.22 
(Ca’/b’/c’/d’/e’), 92.76 (Ca’/b’/c’/d’/e’), 86.10 (Ca’/b’/c’/d’/e’), 82.90 (Ca’/b’/c’/d’/e’), 81.39 (Ca’/b’/c’/d’/e’), 60.67 (Co), 54.21 
(Cn), 9.89 (Cf’/i’), 9.57 (Cf’/i’), 8.64 (Cg’/h’), 8.17 (Cg’/h’). FT-IR (KBr): 1618 cm-1 (C=O), 1598 cm-1, 1580 
cm-1, 1661 cm-1 (C=Npyr, C=Npyrim). (+)-HR-ESI-MS: m/z (%) 880.2172 ([M - Cl]+, 100%), 916.1915 
([M+H]+, 2%) HPLC purity: 97.9%; tr’ = 18.07 min.  
3.4.7 Synthesis of [IrCl(C22H19N5O5S)(C10H15)] (C10) 
 
 
Di-µ-chlorido(bis(chlorido(pentamethyl-η5-cyclopentadienyl))iridium(III)) (50.0 mg, 0.0630 mmol), N-
(4-(N-(5,6-dimethoxypyrimidin-4-yl)sulfamoyl)phenyl)quinoline-2-carboxamide (L5) (58.4 mg, 0.126 
mmol) and NaHCO3 (10.6 mg, 0.126 mmol) were reacted in MeOH (1.50 mL) to afford an orange 
powder in 77% yield (80.5 mg). 1H NMR (400 MHz, CDCl3) δ 8.60 (d, Hi, 1H, 3J(Hi-Hj) 8.7 Hz), 8.34 (d, 
Hd, 1H, 3J(Hd-He) 8.5 Hz), 8.26 - 8.21 (m, Hn,j 3H), 8.17 (s, Ht, 1H), 8.07 (d, Ho, 2H, 3J(Ho-Hn) 8.9 Hz), 
7.93 (d, Hg, 1H, 3J(Hg-Hf) 8.1 Hz), 7.86 (m, He, 1H), 7.72 (m, Hf, 1H), 3.96 (s, Hv, 3H), 3.83 (s, Hu, 3H), 
1.28 (s, Ha, 15H). 13C NMR (101 MHz, CDCl3) δ 168.91 (Cl), 160.73(C), 156.61 (C), 153.36 (C), 
149.78 (C), 145.14 (C), 139.69 (CH), 133.13 (C), 131.10 (CH), 130.70 (C), 129.80 (CH), 128.93(CH), 
128.67 (Co/n), 128.62 (CH), 126.83 (Cn/o), 126.37 (C), 122.41 (CH), 87.16 (Cb), 60.53 (Cv), 54.09 (Cu), 
8.62 (Ca). FT-IR (KBr): 1615 cm-1 (C=O), 1580 cm-1, 1663 cm-1 (shoulder) (C=Nquin, C=Npyrim), 488 
cm-1, 452 cm-1 (Ir-N), 274 cm-1 (Ir-Cl). (+)-HR-ESI-MS: m/z (%) 792.1824 ([M - Cl]+, 100%), 828.1567 
([M+H]+, 7%). HPLC purity: 98.9%; tr’ = 13.61 min. 
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3.4.8 Synthesis of [IrCl(C22H19N5O5S)(C15H17)] (C11) 
 
Di-µ-chlorido-(bis(chlorido(tetramethyl-η5-cyclopentadienylbenzene))iridium(III)) (50.0 mg, 0.054 
mmol), L5 (50.5 mg, 0.109 mmol) and NaHCO3 (9.10 mg, 0.109 mmol) were reacted in MeOH (1.50 
mL) to afford an orange powder in 75% yield (73.0 mg). 1H NMR (300 MHz, CDCl3) δ 8.46 (d, Ho, 
1H, 3J(Ho-Hp) 8.8 Hz), 8.34 (d, Ht, 1H, 3J(Ht-Hu) 8.4 Hz), 8.27 (d, Hu, 1H, 3J(Hu-Ht) 8.4 Hz), 8.17 (s, He’, 1H), 
8.12 (d, Hy, 2H, 3J(Hy-Hz) 9.0 Hz), 8.06 (d, Hz, 2H, 3J(Hz-Hy) 9.0 Hz), 7.87 (d, Hr, 1H, 3J(Hr-Hq) 8.3 Hz), 7.63 
- 7.56 (m, Hp, 1H), 7.45 - 7.30 (m, Hc,b,a,q, 6H), 3.97 (s, Hg’, 3H), 3.84 (s, Hf’, 3H), 1.50 (s, Hf, 3H), 
1.45 (s, Hm, 3H), 1.41 (s, Hh, 3H), 0.90 (s, Hj, 3H). 13C NMR (75 MHz, CDCl3) δ 169.39 (Cw), 160.89 
(C), 156.48 (C), 153.44 (C), 149.92 (C), 145.11 (C), 140.04 (CH), 133.64 (C), 131.16 (C), 131.02 
(CH), 130.81 (C), 130.07 (CH), 129.79 (Cy/z/b/c), 129.07 (Cy/z/b/c), 128.87 (CH), 128.66 (CH), 128.47 
(CH), 127.12 (Cy/z/b/c), 126.53 (C), 122.66 (CH), 95.98 (Ce/g/l/i/k), 95.86 (Ce/g/l/i/k), 87.49 (Ce/g/l/i/k), 83.49 
(Ce/g/l/i/k), 81.57 (Ce/g/l/i/k), 60.69 (Cg’), 54.25 (Cf’), 10.27 (Cf/m), 9.71 (Cf/m), 8.66 (Cj/h), 8.37 (Cj/h). FT-IR 
(KBr): 1622 cm-1 (C=O), 1582 cm-1, 1663 cm-1 (C=Nquin, C=Npyrim). (+)-HR-ESI-MS: m/z (%) 854.2007 
([M - Cl]+, 100%), 890.1763 ([M+H]+, 22%). HPLC purity: 97.2%; tr’ = 16.24 min. 
3.4.9 Synthesis of [IrCl(C22H19N5O5S)(C21H21)] (C12) 
Di-µ-chlorido(bis(chlorido(4-(tetramethyl-η5-cyclopentadienyl)-1,1’-biphenyl))iridium(III)) (50.0 mg, 
0.0470 mmol), L5 (43.4 mg, 0.0930 mmol) and NaHCO3 (7.80 mg, 0.0930 mmol) were reacted in 
MeOH (1.50 mL) to afford an orange powder in 56% yield (50.0 mg). 1H NMR (400 MHz, CDCl3) δ 
8.47 (d, Hb, 1H, 3J(Hb-Hc) 8.8 Hz), 8.34 (d, Hg, 1H, 3J(Hg-Hh) 8.4 Hz), 8.28 (d, Hh, 1H, 3J(Hh-Hg) 8.4 Hz), 
8.17 (s, Hr, 1H), 8.15 (d, Hl, 2H, 3J(Hl-Hm) 8.9 Hz), 8.07 (d, Hm, 2H, 3J(Hm-Hl) 8.9 Hz), 7.86 (d, He, 1H, 
3J(He-Hd) 8.2 Hz), 7.78 (s, HNHSO2, 1H), 7.65 - 7.54 (m, Hk’,l’,c, 5H), 7.51 - 7.44 (m, Hp’, 2H), 7.44 – 7.35 
(m, Ho’,q’,d, 4H), 3.97 (s, Hs, 3H), 3.84 (s, Ht, 3H), 1.52 (s, Hf’, 3H), 1.50 (s, Hi’, 3H), 1.40 (s, Hg’, 3H), 
Stellenbosch University https://scholar.sun.ac.za
71 
 
0.95 (s, Hh’, 3H).13C NMR (101 MHz, CDCl3) δ 169.40 (Cj), 160.89 (C), 156.49 (C), 153.44 (C), 149.92 
(C), 145.13 (C), 141.16 (C), 140.13 (C), 140.06 (CH), 133.67 (C), 131.02 (CH), 130.83 (C), 130.22 
(CH), 130.12 (C), 130.06 (CH), 129.13 (CH), 129.08 (CH), 128.90 (CH), 128.66 (CH), 127.96 (CH), 
127.62 (CH), 127.13 (CH), 127.06 (CH), 126.54 (C), 122.68 (CH), 95.93 (Ca’/b’/c’/d’/e’), 95.73 
(Ca’/b’/c’/d’/e’), 87.82 (Ca’/b’/c’/d’/e’), 83.37 (Ca’/b’/c’/d’/e’), 81.39 (Ca’/b’/c’/d’/e’), 60.69 (Cs), 54.25 (Ct), 10.34 (Cf’/i’), 
9.83 (Cf’/i’), 8.64 (Cg’/h’), 8.36 (Cg’/h’). FT-IR (KBr): 1623 cm-1 (C=O), 1579 cm-1, 1661 cm-1 (C=Nquin, 
C=Npyrim). (+)-HR-ESI-MS: m/z (%) 930.2319 ([M - Cl]+, 100%), 966.2080 ([M+H]+, 18%). HPLC 
purity: 94.3%; tr’ = 20.23 min. 
3.4.10 X-Ray crystallographic data collection 
Crystals of L4 were grown by layering a DCM solution of L4 with hexane and leaving to stand in a 
sealed vial for several days at room temperature. A single needle like transparent crystal of diffraction 
quality was selected for analysis and mounted in oil. Low temperature X-ray diffraction data collection 
for L4 was performed at 100(2) K on a Bruker APEX II DUO CCD diffractometer using graphite-
monochromated Mo K radiation (0.71073 Å ). An Oxford Cryostream plus, 700 series cryostat that 
was attached to the diffractometer cooled the sample. Data were collected up to 55.1º. A colourless 
plate was used of dimensions, 0.118  0.073  0.048 mm3, the crystal was triclinic, space group P1, 
The asymmetric unit cell had parameters: a = 8.319(2), b = 10.194(3), c = 12.280(3) Å, = 
109.559(4), = 100.736(4), = 103.451(4)°, V = 913.9(4) Å3, Z = 2, Dc = 1.510 g cm-3, F000 = 432. 
24537 reflections collected, 4207 unique (Rint = 0.0496).  Final GooF = 1.045, R1  = 0.0402, wR2  = 
0.0970, R indices based on 3483 reflections with I > 2 (refinement on F2), 272 parameters, 0 
restraints.  Lp and absorption corrections applied, µ = 0.221 mm-1. Bruker diffraction, SAINT39 
software was used for data reduction and unit cell determinations, while SADABS40,41 was used for 
absorption corrections. SHELXT-1642 and SHELLXT-1443 was used to refine and solve crystal 
structures with the X-seed44,45 graphical user interface. Calculated positions were used to place 
hydrogen atoms and non-hydrogen atoms were refined anisotropically. Hydrogens on oxygen and 
nitrogen atoms were located with electron density maps. Figures were generated from the 3D crystal 
lattice with Mercury 3.7.46–49 
3.4.11 HPLC method and purity determination 
Purity measurements by HPLC were carried out using the Agilent 1220 system with a DAD and 100 
µL loop. The column used was a Kinetex® 5 µm C18 100 Å, 150 x 4.6 mm with a 5 µm pore size. 
The mobile phase was H2O 0.1% TFA/MeCN 0.1% TFA at gradients of t=0 min 10% B, t=30 min 
80% B, t=40 min 80% B, t=41 min 10% B, and t=55 min 10% B over a 55 min period. The flow rate 
was 1 mL min-1, and the detection wavelength was set at 254 nm and 400 nm with the reference 
wavelength at 360 nm. Samples were dissolved in 10% MeCN/90% H2O at ca. 100 µM. Sample 
injections were half the loop volume (50 µL) with needle washes of MeCN and H2O between 
injections. It was assumed that all species in a sample have the same extinction coefficient at 254 
nm and 400 nm. All peaks were manually integrated. 
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Chapter 4  
Biological investigations and activity against Mycobacterium 
tuberculosis and Plasmodium parasites 
 
4.1 Introduction 
The process of drug discovery is a complicated one, dependant on a multitude of factors for success. 
It does not only rely on the efficacy of the drug candidate to kill or inhibit the chosen target, as there 
are many chemical entities able to accomplish this, but rather requires a candidate that will not 
negatively affect the host and can be safely transported and administered to the target site. The drug 
candidate should also not have toxic metabolites and needs to be able to be excreted in a safe and 
expedient manner after it has served its purpose. It has been estimated that the success rate of 
identifying a hit compound that progresses through clinical trials to the market is only 0.001% and 
that the cost of its discovery and development is more than $1.75 billion.1,2 Because the success of 
a drug candidate depends not only on its potency but also largely on its pharmacological properties, 
it is vital that potential biological processes that drug candidates will be subjected to upon 
administration are able to be mimicked and tested.3,4 There are thus many methods that have been 
developed to test the most important processes that drugs will undergo in the body, collectively 
known as their ADMET properties (absorption, distribution, metabolism, excretion and toxicity) or 
drug-like properties. These tests are routine parts of the drug discovery process and can help 
eliminate candidates that would otherwise have wasted valuable resources.4-6  
Whether candidates should be tested for favourable activity against the target or pharmacokinetic 
properties first is a good question to consider and though it is not currently widely done in industry, 
Lipinski7 suggests that the identification of candidates with optimal pharmacokinetic properties would 
be a more effective and productive approach to drug discovery. The process of drug discovery 
progresses via the identification of several hit compounds followed by their finetuning into lead 
compounds and ultimately the selection of a most suitable target.5,6,8 The optimisation process and 
selection of a lead compound highly favours promising pharmacokinetic properties and allow for the 
most stable, active and least toxic molecules to be selected.5,6,8 
It is thus important that the in vitro properties of potential candidates be investigated as far as 
possible to streamline later target selection and lead optimisation. It is with this purpose that both 
the solubility of the drug candidates, C1 – C12, which provides important information on 
bioavailability, and their potential aquation, which can aid in the identification of the potent species, 
were investigated to identify the most potent and suitable candidates for further testing. 
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4.2 Results and Discussion 
4.2.1 Turbidimetric solubility assays 
Aqueous solubility plays an important part of drug discovery given the physiological environment in 
which medicine is administered in and is thus vital information required to correctly analyse biological 
data. If the solubility of a drug candidate is below that of the IC50 of the compound, then it may be a 
suspension or solid when administered which has important consequences when the method of 
administration is being considered.  
The aqueous solubility of the first and second libraries, consisting of six imino-sulfadoxine iridium 
complexes (C1 – C6) and six amido-sulfadoxine iridium complexes (C7 – C12), respectively (Figure 
4.1), was investigated by means of a turbidimetric assay.  
 
Figure 4.1 - All complexes tested for biological activity against Mtb and P. falciparum. 
The assay analyses the turbidity of the compounds in a solution of 2% DMSO in phosphate buffered 
saline with a pH of 7.4 at 620 nm.  These conditions are chosen with the aim of being applicable to 
the in vitro biological testing that is performed on drug candidates in addition to attempting to 
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resemble physiological conditions as far as is feasible. The measurements were done in triplicate 
with two controls, one for soluble species (hydrocortisone, Figure 4.2) and one for less soluble 
species (reserpine, Figure 4.2).  
 
Figure 4.2 - Controls used for turbidimetric assays. 
The results are shown in Table 4.1 and an example of the graphical data from which the solubility 
values are obtained is shown in Figure 4.3.  
 
Figure 4.3 - Graph of the turbidity of C12 in DMSO and PBS at room temperature. 
Table 4.1 - Solubility data of imino complexes, amido ligands and complexes and control drugs 
Compound 
 
C1 C2 C3 Res Hyd 
Solubility (µM) > 200 > 200 40 - 80 
40 - 80 > 200 
Compound C4 C5 C6 
Solubility (µM) > 160 120 - 160 20 - 40 
Compound L6 C7 C8 C9 
Solubility (µM) > 200 > 200 > 160 40 - 60 
Compound L7 C10 C11 C12 
Solubility (µM) > 200 160 - 200 40 - 60 20 - 40 
Of the two controls reserpine is considered insoluble, while hydrocortisone is soluble. 
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Generally, in the design of a drug candidate, solubility of > 100 µM is the target, however values 
below this are often obtained.8,9 To determine whether the solubility is still within the acceptable 
range other factors such as the potency and the permeability play a large role.8,9 Most of the drug 
candidates investigated lie above the target value and those which do not are typically the most 
effective as is shown later. Thus, these drug candidates are still viable for further investigation. From 
the data in Table 4.1 it is apparent that as the half-sandwich Cpx moiety is extended with arene rings, 
the aqueous solubility of the complexes decreases and conversely the hydrophobicity increases. 
Furthermore, when comparing the pyridyl complexes to the quinolyl complexes the solubility also 
decreases. This trend is to be expected as in both cases mentioned, hydrophobic groups are being 
added to the complex, effectively adding additional hydrophobic character to the complexes. This 
may be beneficial in assisting the complexes to permeate the cell membranes of the targeted 
organisms, as a greater hydrophobicity increases the ease with which the molecules can diffuse 
across the hydrophobic section of the phospholipid bilayer of the relevant cells. The hydrophobicity 
increasing by too large a margin, however, can lead to the compounds being insoluble under 
physiological conditions which would complicate administration thereof. 
4.2.2 Biological testing against Mtb 
Testing of the compounds against the Mycobacterium tuberculosis strain H37Rv was performed by 
Audrey Jordaan working under Prof. Digby Warner at the University of Cape Town. The minimum 
inhibitory concentration that inhibits 90% of cell growth (MIC90) of Mtb was determined by growing 
the cells to an optical density between 0.6 and 0.7 before making a serial dilution with liquid media 
to appropriate concentrations and incubating. The fluorescence intensity was determined after the 
addition of alamar blue reagent and the MIC90 values calculated from dose response curves that 
were generated from the raw fluorescent data. A detailed description of the protocol can be found in 
the experimental section. 
The biological data of the complexes and ligands tested against Mtb is shown in Table 4.2. 
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Table 4.2 - Activity of the imino and amido complexes against Mtb strain H37Rv. 
Media: 7H9 CAS GLU Txa 7H9 ADC GLU Twb 
Compound Day 7 (µM) Day 14 (µM) Day 7 (µM) Day 14 (µM) 
C1 NA* 35.1 NA* NA* 
C2 79.9 32.4 NA* NA* 
C3 13.8 3.62 NA* NA* 
C4 32.6 16.5 NA* NA* 
C5 8.64 1.73 31.5 61.3 
C6 2.78 7.13 14.0 28.6 
L6 NA* NA* NA* NA* 
L7 NA* NA* NA* NA* 
C7 NA* 80.406 NA* NA* 
C8 NA* NA* NA* NA* 
C9 68.3 34.3 NA* NA* 
C10 NA* 75.5 NA* NA* 
C11 NA* NA* NA* NA* 
C12 NA* NA* NA* NA* 
Cp* dimer 78.1 18.6 NA* NA* 
CpxPh dimer 8.51 4.24 NA* NA* 
CpxbiPh dimer 2.32 0.455 NA* NA* 
Rifampicin 0.032 0.016 0.004 0.005 
*Not active at the highest concentration tested (125 µg/ml). 
a – Middlebrook 7H9 media supplemented with casitone, glucose and tyloxapol 
b – Middlebrook 7H9 media supplemented with ADC (albumin-dextrose-catalase), glucose   
      and tween 80. 
 
Each measurement was done in duplicate and compounds were tested in two 7H9 media solutions, 
one enriched with casitone, glucose and tyloxapol and the other with ADC (albumin-dextrose-
catalase), glucose and tween 80. A general decrease in the MIC90 is seen between day 7 and day 
14, except in the case of the quinolyl imino CpxbiPh complex (C6) where an increase in the MIC90 is 
seen. This could be due to the gradual decomposition of the complex in the subsequent 7 days or 
due to association with other species in solution instead. In addition to this, a drastic decrease in 
efficacy is seen when the compounds are tested in the media enriched with ADC (Table 4.2, 7H9 
ADC GLU Tw). This large decrease in activity could be attributed to serum-albumin binding of the 
compounds which would prevent them from inhibiting the growth of the infectious cells.10 If this is the 
case then administration of these compounds would require some form of protection until they are 
released within the targeted cells. Figure 4.4 illustrates the results of the testing in the media 
employing tyloxapol as surfactant. 
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Figure 4.4 – Graph of the activity of the imino and amido complexes and their iridium dimers against Mtb strain 
H37Rv. N.A = Not active at the highest concentration tested. 
From this data it is seen that there is a general increase in activity as the half-sandwich moiety is 
extended (C1 – C3; C4 – C6; C7 – C9; C10 – C12). This is seen particularly clearly when looking at 
the activity of the iridium chlorido dimers, of which the biphenyl analogue exhibits a sub micromolar 
activity of 0.455 µM, whereas the Cp* analogue has an activity of 18.6 µM. The trend is seen for the 
other complexes as well. The apparent exception being C6 in this data set, however, the activity of 
C6 on day 7 was 2.78 µM which is lower than that of C5 which was 8.64 µM on day 7. As mentioned 
earlier this discrepancy in activity is likely due to gradual decomposition of the complex after day 7 
and is seen in the trends mentioned hereafter as well.  Furthermore, when comparing the activity of 
the pyridyl complexes (C1 – C3; C7 – C9) to that of the quinolyl ones (C4 – C6; C10 – C12) a greater 
activity is seen for the quinolyl complexes. This is seen especially in the case of the imino Cp* 
analogues (C1 and C4) in which the quinolyl complex (C4) is nearly twice as potent as the pyridyl 
one (C1). Finally, when comparing the amido complexes (C7 – C12) to their imino analogues (C1 – 
C6), the imino complexes are 2 – 10-fold more active. Purity issues prevented the imino ligands from 
being tested for activity, while the amido ligands along with complexes C8, C11 and C12 did not 
show any activity at the highest concentration tested against Mtb strain H37Rv. Additionally, the 
difference in activity between day 7 and day 14 indicates these drug candidates take some time to 
effectively inhibit Mtb. In summary, the quinolyl CpxbiPh structure (C6) is the most effective in the case 
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of the imino series whereas the activity for the amido series is significantly lower and does not 
conform to the trend. 
4.2.3 Biological testing against P. falciparum 
Testing of the compounds against Plasmodium falciparum malarial parasite strains 3D7, Dd2 and 
HB3 and the human epidermal keratinocytes (HEK) cell line was performed by Sandra Duffy working 
under Prof. Vicky Avery at Griffith University. To summarise the protocol, the compounds were 
serially diluted to appropriate concentrations in a 384-well imaging plate before cultures of the 
parasites were added to the wells and the imaging plates were then incubated for 72 hours under 
the same conditions used to produce the original cultures. The plates were then stained with 4’,6-
diamidino-2-phenylindole (DAPI) and incubated overnight at room temperature before being imaged 
on an Opera confocal high content imaging system. Normalized data was used to determine the % 
inhibition of the compounds and plot the dose response curves from which IC50 values were 
calculated using graph pad prism where appropriate. A detailed description of the protocol can be 
found in the experimental section. 
The complexes, C1 – C5, C7 – C12, and ligands, L7 and L8, were also tested against several strains 
of the malarial parasite P. falciparum as well as to determine the toxicity to healthy cells of these 
compounds, the results of which are shown in Table 4.3. Unfortunately, there was not enough pure 
sample available of C6 to be tested against the malarial strains as well and a full comparison can 
thus not be made for the quinolyl imino system. 
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Table 4.3 - Percentage inhibition of metal complexes and their ligands against Plasmodium parasitic strains and human skin cells with selected IC50 values. 
Strain/Cell 
line 
3D7A 3D7B Dd2A Dd2B HB3A HB3B HEKA HEKB 
Compound 
IC50 
µM 
% inh 80 
µM 
IC50 
µM 
% inh 80 
µM 
IC50 
µM 
% inh 80 
µM 
IC50 
µM 
% inh 80 
µM 
IC50 
µM 
% inh 80 
µM 
IC50 
µM 
% inh 80 
µM 
IC50 
µM 
% inh 80 
µM 
IC50 
µM 
% inh 80 
µM 
Cp* dimer > 45 65 > 45 72 > 45 49 > 45 54 > 45 76 > 45 71 > 45 -3 > 45 -1 
CpxPh 
dimer 
13.5 99 14.4 98 N/A 103 16.9 98 19.3 94 20.4 93 > 45 64 > 45 34 
CpxbiPh 
dimer 
9.02 99 5.87 98 6.54 100 10.3 99 8.99 95 9.29 95 > 45 70 > 45 55 
C1 > 45 3 > 45 -4 > 45 18 > 45 26 > 45 27 > 45 54 > 45 -8 > 45 -4 
C2 > 45 48 > 45 47 > 45 54 > 45 60 > 45 50 > 45 67 > 45 -7 > 45 -2 
C3 > 45 77 > 45 68 > 45 88 > 45 86 > 45 75 > 45 93 > 45 -1 > 45 1 
C4 > 45 99 > 45 99 > 45 92 > 45 92 > 45 92 > 45 99 > 45 -2 > 45 -2 
C5 13.8 98 14.5 99 19.6 98 16.6 98 15.1 96 9.44 85 > 45 7 > 45 14 
C7 > 45 50 > 45 39 > 45 38 > 45 51 > 45 32 > 45 28 > 45 -3 > 45 -2 
C8 > 45 1 > 45 -4 > 45 13 > 45 23 > 45 7 > 45 21 > 45 -3 > 45 0 
C9 > 45 21 > 45 7 > 45 25 > 45 55 > 45 3 > 45 94 > 45 3 > 45 2 
C10 > 45 97 > 45 88 > 45 92 > 45 93 > 45 80 > 45 94 > 45 40 > 45 67 
C11 > 45 48 > 45 42 > 45 38 > 45 32 > 45 48 > 45 37 > 45 52 > 45 25 
C12 0.975 97 0.574 97 1.41 96 0.766 98 0.941 93 0.721 91 > 45 73 > 45 53 
L4 > 45 13 > 45 -1 > 45 23 > 45 22 > 45 15 > 45 28 > 45 -3 > 45 -2 
L5 > 45 14 > 45 11 > 45 24 > 45 30 > 45 30 > 45 60 > 45 -7 > 45 -5 
All IC50 values labelled as > 45, did not give a plateau in the graphing data and as such GraphPad prism 4.0 was unable to determine an exact value. Compounds from which 
the IC50 values could be exactly determined have been highlighted in green. 
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Strain 3D7 is chloroquine sensitive and the standard genomic reference strain11,12, whereas strain 
Dd2 is a multidrug resistant strain13,14 and strain HB3 is a gametocyte forming pyrimethamine 
resistant and chloroquine sensitive strain.15,16 Each of the strains were tested in duplicate with two 
biological replicates (labelled A and B). The percentage inhibition at a compound concentration of 
80 µM has been calculated along with the subsequent IC50 of the compound where an Emax value 
was able to be determined from the sigmoidal dose response curves (the determination of which 
required a plateau with minimum two points to be reached in the sigmoidal curve). Compounds which 
did not give a plateau and for which IC50 values could not be determined were given values of > 45 
µM. Table 4.3 highlights in green the compounds for which IC50 values were calculated. 
The percentage inhibition values are generally similar between biological replicates, as would be 
expected, with several exceptions – in particular for the HB3 strain where there are some drastic 
differences for compounds C1, C9, L4 and L5. C9 also shows a large difference for the strains 3D7 
and Dd2 which could indicate that one of these readings was faulty for this compound. There is also 
a significant difference in the inhibition of the HEK cell line for compounds C10 – C12 and the CpxPh 
dimer. Figure 4.5 shows the average percentage inhibition between the two biological replicates of 
each strain and the HEK cell line, and several trends in the activity can be observed through this 
representation.  
 
Figure 4.5 – Graph of the inhibition of P. falciparum and cytotoxicity of tested compounds. 
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When looking at the imino pyridyl complexes (C1 – C3), an increase in the percentage inhibition for 
all the strains is seen as the Cpx moiety is extended, similar to the increase in activity that was seen 
for Mtb. This same trend is observed for the iridium chlorido dimers, though the percentage inhibition 
of the CpxPh and CpxbiPh dimers are both near to 100%. The quinolyl imino analogues (C4 and C5) 
both also have > 90% inhibition for all the strains. Due to this, a further increase in inhibition cannot 
be seen for these two sets of compounds. The large increase in inhibition seen when moving from 
the pyridyl (C1 – C3, C7 – C9) to the quinolyl systems (C4 – C6, C10 – C12) for both the imino and 
the amido complexes, and the earlier trend in increased inhibition as the Cpx moiety is lengthened, 
indicates that an increase in hydrophobicity can be linked to an increase in inhibition of the malarial 
strains. This is also observed for the two ligands of the amido series (L4 and L5).  
The amido complexes do not fully follow this trend as both the CpxPh analogues (C8 and C11) have 
lower percentage inhibition than the rest of the series. CpxbiPh analogues (C9 and C12) are still more 
active than their Cp* counterparts (C7 and C10), except in the case of the 3D7 and Dd2 strains, for 
which C7 is more active than C9. Looking at the cytotoxicity of the tested compounds to the HEK 
cell line it is clear from the iridium chlorido dimers that an increase in hydrophobicity could also be 
linked to an increased cytotoxicity. The cytotoxicity is significantly mitigated by the coordination of 
the ligands as is seen especially in the case of the CpxPh dimer and compounds C2, C5, C8 and for 
the CpxbiPh dimer it is seen in compounds C3 and C9. Structurally, when the hydrophobicity is 
increased by too large a margin, this mitigation of cytotoxicity is no longer as significant, as is seen 
for compounds C11 and C12. The mitigation of the cytotoxicity is still important in these cases 
however, as illustrated by the sub-micromolar IC50 of compound C12 which ranges between 0.574 
µM and 1.41 µM and was consistently toxic to all strains tested against. This means that even though 
it is significantly more cytotoxic than the other compounds, given its potency it could be administered 
in a dose significantly lower than would be detrimental to healthy cells – which illustrates the 
advantage of such selectivity. 
4.2.4 Investigation and monitoring of the aqua species 
Given the aqueous environment that drugs are administered and tested in, the aqua species of the 
metal complexes could be the actual active species in vivo. This is due to the possible displacement 
of the chlorido ligand and substitution by an aqua molecule. Considering that this species would be 
significantly more soluble and could be easier or more effective to administer, it was thought 
beneficial to probe the active species. An investigation was consequently undertaken to determine 
the nature of the potential active species. It was envisioned that generating the aqua species in situ 
and then comparing this species to the chlorido species that had been incubated in deuterium oxide 
at physiological temperatures would provide some insightful knowledge as to whether this was a 
facile process or not and thus this route was pursued.  
The experiment was designed such that the selected chlorido complex, which was insoluble in 
deuterium oxide, was stirred at 37 °C in the presence of silver nitrate for 18 hours after which the 
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solution was filtered through a plug of Celite™ and analysed via 1H NMR spectroscopy. It was 
assumed that any material that subsequently dissolved in the deuterium oxide had to be the aqua 
species, where a deuterium molecule was coordinating to the metal centre, forming a doubly charged 
cationic complex with NO3- and PF6- acting as the counterions for the imino complexes and a singly 
charged cationic complex with NO3- as the counterion for the amido complexes. This spectrum was 
then compared to that of the same complex which was incubated under the same conditions in a 
25% acetone/deuterium oxide solution without silver nitrate. TMS was added to both samples as an 
internal standard to compare the relative shifts of the protons. The samples were analysed with mass 
spectrometry thereafter to further confirm the species in solution. A general scheme for the in situ 
generation of the imino aqua species is shown in Scheme 4.1 to illustrate the process. 
 
Scheme 4.1 – General scheme for the generation of the imino aqua complexes. 
The amido complexes were labelled and generated in the exact same way and thus have not been 
shown. The complexes C5 and C6 were not investigated due to the scarcity of pure material for 
these complexes and C12 was not investigated as the increasing hydrophobic character of the metal 
complexes led to it being extremely insoluble even under the conditions used. The overlaid 1H NMR 
spectra of the C1 aqua and incubated chlorido species are shown in Figure 4.6. 
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Figure 4.6 - Aqua species of C1 (Blue), prepared by incubation with silver nitrate, overlaid with the incubated 
chlorido species of C1 (Red) with no silver nitrate. Both spectra are referenced to TMS and analysed at 400 
MHz. 
There is a clear difference in the shift of the aqua species imine proton (9.44 ppm) and that of the 
incubated species (9.29 ppm). There is also a large difference seen for the proton ortho to the 
nitrogen of the pyridyl ring which is at 9.22 ppm and 9.05 ppm for the aqua and incubated species, 
respectively. Given that the metal is coordinated to these two functionalities, it is logical that they 
would experience the greatest shifts when the electron density of the metal is changed. This 
indicates that for C1, the aqua species does not form over a short period of time or in the absence 
of a moderate coordinating group. The initial plan was to immediately analyse via MS after analysis 
by 1H NMR, however, the MS analysis is done on a batch to batch basis and as such, samples 
typically stood for extended periods of time before they were analysed. This allowed for significant 
breakdown of the original species and subsequent formation of various other species given the 
mixture present in solution. The MS results of these two solutions both have a base peak at a m/z of 
450.1042 which could equate to a [(M-D2O) + TMS + NaNO3]2+ fragment, however, it is also likely 
that hydrolysis occurred and the dimeric species shown in Figure 4.7 is the fragment. Additionally, 
the [M-PF6]+ fragment is seen in the incubated chlorido solution at 762.1459 m/z. The [M-PF6-Cl]2+ 
and the [M-PF6-Cl+4K]6+ fragments are also observed in the aqua species at 363.5898 and 147.9303 
m/z, respectively, providing further support that the proposed species are as stated in the 1H NMR 
in Figure 4.6. 
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Figure 4.7 - Potential 450 m/z fragment present in C1 aqua and incubated chlorido solutions. 
C2 also shows a significant shift when comparing its aqua and incubated species for the imine, seen 
at 9.48 ppm in the aqua and 9.35 ppm in the incubated species, and for the proton ortho to the 
nitrogen of the pyridyl ring, at 9.09 ppm in the aqua and 8.83 ppm in the incubated species. 
Furthermore, the incubated species in this case is seen to form three different species, the smallest 
of which corresponds to the aqua species and another to the chlorido species. The nature of the 
third species is not certain at this stage. This indicates gradual aquation of the metal centre. The MS 
spectrum has the same species present as the base peak as that mentioned for C1 with a m/z of 
512.1201, the difference in weight coinciding exactly with the extension of Cp* to CpxPh. The [M-PF6]+ 
fragment is still observed in the incubated species of C2 at 824.1764 m/z, though in this case the 
[M-PF6-Cl]2+ and the [M-PF6-Cl+4K]6+ fragments are not observed for the C2 aqua species. C3 did 
not aquate even at increased temperatures of 45 °C – 50 °C, instead only the original chlorido 
species was obtained when the solid in the suspension of D2O was analysed. This was also the case 
for the amido analogue, C9, and it is likely that given the large nature of the biphenyl moiety on the 
metal centre, the removal of the chlorido ligand is prevented by its steric bulk. Only one species was 
present in the incubated sample, the chlorido species, confirmed with MS by the subsequent 
identification of the [M-PF6]+ fragment seen at 900.1959 m/z and no fragment seen for the species 
without the chlorido, although a fragment at 333.0628 m/z was identified as the [M-CpxbiPh-
PF6+D2O]2+ ion which likely formed due to the extended time in solution. 
The analysis of C4 showed similar differences as that seen for C1 and C2 between its aqua and 
incubated species with the imine see at 9.72 ppm and 9.59 ppm in the aqua and incubated species, 
respectively. Additionally, as the hydrophobicity of the compounds increased, the species generally 
became less soluble and had to be analysed for longer periods of time to obtain a visible spectrum. 
The [M-PF6]+ fragment was identified at 812.1613 m/z in the incubated C4 species. Unfortunately no 
significant or realistic fragments could be identified from the aqua solution, likely due to how dilute it 
was and the length of time it stood before MS analysis. 
The amido complexes were investigated in the same fashion as described above and the overlaid 
spectrum of the aqua and incubated species for C7, the pyridyl amido Cp* complex, is shown in 
Figure 4.8. 
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Figure 4.8 - Aqua species of C7 (Blue), prepared by incubation with silver nitrate, overlaid with the incubated 
chlorido species of C7 (Red) with no silver nitrate. Both spectra are referenced to TMS and analysed at 400 
MHz. 
The proton ortho to the nitrogen of the pyridyl ring for the aqua species of C7 (Figure 4.8, Blue 
spectrum) is seen at 9.01 ppm, while that of the incubated chlorido complex is at 8.91 ppm. The MS 
of the amido compounds generally show the base peak as the [M-Cl]+ fragment and under softer 
ionisation the [M+H]+ ion can be seen. The MS of the two solutions both show the [M-Cl]+ ion at 
742.1680 m/z, however only the incubated chlorido species shows the [M+H]+ fragment at  778.1426 
m/z. The fragment at 764.1522 m/z in the aqua species is proposed to be the [M-Cl+D2O]+ ion, with 
the additional 2 m/z extra being attributed to the lengthy time in deuterated solvent and consequently 
some exchange between protons on the compound and deuteriums. This fragment is not seen in 
the original MS of the amido complexes but is observed for the incubated chlorido species of C7 as 
well, though it is not the base peak as is the case for the aqua species. Additionally, aggregates for 
[M-Cl]+ and [M-Cl+D2O]+ at twice the m/z of the aqua species fragments are seen. 
The 1H NMR spectrum for the aqua species of C8 has the proton ortho to the nitrogen of the pyridyl 
ring appearing at 8.94 ppm; the same proton appears at 8.74 ppm in the incubated chlorido 
spectrum. This once again confirms two different species and the successful formation of the aqua 
complex of C8 in situ. The MS shows the [M+H]+ and [M-Cl]+ ions for the incubated chlorido complex 
C8 at 840.1631 m/z and 804.1835 m/z, respectively. The [M-Cl]+ ion is seen in the aqua complex of 
C8 at 804.1833 m/z but the [M+H]+ ion is not seen. Unlike as was the case for C7, the [M-Cl+D2O]+ 
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is not seen, although there are aggregates that could be attributed to it, but not conclusively. As 
discussed earlier, the same results were obtained for C9 as for C3. 
Besides the gradual decrease in solubility, the quinolyl amido complexes behaved in similar fashion 
to the other complexes. The doublets of the quinolyl ring were identified at 8.79, 8.50, 8.23 and 8.17 
ppm in the aqua complex of C10. The doublets were seen at 8.73, 8.46, 8.16 and 8.10 ppm, 
respectively, in the incubated chlorido complex, indicating that these were two different species. C11 
was the last compound that was investigated as half an hour of analysis barely gave a visible 
spectrum and the results of C3 and C9 suggested that similar results for C12 would be obtained. 
Unfortunately, the species in solution was too dilute and no definitive conclusions could be made 
from the spectra of C11. From the above data it was clear that without a driving force or moderately 
coordinating group present, the chlorido was either not displaced by H2O or was extremely slow in 
being substituted. Wanting to follow the aquation over time, it was decided to select complex C2 and 
monitor it with 1H NMR spectroscopy over time in a solution of 25% acetone-d6/D2O in the presence 
of silver nitrate at 37 °C. The spectra at room temperature showed no difference to that at 37 °C and 
in the absence of silver nitrate no change was seen in the spectrum. The aquation was followed by 
means of a pre-acquisition array experiment at 400 MHz. Spectra were acquired every 15 min for 1 
hour followed by every 30 min for 3 hours and finally every hour for 6 hours (Figure 4.9). 
 
Figure 4.9  - C2 with an equimolar amount of silver nitrate present in 25% acetone-d6/D2O at 37 °C. Spectra 
were acquired every 15 min for 1 hour followed by every 30 min for 3 hours and finally every hour for 6 hours.  
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The stacked spectra are shown in Figure 4.9 and two main changes are observed to occur 
simultaneously. Firstly, some degradation is seen as is evidenced by the formation of the doublet at 
6.69 ppm which is indicative of the presence of sulfadoxine. Secondly, the aqua species is observed 
as a second imine forms downfield at 9.45 ppm compared to the original which is at 9.27 ppm. 
Further evidence of formation of these species is particularly seen when looking at the signals for 
the methoxy methyls, between 3.5 ppm and 4.5 ppm, and the CpxPh methyls, between 1.0 ppm and 
2.0 ppm, respectively. Figure 4.10 shows an expanded spectrum of this region for easier discussion. 
  
Figure 4.10 - An expansion of the aliphatic region of the spectra that monitored the formation of the aqua 
species of C2. 
The original species has the singlets for the methoxy methyls of the pyrimidine ring at 3.72 ppm and 
3.90 ppm. Two new singlets appear at 3.90 ppm and 3.69 ppm, upfield from the previous signals. 
The original species singlet at 3.90 ppm shifts downfield gradually to 3.94 ppm. The increased 
broadness of these signals is due to the gradual formation of the sulfadoxine as mentioned above, 
which contributes another set of signals. The methyl singlets of the CpxPh moiety clearly show the 
formation of the aqua species with their large downfield shift as the metal centre becomes more 
cationic. The original chlorido species in the first spectrum shows the singlets at 1.11, 1.30 and 1.51 
ppm (representing two methyls). Two new signals appear downfield at 1.62 ppm and 1.74 ppm, each 
representing two methyls. The original signal becomes rather messy, however, with several new 
signals appearing around 1.50 ppm, most likely due to the degradation process mentioned earlier. 
Degradation could be taking place due to the instability of the doubly cationic species, which would 
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also lend credence to the dimeric species noted during the discussion of the MS of the incubated 
and aqua species which had stood for a lengthy period before analysis.  
4.3 Conclusion 
In summary, the decrease in solubility as illustrated by the results of the turbidimetric assays is very 
clearly linked to an increase in activity for both the Mtb and malaria testing performed. This, along 
with the general increased difficulty in removing of the chlorido ligand as the bulk of the half-sandwich 
moiety is increased during the investigation of the aqua species, especially for the biphenyl 
analogues, would seem to indicate that the most active species is the chlorido complex. This species 
is more likely to reach the target site in tact if protected by a bulky group such as the biphenyl half-
sandwich moiety. The imino series of complexes generally exhibits better activity than their amido 
analogues, especially in the case of Mtb, while simultaneously being less toxic. It is unclear whether 
this increased activity and lower toxicity is due to the imino functionality itself or if the cationic nature 
of the metal centre also contributes and thus should be investigated further. The trends for the amido 
complexes against malaria was not as simple but some promising data was obtained for C12 which 
exhibited consistent toxicity against all strains. 
4.4 Experimental  
Chemicals and reagents. Silver nitrate, hydrocortisone, reserpine, phosphate buffered saline and 
all reagent solvents and deuterated solvents (deuterium oxide and acetone-d6) were obtained from 
Sigma Aldrich (Merck). 
Instrumentation.  NMR data (1H, 13C) were recorded on either a 300 MHz Varian VNMRS or a 400 
MHz Varian Unity Inova spectrometer. 1H NMR chemical shifts are reported in ppm and coupling 
constants in Hertz and were internally referenced to tetramethylsilane (0.00 ppm). Data was 
processed using MestReNova 11.0.4-18998. Mass spectrometry was performed on a Waters Synapt 
G2 with an ESI probe in ESI positive mode using a cone voltage of 15 V. Uv-Vis data for the 
turbidimetric solubility assay were recorded with a Thermo Scientific Multiscan Go plate reader at 
620 nm. 
4.4.1 General procedure for the preparation of the aqua species 
The complex was stirred for 18 hours with an equimolar quantity of AgNO3 in deuterium oxide (1.20 
mL) at 37 °C in an oil bath. The liquid was subsequently filtered through a plug of Celite™ and 
collected in an NMR tube. 1H NMR was run on the samples after 1-2 drops of TMS was added as 
internal reference and the samples were then submitted for analysis by mass spectrometry. 
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4.4.2 Synthesis of [IrD2O(C18H17N5O4S)(C10H15)PF6NO3] (C1 - aqua)  
C1 (12.2 mg, 1.30 x 10-2 mmol) and AgNO3 (2.30 mg, 1.30 x 10-2 mmol) were reacted in D2O (1.20 
mL) and then analysed. 1H NMR (400 MHz, D2O) δ 9.44 (s, Hf, 1H), 9.20 (d, He, 1H, 3J(He-Hd) 5.4 Hz), 
8.47 - 8.38 (m, Hb,d, 2H), 8.29 (d, Hg, 2H, 3J(Hg-Hh) 8.7 Hz), 8.10 - 8.04 (m, Hc,j, 2H), 7.69 (d, Hh, 2H, 
3J(Hh-Hg) 8.7 Hz), 4.00 (s, Hl, 3H), 3.83 (s, Hk, 3H), 1.36 (s, Ha, 15H). 
4.4.3  Synthesis of [IrD2O(C18H17N5O4S)(C15H17)PF6NO3] (C2 - aqua) 
 
 C2 (12.0 mg, 1.20 x 10-2 mmol) and AgNO3 (2.10 mg, 1.20 x 10-2 mmol) were reacted in D2O (1.20 
mL) and then analysed. 1H NMR (400 MHz, D2O) δ 9.50 (s, Hf, 1H), 9.10 (d, He, 1H, 3J(He-Hd) 5.4 Hz), 
8.51 (d, Hb, 1H, 3J(Hb-Hc) 7.5 Hz), 8.44 (t, Hd, 1H, 3J(Hd-Hc,e) 7.7 Hz), 8.06 – 7.97 (m, Hc,g, 3H), 7.93 (s, 
Hj, 1H), 7.51 – 7.43 (m, Hh,o, 3H), 7.36 (t, Hn, 2H, 3J(Hn-Hm,o)7.7 Hz), 7.15 (d, Hm, 2H, 3J(Hm-Hn) 7.7 Hz), 
4.03 (s, Hl, 3H), 3.81 (s, Hk, 3H), 1.63 (s, Ha, 3H), 1.55 (s, Ha, 3H), 1.51 (s, Ha, 3H), 1.12 (s, Ha, 3H). 
4.4.4 Attempted Synthesis of [IrD2O(C18H17N5O4S)(C15H17)PF6NO3] 
(C3 - aqua) 
C3 (12.5 mg, 1.20 x 10-2 mmol) and AgNO3 (2.00 mg, 1.20 x 10-2 mmol) were reacted in D2O (1.20 
mL) and then analysed. The chlorido complex was obtained as a solid; no material was present in 
the deuterium oxide. 
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4.4.5 Synthesis of [IrD2O(C22H21N5O4S)(C10H15)PF6NO3] (C4 - aqua) 
 
C4 (12.4 mg, 1.30 x 10-2 mmol) and AgNO3 (2.30 mg, 1.30 x 10-2 mmol) were reacted in D2O (1.20 
mL) and then analysed. 1H NMR (400 MHz, D2O) δ 9.72 (s, Hg, 1H), 8.95 (d, Hd, 1H, 3J(Hd-He) 8.4 Hz), 
8.49 (d, Hf, 1H, 3J(Hf-Ha) 8.9 Hz), 8.42 (d, He, 1H, 3J(He-Hd) 8.4 Hz), 8.37 - 8.32 (m, Hh,c, 3H), 8.15 (s, Hj, 
1H), 8.06 (m, Ha/b, 1H), 8.00 (m, Ha/b, 1H), 7.93 (d, Hi, 2H, 3J(Hi-Hh) 8.6 Hz), 4.02 (s, Hl, 3H), 3.84 (s, 
Hk, 3H), 1.28 (s, Hm, 15H). 
4.4.6 Synthesis of [IrD2O(C18H16N5O5S)(C10H15)NO3] (C7 - aqua)  
 
C7 (9.30 mg, 1.20 x 10-2 mmol) and AgNO3 (2.10 mg, 1.20 x 10-2 mmol) were reacted in D2O (1.20 
mL) and then analysed. 1H NMR (400 MHz, D2O) δ 9.01 (d, He, 1H, 3J(He-Hd) 5.4 Hz), 8.30 - 8.24 (m, 
Hc, 1H), 8.16 - 8.06 (m, Hb,g,j, 4H), 7.91 - 7.85 (m, Hd, 1H), 7.46 (d, Hh, 2H, 3J(Hh-Hg) 8.9 Hz), 3.99 (s, 
Hl, 3H), 3.83 (s, Hk, 3H), 1.27 (s, Ha, 15H). 
4.4.7 Synthesis of [IrD2O(C18H16N5O5S)(C15H17)NO3] (C8 - aqua) 
 
C8 (10.0 mg, 1.20 x 10-2 mmol) and AgNO3 (2.10 mg, 1.20 x 10-2 mmol) were reacted in D2O (1.20 
mL) and then analysed. 1H NMR (400 MHz, D2O) δ 8.94 (d, He, 1H, 3J(Hn-Ho) 5.4 Hz), 8.31 (m, Hp, 1H), 
8.17 (d, Hq, 1H, 3J(Hq-Hp) 7.6 Hz), 8.04 (s, Ha’, 1H), 7.92 (d, Hu, 2H, 3J(Hu-Hv) 8.6 Hz), 7.85 (m, Ho, 1H), 
7.47 (t, Ha, 1H, 3J(Ha-Hb) 7.7 Hz), 7.36 (t, Hb, 2H, 3J(Hb-Ha,c) 7.7 Hz), 7.18(d, Hv, 2H, 3J(Hv-Hu) 8.6 Hz), 7.12 
(d, Hc, 2H, 3J(Hc-Hb) 7.7 Hz), 4.03 (s, Hb’, 3H), 3.80 (s, Hc’, 3H), 1.58 (s, Hf,m, 6H), 1.09 (s, Hh,j, 6H). 
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4.4.8 Attempted Synthesis of [IrD2O(C18H17N5O4S)(C15H17)PF6NO3] 
(C9 - aqua) 
 
C9 (10.8 mg, 1.20 x 10-2 mmol) and AgNO3 (2.00 mg, 1.20 x 10-2 mmol) were reacted in D2O (1.20 
mL) and then analysed. The chlorido complex was obtained as a solid; no material was present in 
the deuterium oxide. 
4.4.9 Synthesis of [IrD2O(C18H16N5O5S)(C10H15)NO3] (C10 - aqua)  
 
C10 (9.90 mg, 1.20 x 10-2 mmol) and AgNO3 (2.00 mg, 1.20 x 10-2 mmol) were reacted in D2O (1.20 
mL) and then analysed. 1H NMR (400 MHz, D2O) δ 8.79 (d, Hd, 1H, 3J(Hd-He) 8.6 Hz), 8.50 (d, Hf, 1H, 
3J(Hf-Ha) 9.0 Hz), 8.23 (d, Hc, 1H, 3J(Hc-Hb) 8.2 Hz)  8.14 - 8.20 (m, He,b, 2H), 8.03 (d, Hh, 2H, 3J(Hh-Hi) 8.5 
Hz), 7.90 - 7.97 (m, Ha,j, 2H), 7.67 (d, Hi, 2H, 3J(Hi-Hh) 8.5 Hz), 3.94 (s, Hl, 3H), 3.82 (s, Hk, 3H), 1.19 
(s, Hm, 15H). 
4.4.10 General procedure for the incubation of the chlorido complexes 
The complex was dissolved in deuterated acetone (300 µL) and then mixed with deuterium oxide 
(900 µL) in a vial for a final solution constitution of 25% deuterated acetone/deuterium oxide (1.20 
mL). The resultant mixture was then stirred for 18 hours at 37 °C in an oil bath. The liquid was 
subsequently filtered through a plug of Celite™ and collected in an NMR tube. 1H NMR was run on 
the samples after 1-2 drops of TMS was added as internal reference and the samples were then 
submitted for mass spectrometry analysis. The 1H NMR was compared with that of the relevant 
aquated species generated above, both referenced to TMS, to determine whether aquation readily 
takes place. 
4.4.11 Turbidimetric solubility assays 
All compounds including the two positive controls, hydrocortisone (soluble) and reserpine (effectively 
insoluble), were made up to a 10 mM stock solution in 100% DMSO. All tests were run in duplicate 
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of triplicate, with the second triplicate run done on a different day. No significant changes in value 
were observed between the days. The stock solutions were serially diluted with DMSO on a 
preparatory 96-well plate to concentrations of 8 mM, 4 mM, 2 mM, 1 mM, 0.50 mM, 0.25 mM and 0 
mM. These dilutions were then further diluted in DMSO to concentrations of 200 µM, 160 µM, 80 
µM, 40 µM, 20 µM, 10 µM, 5 µM and 0 µM. They were also diluted to the same concentrations in 
0.01 M phosphate buffered saline at a pH of 7.4 to yield a 2% DMSO/buffer solution. The 96-well 
plates were then incubated for 2 hours in the dark at room temperature. Thereafter, the absorbance 
was measured at 620 nm and the data analysed using Microsoft Excel 2016. 
4.4.12 Antitubercular testing 
The minimum inhibitory concentration that inhibits 90% of cell growth (MIC90) of Mtb strain H37Rv17 
of the synthesized compounds was determined through the broth micro dilution method.18 A 10 mL 
culture of this strain was grown to an optical density between 0.6 and 0.7 and diluted 1:500 in 
Middlebrook 7H9 media (Difco) supplemented with 0.2% glucose, Middlebrook albumin-dextrose-
catalase (ADC) enrichment (Difco) and 0.05% Tween 80.19 A second 1:500 dilution was prepared 
with Middlebrook 7H9 media (Difco) supplemented with 0.03% casitone, 0.4% glucose and 0.05% 
tyloxapol.20 Stock solutions of the compounds to be tested were made up in DMSO and the 
compounds were then diluted to appropriate concentrations in the 7H9 media. A serial dilution was 
prepared in duplicate across 10 wells in a 96-well micro titre plate with volumes of 50 µL in each 
well. The diluted mycobacterial cultures were then added to the wells to make up a final volume of 
100 µL. The plate layout was a modification of a previously described method.21 The controls used 
were a minimum growth control with rifampicin at twice its known MIC (0.150 µM), a maximum growth 
control with DMSO, the final concentration of which was equal to that of its concentration used in the 
dose response assay for the test material, and a rifampicin dose response control ranging between 
0.15 µM and 0.0002 µM. The micro titre plate was then sealed in a secondary container and 
incubated at 37 °C with 5% CO2 and humidification. Twenty-four hours before the assay data was to 
be collected alamar blue reagent was added to each well and the assay plate was reincubated for 
the remaining 24 hours. After 7 days the assay was scored visually and the MIC90 allocated to the 
lowest concentration of material that did not display visible growth. The relative fluorescence was 
then measured using a SpecraMax i3x plate reader (excitation 540 nm; emission 590 nm) and the 
raw fluorescent data analysed with Softmax® Pro 6 software version 6.5.1. The 4-parameter curve 
fit protocol was used to generate the calculated MIC90. The raw fluorescent data was normalised to 
the minimum and maximum inhibition controls from which a dose response curve was generated 
through the Levenberg-Marquardt damped least-squares method from which the MIC90 was 
subsequently calculated. All procedures requiring the handling of pathogenic mycobacterial strains 
were performed in a biosafety level III certified and compliant facility. MIC90 values were also 
determined after 14 days. 
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4.4.13 Antiplasmodial testing22 
Stock solutions in DMSO of 20 mM of the compounds to be tested were prepared. The stock 
solutions were further diluted in 384-well polypropylene micro titre plates to produce 3 doses per log 
dose response with final assay concentrations of the compounds ranging between 80 µM and 0.8 
nM. A 1:25 dilution was then made of the compound plates with sterile water in a 384-well 
polystyrene plate and 5 µL of these wells were then transferred into a 384-well imaging plate. 4% 
DMSO and 50 µM Puromycin were used as controls under the same conditions and dilutions as that 
of the compounds.  
A Plasmodium falciparum standard genomic reference strain (3D7), multidrug resistant strain (Dd2) 
and gametocyte forming pyrimethamine resistant and chloroquine sensitive strain (HB3) were 
cultured within the medium RPMI-1640 which was supplemented with 10 mM HEPES, 25 µg/mL 
hypoxanthine, 5% human serum and 2.5 mg/mL Albumax while being incubated at 37 °C under 5% 
CO2, 5% O2 and 90% N2. Sorbitol synchronization was performed twice, consecutively, during the 
intra-erythrocytic lifecycles to provide ring-stage parasites for the assays.23 The ring stage parasite 
culture had its percentage parasitaemia and percentage haematocrit adjusted to 2% and 0.3%, 
respectively, and thereafter 45 µL of the adjusted parasite culture was added to compound 
containing imaging plates prepared as described earlier. The imaging plates were then incubated for 
72 hours under the same conditions as described for the original cultures. The plates were then 
stained with 4’,6-diamidino-2-phenylindole (DAPI) and incubated overnight at room temperature 
before being imaged on an Opera confocal high content imaging system. Accapella scripting 
software was used to determine the number of classified parasites which was subsequently 
normalized to obtain the percentage inhibition with regards to the two plate controls, 0.4% DMSO 
and 5 µM puromycin. The normalized inhibition data was then plotted against the log concentration 
of the compounds using GraphPad Prism 4.0, and the non-linear regression, sigmoidal dose 
response variable slope and the IC50 determined (where two or more points formed a plateau in the 
software). The data was generated from two biological replicates in duplicate of the three strains 
used.  
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Chapter 5  
Conclusions and future work 
 
5.1 Summary and conclusions 
The imino ligands (L1 and L3) and complexes (C1 – C6) had been synthesized before by Chellan et 
al.1 A new synthetic method was developed for the synthesis of L1 which achieved a percentage 
composition as analysed by 1H NMR of 78%, a great success given the equilibrium nature of imine 
formation. From this point, recrystallisation no longer posed a problem as had previously been the 
case and several recrystallisations could be used for further purification. The same method was used 
for the synthesis of L3, however it was found to be lacking and gave product conversion of ca. 30%. 
Various synthetic methods were investigated until a product conversion of 50% was achieved, before 
other aspects of the project had to be focussed on. The iridium chlorido dimers were synthesized in 
generally good yields according to a method from literature2 and their isolation was a facile process. 
The crude nature of L1 did not prevent the isolation of the pure metal complexes C1 – C3, however 
complexes C4 – C6 proved significantly more challenging. This was likely due to the much greater 
impurity of the crude of L3 as compared to L1.  
After the successful synthesis of the imino sulfadoxine iridium complexes, a second library of iridium 
conjugates was investigated which had not been synthesized before, as determined by a literature 
search. This library focussed on the incorporation of the amide moiety instead of the imine. The 
pyridyl and quinolyl amido sulfadoxine ligands, L4 and L5, were successfully synthesized via the in 
situ generation of an acid chloride from the parent carboxylic acid and gave moderate yields of 73% 
and 60%, respectively. Transparent needle-like crystals were obtained for L4 which were found to 
crystallise in the triclinic, P1 space group. A facile microwave synthetic procedure was discovered in 
literature3 for the synthesis of the subsequent complexes, C7 – C12, after the initial synthetic route 
gave low yields and employed long reaction times. This new method used significantly shorter 
reaction times and gave moderate to excellent yields, 56% - 84%, for the complexes C7 – C12. The 
successful generation of the amido iridium complexes were characterised by the disappearance of 
the amide NH in both FTIR and 1H NMR spectra. Furthermore, the phenylene carbons overlapped 
with an additional CH carbon signal, as there was consistently one signal less in the 13C NMR spectra 
of both the ligands and complexes than would be expected after symmetry has been taken into 
account. The MS spectra generally gave the [M-Cl]+ ion as the base peak, though the [M+H]+ ion 
was observed as base peak under softer ionisation conditions. Unfortunately, crystal structures were 
unable to be obtained of the complexes as the crystals were consistently too small for analysis. 
Confirming whether the coordination took place between the nitrogen of the amide and of the pyridyl 
or quinolyl moiety thus required investigation with Far-IR spectroscopy. C10 was investigated as a 
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representative with caesium iodide pellets and iridium-nitrogen absorption bands were successfully 
identified at 488 cm-1 and 452 cm-1 for the amide and quinolyl nitrogens, respectively. It was thus 
concluded that all the complexes coordinated in N, N fashion as was determined for C10. 
Following the synthesis of the two small libraries of complexes, C1 – C12, some of their physico-
chemical properties were determined. Turbidimetric assays were run in triplicate to determine the 
range of solubility of the compounds. The results determined that as the Cpx moiety was extended 
a general decrease in solubility was observed. There were also decreases in solubility going from a 
pyridyl to a quinolyl system and from an imine to an amide. Following this the nature of the active 
species was probed by investigating the substitution of the chlorido on the metal centre with an aqua 
group. To do this, the in situ generated analogues of C1 – C12 were compared to their parent 
complexes which had been incubated under similar conditions. This was to determine if the 
substitution of the chlorido was a facile process or not. It was found that as the bulk of the half-
sandwich moiety was increased it was increasingly difficult to remove the chlorido, especially seen 
for C3 and C9, in which it could not be removed under the conditions used. This data suggests that 
the actual active species is likely the chlorido complex. The complexes were sent for biological 
testing against Mtb strain H37Rv and P. falciparum strains 3D7, Dd2 and HB3. The imino series of 
complexes generally exhibited better activity than their amido analogues, especially in the case of 
Mtb, while simultaneously being less toxic. It is unclear whether this increased activity and lower 
toxicity is due to the imino functionality itself or if the cationic nature of the metal centre also 
contributes and should be investigated further. The complex found to be most active against Mtb 
was C6, which after 7 days displayed an MIC90 of 2.78 µM. Regarding the IC50’s that were determined 
against P. falciparum strains, C12 was found to be the most active with an IC50 of 0.975 µM. The 
biological data showed that as the solubility decreased there was a general increase in the activity 
against the strains tested. Furthermore, the intact chlorido species is more likely to reach the target 
site if protected by a bulky group such as the biphenyl half-sandwich moiety, which could explain the 
increased activity of these analogues.  
These results have aided in further investigating the properties of an existing set of biologically active 
complexes and identifying a new set of biologically active complexes and several of their relevant 
drug-like properties, from which more detailed lead compounds can be identified. 
5.2 Future work 
There are a variety of investigations that can still be done on the current system. One of these would 
be to continue exploring the conditions for the formation of the aqua analogues of the complexes. 
This could be done with UV spectroscopy which gives more sensitive measurements than could be 
achieved with an NMR spectrometer. Additionally, the NMR aquation experiments detailed in chapter 
4 could be repeated with immediate detection of the species in solution. LC-MS could be employed 
to provide a much greater breadth of knowledge on the species present. 
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The aqua analogues of C1 – C12 can also be isolated and themselves tested for biological activity 
to determine any difference in activity that might occur between these species. This could also 
confirm the previous hypothesis of the active species being the chlorido complexes. The lipophilicity 
of these compounds should be investigated to find whether the data follows the same trends that 
were determined for the solubility as this could give insight into part of the mechanism by which these 
drug candidates reach the target cells. This can be done via octanol water studies to determine the 
Log P, by determining Log D which accounts for the ionized and non-ionized forms, or through in 
silico methods.4  All complexes were isolated as chiral mixtures and tested without further separation. 
Given that there can be activity difference between enantiomers, the enantiomers of the iridium 
complexes should be investigated to identify whether they are separable and if there is a difference 
in activity or cytotoxicity between them. 
A decrease larger than four-fold in activity was seen for the complexes during testing against Mtb 
when a medium containing serum albumin was used. It is thus important that incubation tests be 
done with the compounds to ascertain whether they undergo serum-albumin binding as this could 
lead to their inefficacy in a biological system if this was the case. A variety of other biological assays 
could also be investigated to further determine the drug-like character (ADMET) of these complexes 
if they warranted further investigation.  
To identify a specific lead compound for potential clinical evaluation, a series of further analogues 
should be synthesized focussing on the CpxbiPh half sandwich moiety, as these complexes have 
proved the most active. This series can involve the investigation of both C, N coordination systems 
as well as N, O coordination by varying the aldehyde or acid used to derivatise sulfadoxine. 
Additionally, several different sulfonamides (Figure 5.1), such as sulfadiazine, sulfasalazine and 
sulfamethoxazole, which have all found clinical application,5 can be employed to investigate the 
difference in efficacy between derivatised species.  
 
Figure 5.1 - The clinically used sulfonamides, sulfadiazine, sulfasalazine and sulfamethoxazole. 
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A variety of different metal centres with varying oxidation potentials and coordination numbers could 
also be incorporated, as it has already been shown that the type of metal used influences the 
activity.1 One other approach would be to identify clinical drugs that have synergistic effects, such 
as sulfamethoxazole and trimethoprim6 and synthesize their respective complexes to investigate 
whether this synergism is still present and if their efficacy is greatly improved. Finally, C1 – C12 and 
the various analogues mentioned should be tested against a variety of other diseases to determine 
potential selectivity or pronounced activity against them. Particularly testing against cancer cell lines 
could prove successful as many similar half-sandwich complexes have shown good activity against 
cancers.7  
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